
<html lang="en"     class="pb-page"  data-request-id="01ecd3eb-6bf1-44d4-83da-175159d995be"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-8;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.0c00200;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors" /></meta><meta name="dc.Creator" content="David E.  Heppner" /></meta><meta name="dc.Creator" content="Marcel  Günther" /></meta><meta name="dc.Creator" content="Florian  Wittlinger" /></meta><meta name="dc.Creator" content="Stefan A.  Laufer" /></meta><meta name="dc.Creator" content="Michael J.  Eck" /></meta><meta name="dc.Description" content="Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in cancer therapy. Previous studies of trisubstituted imidazole inhib..." /></meta><meta name="Description" content="Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in cancer therapy. Previous studies of trisubstituted imidazole inhib..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 3, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00200" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00200" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00200" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00200" /></link>
        
    
    

<title>Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00200" /></meta><meta property="og:title" content="Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0010.jpeg" /></meta><meta property="og:description" content="Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in cancer therapy. Previous studies of trisubstituted imidazole inhibitors led to the serendipitous discovery of inhibitors that target the drug resistant EGFR(L858R/T790M/C797S) mutant with nanomolar potencies in a reversible binding mechanism. To dissect the molecular basis for their activity, we determined the binding modes of several trisubstituted imidazole inhibitors in complex with the EGFR kinase domain with X-ray crystallography. These structures reveal that the imidazole core acts as an H-bond acceptor for the catalytic lysine (K745) in the “αC-helix out” inactive state. Selective N-methylation of the H-bond accepting nitrogen ablates inhibitor potency, confirming the role of the K745 H-bond in potent, noncovalent inhibition of the C797S variant. Insights from these studies offer new strategies for developing next generation inhibitors targeting EGFR in non-small-cell lung cancer." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00200"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00200">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00200&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00200&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00200&amp;href=/doi/10.1021/acs.jmedchem.0c00200" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 4293-4305</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00193" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00211" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">David E. Heppner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David E. Heppner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</div><div class="loa-info-affiliations-info">Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+E.++Heppner">David E. Heppner</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0722-5160" title="Orcid link">http://orcid.org/0000-0002-0722-5160</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marcel Günther</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marcel Günther</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Tübingen 72076, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marcel++G%C3%BCnther">Marcel Günther</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Florian Wittlinger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Florian Wittlinger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Tübingen 72076, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Florian++Wittlinger">Florian Wittlinger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stefan A. Laufer</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefan A. Laufer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Tübingen 72076, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>S.A.L.: email, <a href="/cdn-cgi/l/email-protection#f182859497909fdf9d9084979483b1849f9885849493989f96949fdf9594"><span class="__cf_email__" data-cfemail="a9daddcccfc8c787c5c8dccfccdbe9dcc7c0dddccccbc0c7ceccc787cdcc">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefan+A.++Laufer">Stefan A. Laufer</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6952-1486" title="Orcid link">http://orcid.org/0000-0001-6952-1486</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Michael J. Eck</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael J. Eck</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</div><div class="loa-info-affiliations-info">Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</div></div><span class="conrtib-corresp"><strong>*</strong>M.J.E.: email, <a href="/cdn-cgi/l/email-protection#6c090f072c0f1e151f180d0042040d1e1a0d1e0842090819"><span class="__cf_email__" data-cfemail="bbded8d0fbd8c9c2c8cfdad795d3dac9cddac9df95dedfce">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Eck">Michael J. Eck</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00200&amp;href=/doi/10.1021%2Facs.jmedchem.0c00200" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 4293–4305</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 3, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 February 2020</li><li><span class="item_label"><b>Published</b> online</span>3 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 April 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00200" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00200</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4293%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDavid%2BE.%2BHeppner%252C%2BMarcel%2BG%25C3%25BCnther%252C%2BFlorian%2BWittlinger%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D8%26contentID%3Dacs.jmedchem.0c00200%26title%3DStructural%2BBasis%2Bfor%2BEGFR%2BMutant%2BInhibition%2Bby%2BTrisubstituted%2BImidazole%2BInhibitors%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4305%26publicationDate%3DApril%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00200"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2142</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00200" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;E. Heppner&quot;},{&quot;first_name&quot;:&quot;Marcel&quot;,&quot;last_name&quot;:&quot;Günther&quot;},{&quot;first_name&quot;:&quot;Florian&quot;,&quot;last_name&quot;:&quot;Wittlinger&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;A. Laufer&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Eck&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;4293-4305&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00200&quot;},&quot;abstract&quot;:&quot;Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in cancer therapy. Previous studies of trisubstituted imidazole inhibitors led to the serendipitous discovery of inhibitors that target the drug resistant EGFR(L858R/T790M/C797S) mutant with nanomolar potencies in a reversible binding mechanism. To dissect the molecular basis for their activity, we determined the binding modes of several trisubstituted imidazole inhibitors in complex with the EGFR kinase domain with X-ray crystallography. These structures reveal that the imidazole core acts as an H-bond acceptor for the catalytic lysine (K745) in the “αC-helix out” inactive state. Selective N-methylation of the H-bond accepting nitrogen ablates inhibitor potency, confirming the role of the K745 H-bond in potent, noncovalent inhibition of the C797S variant. Insights from these studies offer new strategies for developing next generation inhibitors targeting EGFR in non-small-cell lung &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00200&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00200" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00200&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00200" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00200&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00200" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00200&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00200&amp;href=/doi/10.1021/acs.jmedchem.0c00200" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00200" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00200" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00200%26sid%3Dliteratum%253Aachs%26pmid%3D32243152%26genre%3Darticle%26aulast%3DHeppner%26date%3D2020%26atitle%3DStructural%2BBasis%2Bfor%2BEGFR%2BMutant%2BInhibition%2Bby%2BTrisubstituted%2BImidazole%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D8%26spage%3D4293%26epage%3D4305%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290860" title="Solution chemistry">Solution chemistry</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292253" title="Imidazoles">Imidazoles</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/jmcmar.2020.63.issue-8/20200423/jmcmar.2020.63.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in cancer therapy. Previous studies of trisubstituted imidazole inhibitors led to the serendipitous discovery of inhibitors that target the drug resistant EGFR(L858R/T790M/C797S) mutant with nanomolar potencies in a reversible binding mechanism. To dissect the molecular basis for their activity, we determined the binding modes of several trisubstituted imidazole inhibitors in complex with the EGFR kinase domain with X-ray crystallography. These structures reveal that the imidazole core acts as an H-bond acceptor for the catalytic lysine (K745) in the “αC-helix out” inactive state. Selective N-methylation of the H-bond accepting nitrogen ablates inhibitor potency, confirming the role of the K745 H-bond in potent, noncovalent inhibition of the C797S variant. Insights from these studies offer new strategies for developing next generation inhibitors targeting EGFR in non-small-cell lung cancer.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72635" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72635" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Activating mutations within the kinase domain of the epidermal growth factor receptor (EGFR), including L858R and in-frame exon-19 deletions (del), drive tumor carcinogenesis in non-small-cell lung cancer (NSCLC) and are prognostic indicators for the clinical effectiveness for treatment with tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Although patients initially respond well to TKIs, drug resistance occurs due to the acquisition of the T790M “gatekeeper” mutation rendering TKIs ineffective due to increased ATP affinity within the kinase domain.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Development of a novel irreversible binding anilinopyrimidine inhibitor (WZ4002), containing a C797S-targeting acrylamide Michael acceptor, exhibited exquisite potency against the T790M mutant while minimally inhibiting WT EGFR.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> This tool compound provided proof of principle for mutant-selective irreversible inhibition of T790M-mutant EGFR, and subsequently the third generation EGFR TKI osimertinib was approved for treatment of NCSLC patients harboring T790M positive tumors<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> and more recently as a front-line therapy in untreated EGFR mutant NSCLC.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> However, in the context of T790M-positive NSCLC, patients acquire resistance to osimertinib through several mechanisms, including around 30–40% of patients acquiring an additional C797S mutation that renders third-generation TKIs incapable of forming their potency-enabling covalent bond.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Therefore, efforts to develop inhibitors targeting both EGFR(T790M) and EGFR(C797S) mutations represent a critical unmet need in the treatment of NSCLC.</div><div class="NLM_p">To overcome resistance to third-generation inhibitors via the acquisition of the C797S mutation, various drug discovery efforts have been dedicated to identification of novel scaffolds that selectively target this mutation.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> While screening for highly effective p38 MAP kinase inhibitors, trisubstituted imidazole compounds were discovered to exhibit off-target inhibition of EGFR.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Medicinal chemistry optimization and molecular docking approaches produced a series of reversible and irreversible trisubstituted imidazole-based compounds that effectively inhibited mutant EGFR (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <b>1</b>–<b>5</b>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Surprisingly, these molecules exhibited low nanomolar potency against EGFR(L858R/T790M/C797S) irrespective of whether they contained the covalent warhead.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> Subsequently, several examples of reversible ATP-competitive inhibitors targeting EGFR(del/T790/C797S) and/or EGFR(L858R/T790M/C797S) variants have been described, including brigatinib,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> 2-aryl-4-aminoquinazolines,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> pyrimidopyrimidinones,<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> pyrrolopyrimidines,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> 9-heterocyclylpurines,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and rationally designed macrocycles based on aminobenzimidazoles.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Despite these successes in developing trisubstituted imidazole EGFR(T790M/C797S) targeting reversible inhibitors, the structural basis for their potency for this drug resistant oncogenic EGFR variant remains unclear.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Trisubstituted imidazole inhibitor chemical structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this study, we structurally characterize the binding modes of reversible and irreversible binding trisubstituted imidazole EGFR inhibitors with X-ray crystallography to understand their targeting of the EGFR drug resistant mutant C797S. Crystal structures of inhibitors bound to both inactive and active EGFR kinases reveal that the imidazole moiety functions as a H-bond acceptor for the ε-ammonium group of the catalytic lysine (K745) in the “αC-helix out” inactive state, and blocking this interaction via the synthesis of selective imidazole N-methylation abolishes potency for EGFR(L858R/T790M/C797S). This H-bonding interaction with the EGFR kinase, which is not possible with WZ4002 or osimertinib but is observed in examples of other C797S inhibitors, is key for enabling strong, reversible binding rendering the trisubstituted imidazole molecules as effective inhibitors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20125" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20125" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We determined crystal structures of reversible (<b>1</b>, <b>2</b>) and irreversible binding (<b>3</b>–<b>5</b>) imidazole-based inhibitors (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) soaked into crystals of EGFR(T790M/V948R) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_002.pdf" class="ext-link">S1, and S2 and Table S1</a>).<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13−15)</a> The inclusion of the V948R variant enables crystallization of EGFR in the inactive state by precluding the formation of the activating asymmetric dimer. The structural hallmark of the inactive EGFR kinase is the outward arrangement of the αC-helix (“αC-helix out”), which is rotated inward due in the active “αC-helix in” asymmetric kinase dimer.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Expectedly, reversible imidazole inhibitors (<b>1</b> and <b>2</b>) bind to the ATP pocket anchored by H-bonds to kinase hinge via the pyrrolopyridine (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A,B). C797 at the periphery of the ATP binding site is distant from the inhibitor (∼5.0 Å) indicating that the binding modes of <b>1</b> and <b>2</b> are likely agnostic with respect to the C797S mutation. The imidazole group extends away from the hinge toward K745, the catalytic lysine, and the fluorophenyl group extends into the hydrophobic pocket positioned between the T790M gatekeeper mutation and K745. The imidazole N3 forms an H-bond with K745, which is also H-bonded to D855 of the DFG motif. The flexible functional groups extending from the imidazole C2 adopt subtly different conformations in the four copies of the EGFR kinase domain in the asymmetric unit of the crystal structures of <b>1</b> and <b>2</b>. As representative examples, the propanol group of <b>1</b> engages in H-bonding with D855 and N842, while the propyl ether moiety of <b>2</b> is incapable of such interactions and forms an intramolecular H-bond to the imidazole N1. Generally, this experimentally determined binding mode of the inhibitor is in good agreement with the previously reported poses generated with <i>in silico</i> docking approaches.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13−15)</a> Additionally, in both cases electron density difference maps indicate the presence of an ion bound underneath the EGFR kinase P-loop directly interacting with K745 in all cases and R841 in the case of <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_002.pdf" class="ext-link">Figures S2 and S3</a>). While we have not experimentally determined the identity of this ion, we have modeled this density as a chloride ion since it is closely associated with positive side chains and backbone amides and a water molecule was not sufficiently electron-dense to model it. We also note the high concentration of chloride present in the purification and crystallization buffer.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures and binding modes of <b>1</b> (A, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5N">6V5N</a>), <b>2</b> (B, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5P">6V5P</a>), <b>3</b> (C, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6O">6V6O</a>), <b>4</b> (D, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6K">6V6K</a>), and <b>5</b> (E, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V66">6V66</a>) in complex with EGFR(T790M/V948R). The V948R mutation enables the kinase domain to crystallize in the inactive state.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also determined structures of inactive “αC-helix out” EGFR(T790M/V948R) crystals soaked with irreversible compounds <b>3</b>–<b>5</b>, which contain a 2-aminopyridine phenylacrylamide Michael acceptor to target C797S (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C–E). Indeed, crystal structure electron density maps indicate that <b>3</b>–<b>5</b> form their expected covalent bonds with C797 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_002.pdf" class="ext-link">Figure S2</a>). The phenylacrylamide group is found to engage in intramolecular H-bonding with the imidazole N1 as predicted by molecular modeling.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The formation of the covalent bond to C797 does not significantly alter the inhibitor binding mode in comparison to the reversibly binding compounds (<b>1</b> and <b>2</b>), indicating that both covalent and noncovalent imidazole inhibitors bind EGFR involving conserved H-bonds to K745.</div><div class="NLM_p">Active “αC-helix in” kinase structures were determined through compound soaking with crystals of WT EGFR kinase domain. We were successful in obtaining crystal structures of the irreversible inhibitors (<b>3</b>–<b>5</b>) but failed to obtain structures in complex with reversibly binding compounds (<b>1</b> and <b>2</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). As expected, these imidazole-based inhibitors bind to the kinase hinge in essentially the same manner observed in the inactive-state complexes (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_002.pdf" class="ext-link">Figure S4, and Table S2</a>). Due to the inward rotation of that αC-helix (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, red) in the kinase active state, the E762 carboxylate side chain is now positioned toward K745, establishing a salt bridge competing the K745 ammonium group away from the imidazole. The crystal structures of <b>3</b> and <b>5</b> show a covalent bond formed between the inhibitor and C797, while this is not the case for <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The absence of a covalent bond with <b>4</b> is unclear but may be due to differences in compound reactivity and potency (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_002.pdf" class="ext-link">S4</a>). A structural overlay of the “αC-helix out” inactive (green) and “αC-helix in” active (blue) kinase crystal structures in complex with <b>3</b> illustrates how K745 can toggle between functions as an H-bond donor to the imidazole and E762 carboxylate as dependent on the orientation of the kinase αC-helix (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures and binding modes of <b>3</b> (A, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VH4">6VH4</a>), <b>4</b> (B, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VHN">6VHN</a>), and <b>5</b> (C, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VHP">6VHP</a>) bound to WT EGFR kinase domain in the active state.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structural overlay of <b>3</b> crystallized in complex with EGFR(T790M/V948R) (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6O">6V6O</a>) in the inactive state and WT EGFR (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VH4">6VH4</a>) in the active state.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SeO<sub>2</sub>, 1,4-dioxane, H<sub>2</sub>O, 60 °C to rf (73%); (b) 4-methoxybutanal, NH<sub>4</sub>OAc, MeOH, rt (16%); (c) NaH, MOM-Cl, THF, 0 °C to rt (77%); (d) <i>N</i>-iodosuccinimide, MeOH, 0°C (94%); (e) <i>i</i>-PrMgCl·LiCl, Sn(Bu)<sub>3</sub>Cl, THF (quant); (f) 4-chloro-1-(methoxymethyl)-2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine, Pd(OAc)<sub>2</sub>, XPhos, 1,4-dioxane, rf (52%); (g) HCl(aq), MeOH, rf (58%).</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Impact of N-Methylation of <b>4</b> on Biochemical IC<sub>50</sub></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0009.gif" alt="" id="gr8" /></img><div></div></div><div class="NLM_p">We synthesized <b>2</b> according to an improved sequence of our recently published synthetic procedure starting from commercially available 4-fluoro acetophenone (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> After MOM-protection of the  corresponding imidazole core <b>10</b>, we applied a versatile sequence of core halogenation followed by halogen-magnesium exchange  with the Turbo-Hauser base <i>i</i>-PrMgCl·LiCl and subsequent stanylation, which gave access to the key intermediate <b>12</b>. We applied a Stille coupling with the corresponding protected heterocycle to obtain the final compound after acidic deprotection in suitable yields. To assess the functional relevance of the imidazole-K745 H-bond for inhibitor potency, we prepared both regioisomeric <i>N</i>-methylimidazole derivatives based on compound <b>4</b>. To this end, we have synthesized compounds <b>4</b>, <b>6</b> and <b>7</b> according to our previously reported procedures.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> For the N3-regioselective introduction of the methyl group, an N1-SEM protected precursor was methylated with methyl trifluoromethanesulfonate according to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Subsequent acidic deprotection of the intermediate imidazolium trifluoromethanesulfonate yielded the desired methylated precursor in one pot. The identity of the desired <i>N</i>-methyl regioisomer was determined by X-ray crystallography (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_002.pdf" class="ext-link">Table S3 and Figure S4</a>). Subsequent Suzuki cross-coupling reaction, followed by a deprotection step and a Buchwald–Hartwig aryl amination yielded the final compound analogous to our previously described route (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>S</i>-methylisothiourea, NaHCO<sub>3</sub>, THF/water, reflux (50%); (b) NaH, SEM-Cl, THF, 0 °C to rt (91%); (c) NBS, THF, −30°C (85%); (d) MeOtf, DCM, TFA, rt (70%); (e)<i>N</i>-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetamide, P(<i>t</i>-Bu)<sub>3</sub> Pd G3, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane/water, 50°C (39%); (f) NaOH, MeOH/water, 50 °C (88%); (g) <i>N</i>-(3-bromo-4-methoxyphenyl)acrylamide, Brettphos Pd G3, Cs<sub>2</sub>CO<sub>3</sub>, t-BuOH/1,4-dioxane, rf (67%).</p></p></figure><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) urotropine, chloroform, 50 °C, then EtOH, HCl(aq), rf (97%); (b) KSCN, HOAc, rf (71%); (c) 2-bromoethan-1-ol, K<sub>2</sub>CO<sub>3</sub>, MeOH, rt (quant); (d) NaH, SEM-Cl, THF, 0 °C (67%); (e) NBS, MeCN, −30°C (quant); (f) NaH, MeI, THF, −15°C (75%); (g) <i>N</i>-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetamide, P(<i>t</i>-Bu)<sub>3</sub> Pd G3, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane/water, 50 °C (56%%); (h) NaOH, THF/water, 50°C (59%); (i) <i>N</i>-(3-bromo-4-methoxyphenyl)acrylamide, Brettphos Pd G3, Cs2CO3, <i>t</i>-BuOH/1,4-dioxane, rf (44%); (j) HCl in EtOH 2.5 M, rt (70%).</p></p></figure><div class="NLM_p last">Biochemical EGFR inhibitory capacities at 50% activity (IC<sub>50</sub>) measurements were performed with <b>4</b> and selectively N-methylated derivatives <b>6</b> and <b>7</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_002.pdf" class="ext-link">S4</a>). Methylation of N1 is found to significantly impair the potency of the inhibitor against EGFR(L858R/T790M), indicating that the intramolecular H-bond formed between the imidazole and the acrylamide is structurally required for inhibitor binding. Correspondingly, methylation of N3, the nitrogen involved in H-bonding to K745 in the inactive “αC-helix out” kinase, does not significantly alter inhibition of EGFR(L858R/T790M), showing that the potency of <b>4</b> does not depend on the K745 H-bond and more likely is driven by the formation of the C797-mediated covalent bond. It should be noted that methylation at N3 produces an imidazole derivative that would not form an identical intramolecular H-bond with the acrylamide as seen in the crystal structures of <b>4</b>. The impact of this alternative isomer is likely a minor effect, which is likely since <b>7</b> exhibits low nanomolar potency against EGFR(L858R/T790M) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In the case of EGFR(L858R/T790M/C797S), where <b>4</b> inhibits entirely through reversible binding, it is found that N-methylation at either N1 or N3 completely abrogates compound potency, demonstrating the critical role for both imidazole nitrogens. Our inactive “αC-helix out” crystal structures (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) demonstrate that the N3 imidazole is engaged in H-bonding with K745, whereas this interaction is not present in the active kinase state (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Additionally, there is a possibility for N-methylation of these inhibitors to have diminished binding affinity due to steric hindrance with the EGFR protein. The binding mode of <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>D and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B) indicates that N-methylation at N1 will not interfere with EGFR, as this nitrogen is pointed away from EGFR and out into solvent, while N-methylation at N3 could sterically clash with K745 in the inactive “αC-helix out” state. Since the H-bond to K745 is a conserved feature in all of our inactive “αC-helix out” structures, we expect any resulting steric hindrance from the N3 methylation to be minimal and the dominant component of inhibitor reversible binding is the H-bond. Therefore, these collective findings demonstrate that reversible binding trisubstituted imidazole inhibitors acquire stronger affinity to the EGFR kinase through an H-bond with K745 of the inactive kinase state, which enables inhibitor potency against EGFR(L858R/T790M/C797S).</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67326" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67326" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">While osimertinib is a highly effective therapeutic for NSCLC driven by sensitive EGFR mutants, including the treatment-acquired T790M resistance mutation, the C797S mutation abolishes its efficacy as well as that of other third-generation EGFR TKIs. Inhibitors based on a trisubstituted imidazole scaffold, initially optimized to target EGFR(L858R/T790M), were found to unexpectedly exhibit low nanomolar activity against EGFR(L858R/T790M/C797S).<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13−15)</a> To determine the structural basis for their unique ability to target this drug resistant EGFR mutation through a noncovalent mechanism, we determined the binding modes of several trisubstituted imidazole inhibitors in complex with the EGFR kinase domain using X-ray crystallography. While all inhibitors bind to the EGFR kinase through conserved H-bonding to the kinase hinge, as expected, marked differences with respect to interactions with the imidazole are observed depending on the state of the kinase. In the inactive “αC-helix out” state, the imidazole inhibitors all are directly involved in H-bonding to the catalytic lysine (K745) through the imidazole N3 nitrogen, whereas the inward rotation of the αC-helix in the active state results in a H-bond with E762, which apparently outcompetes K745 from the inhibitor. Overall, these structures are consistent with previous crystal structures of related pyridinylimidazole inhibitors in complex with p38<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> and JNK3.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> To assess the dependence of inhibitor potency on the ability of K745 to form an H-bond with the imidazole, we synthesized a variant of <b>4</b> with selective N-methylation at either of the two imidazole nitrogens. Biochemical potencies with selective N-methylation at the imidazole N3 nitrogen of <b>4</b> was found to minimally impact inhibitor binding to EGFR(L858R/T790M) while entirely ablating inhibitor efficacy for EGFR(L858R/T790M/C797S). Collectively, our findings suggest that the imidazole N3-K745 H-bond, present only in the inactive “αC-helix out” kinase, is responsible for driving reversible binding and inhibition of EGFR(L858R/T790M/C797S).</div><div class="NLM_p">Our structures demonstrate the key molecular features of the imidazole compounds in directing reversible inhibition of the EGFR(L858R/T790M/C797S), which resists inhibition by third-generation EGFR TKIs. Third-generation EGFR TKIs such as WZ4002 and osimertinib lack the ability to make this H-bond and reversibly bind EGFR more weakly compared to imidazole-based inhibitors, rendering them ineffective against the C797S mutation (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). This is consistent as the imidazole inhibitors are found to inhibit EGFR with enhanced <i>K</i><sub>i</sub> of ∼15-fold compared to osimertinib.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> While reversible inhibitors that bind EGFR more tightly may be able to overcome the drug-resistant C797S mutant, it is more so a liability with respect to developing a targeted drug since strong interactions with conserved amino acids will diminish the ability for the inhibitor to preferentially bind to the mutant compared to the wild-type kinase. Since this is the case for the trisubstitued imidazole inhibitors in this study, further optimization is required to achieve mutant selectivity.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Structural overlay of EGFR crystals structures in complex with <b>1</b> (green, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5N">6V5N</a>) and WZ4002 (magenta, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>). (B) EGFR crystal structures of JN3229 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZT0">5ZT0</a>) and (C) aminobenzimidazole compound <b>1</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B">6S9B</a>) from ref <a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to the trisubstituted imidazoles, several small molecules have been subsequently reported to inhibit C797S-containing EGFR mutants operating through noncovalent mechanisms.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Analysis of all structurally characterized inhibitor binding modes reveals that many of these compounds function as a H-bond acceptor for K745. The inhibitor brigatinib, originally developed as an ALK inhibitor, was shown to exhibit off-target inhibition of other kinases, including EGFR(del/T790M/C797S), which is maximally effective if dosed in combination with an anti-EGFR antibody cetuximab.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> While no structure of brigatinib bound to EGFR is reported to our knowledge, the crystal structure of brigatinib in complex with ALK in the active state shows that the inhibitor phosphine oxide moiety is pointing toward the catalytic lysine (K1150), potentially confirming enhanced potency in a similar mechanism as the trisubstituted imidazoles.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Related compounds containing a sulfonamide in the position of the phosphine oxide effectively inhibit ALK and EGFR and, based on docking models, are expected to form H-bonds with the respective EGFR/ALK catalytic lysine in the active state.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Additionally, pyrimidopyrimidinone inhibitors were developed to target EGFR(C797S), and cocrystal structures indicate that the inhibitor ketone is positioned as a H-bond acceptor with K745 through a bridging water molecule in the active kinase (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B).<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> It is likely that in the inactive “αC-helix out” kinase state such molecules form a stronger, more direct H-bond with K745 operating through a similar mechanism to the trisubstituted imidazole inhibitors (<b>1</b>, <b>2</b>). A more distinct example is the recent report of a macrocyclic aminobenzimidazole inhibitor (BI-4020) that selectively inhibits T790M/C797S-containing EGFR due to the compounds macrocyclic structure with marked efficacy for regressing EGFR(del/T790M/C797S) tumor xenografts <i>in vivo</i>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> While the best performing macrocycle inhibitor has not been structurally characterized, crystal structures of several precursor molecules indicate that the mutant-selective aminobenzimidazole obtains their strong potency through direct H-bonds with K745 and T854 in the active kinase state and is potentially made mutant selective due to limited steric interference with T790M (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Compared to our structures here, the lack of mutant selectivity in the imidazole inhibitors may be due to steric clashing between T790M and the fluorophenyl group on C4 of the imidazole inhibitor, requiring the methionine to adopt a forced conformation (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A, C).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In addition, a distinct strategy has also emerged, which involves designing EGFR drug molecules that purposefully form strong H-bonds with the mutant C797S serine alcohol. Inhibitors consisting of 2-aryl-4-aminoquinazoline<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and 9-heterocyclyl substituted 9<i>H</i>-purine<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> scaffolds have been reported to exhibit selectivity for EGFR(T790M/C797S) mutations. It is clear that an EGFR inhibitor operating through a noncovalent mechanism can overcome the C797S mutation through the engineering of additional intermolecular interactions with the kinase, although with the caveat that targeting conserved residues, such as K745, will negatively impact the inhibitor mutant selectivity as well as overall kinase selectivity.</div><div class="NLM_p last">As an alternative to ATP-competitive TKIs, a new class of highly mutant-selective EGFR allosteric inhibitors (EAIs) has been developed to bind within an allosteric pocket of the inactive EGFR kinase made accessible by the oncogenic EGFR(L858R/T790M) mutations.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29−31)</a> Importantly, the most effective single agent of the EAIs (JBJ-04-125-02) exhibits synergy <i>in vivo</i> with the third-generation TKI osimertinib, potentially in a cooperative mechanism involving simultaneous inhibitor binding of the EGFR kinase domain.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Efforts to completely span these two sites have resulted in a compound consisting of a chimeric fusion of an EAI scaffold (EAI045) with a TKI (vandetinib) that exhibited low nanomolar potency against EGFR(L858R/T790M/C797S), however at similar potencies for the WT kinase.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Although this is a single example, it is probable that compounds consisting of elements of effective TKIs and mutant-selective allosteric inhibitors may represent a productive avenue to produce a C797S-targeting reversible inhibitor with enhanced mutant selectivity.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have employed a combination of structural and biochemical studies to define the molecular basis for noncovalent inhibition of EGFR(L858R/T790M/C797S) by trisubstituted imidazole inhibitors. The reversible binding imidazole inhibitors overcome the C797S mutation through stabilization of the inactive kinase state anchored by an imidazole-dependent H-bond with K745. Insights from this work demonstrate the diversity of avenues available for the development of next generation therapies in EGFR mutant NSCLC. Future directions of these inhibitors are dependent on further optimization for compounds with selectivity for the oncogenic mutants and sparingly limited potency against the WT EGFR kinase.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82550" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82550" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> General Information</h3><div class="NLM_p last">Reagents and solvents were purchased from Sigma-Aldrich, Acros, CombiBlocks or Fluorochem. Commercially available reagents and solvents were used as received without any further purification or drying procedures unless otherwise noted. All NMR spectra were measured with a Bruker Avance 200, with a Bruker Avance 400, or with a Bruker Avance 600 MHz (research group of Prof. Dr. Pichler, Department of Preclinical Imaging and Radio Pharmacy, Tübingen). Solvents for NMR are noted in the experimental procedures for each compound. Residual solvent peaks were used to calibrate the chemical shifts. Chemical shifts (δ) are reported in parts per million (ppm). LRMS results were determined by either TLC-MS (Advion expressions) (ESI) or FAB-MS at the Mass Spectrometry Department, Institute of Organic Chemistry, Eberhard Karls Universität Tübingen. ESI-HRMS results were obtained from the research group of Prof. Dr. Lämmerhofer (Pharmaceutical (Bio)-Analyses), University of Tübingen. TLC analyses were performed on fluorescent silica gel 60 F254 plates (Merck). Compound spots were identified via UV illumination at 254 and 366 nm or developed with a suitable stain. For column chromatography either Davisil LC60A 20–45 μm silica from Grace Davison or Geduran Si60 63–200 μm silica from Merck was used as stationary phase. VWR LaFlash automated flash chromatography system or standard glass columns were used for flash chromatography. The purity of tested compounds was determined via reverse phase high performance liquid chromatography (HPLC) on Agilent 1100 LC equipped with a UV diode array detector (DAD, detection at 230 and 254 nm) and in all cases was determined to be >95%. The chromatographic separation was performed on a Phenomenex Luna 5u C8 column (150 mm × 4.6 mm, 5 μm) at 35 °C oven temperature. The injection volume was 5 μL and the gradient of the used method was the following (flow, 1.5 mL/min): 0.01 M KH<sub>2</sub>PO<sub>4</sub>, pH 2.3 (solvent A); methanol (solvent B); 40% B to 85% B in 8 min, 85% B for 5 min, 85% to 40% B in 1 min, 40% B for 2 min, stop time 16 min.</div></div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Synthesis. 2-(4-Fluorophenyl)-2-oxoacetaldehyde (<b>8</b>)</h3><div class="NLM_p last">Selenium dioxide (14.89 g, 134.2 mmol) in 200 mL of 1,4-dioxane and 6 mL of water was heated to 60 °C until a clear solution formed. Then 4′-fluoroacetophenone (16.85 g, 14.8 mL, 122.0 mmol) was added and the solution was refluxed for 16 h. After cooling to room temperature, the solid was filtered. The filtrate was evaporated in vacuum to yield a yellow oil that was distilled at 85 °C at 1 mbar to give the pure product in 73% yield (13.52 g, 88.9 mmol). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 9.62 (s, 1H), 8.47–7.84 (m, 2H), 7.19 (t, <i>J</i> = 8.7 Hz, 2H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 189.6, 186.0, 167.1 (d, <i>J</i> = 258.8 Hz), 133.6 (d, <i>J</i> = 9.8 Hz), 128.3 (d, <i>J</i> = 3.0 Hz), 116.5 (d, <i>J</i> = 22.0 Hz). FAB: calculated, 152.03 for C<sub>13</sub>H<sub>10</sub>N<sub>2</sub>. Found: 153.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> 4-(4-Fluorophenyl)-2-(3-methoxypropyl)-1<i>H</i>-imidazole (<b>9</b>)</h3><div class="NLM_p last">A solution of <b>8</b> (3.09 g, 20.3 mmol) in methanol was added dropwise over 30 min to a stirred solution of 4-methoxybutanal (2.07 g, 20.3 mmol) and NH<sub>4</sub>OAc (7.51 g, 97.4 mmol) in methanol. The mixture was stirred overnight. The reaction was quenched by the addition of a saturated aqueous NaHCO<sub>3</sub> solution and stirred for 30 min. Methanol was removed by rotary evaporation and the residual aqueous phase extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified by flash chromatography (ethyl acetate + 2% NH<sub>3</sub> in MeOH (7 M)) to give an orange gum in 16% yield (761 mg, 3.25 mmol). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 9.92 (s, 1H), 7.71–7.55 (m, 2H), 7.13 (s, 1H), 7.10–6.96 (m, 2H), 3.47 (t, <i>J</i> = 5.8 Hz, 2H), 3.37 (s, 3H), 2.88 (t, <i>J</i> = 6.9 Hz, 2H), 2.04–1.90 (m, 2H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 161.8 (d, <i>J</i> = 245.0 Hz), 149.2, 129.9 (d, <i>J</i> = 2.7 Hz), 126.3 (d, <i>J</i> = 7.9 Hz), 115.6 (d, <i>J</i> = 21.5 Hz), 72.6, 58.8, 28.0, 26.3. TLC-MS (ESI+) (<i>m</i>/<i>z</i>): calculated, 234,12 for C<sub>13</sub>H<sub>15</sub>FN<sub>2</sub>O. Found: 234.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> 4-(4-Fluorophenyl)-1-(methoxymethyl)-2-(3-methoxypropyl)-1<i>H</i>-imidazole (<b>10</b>)</h3><div class="NLM_p last">A cooled solution of <b>9</b> (719 mg, 3.06 mmol) in 20 mL of dry DMF was treated portionwise with sodium hydride (60%, 3.52 mmol) and stirred for 30 min at 0 °C. MOM-Cl (2.5 M in toluene, 3.06 mmol, 1.22 mL) was added dropwise to the stirred solution. The mixture was stirred for 10 min at 0 °C and for 30 min at room temperature. The reaction was quenched by the addition of a saturated aqueous NH<sub>4</sub>Cl solution and stirred for 30 min. The aqueous mixture was extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified by gradient flash chromatography with 100% DCM to DCM/MeOH 93:7 to give the pure product as a yellow oil in 77% yield (657 mg, 2.36 mmol). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 7.77–7.64 (m, 2H), 7.14 (s, 1H), 7.10–6.95 (m, 2H), 5.20 (s, 2H), 3.46 (t, <i>J</i> = 6.1 Hz, 2H), 3.34 (s, 3H), 3.31 (s, 3H), 2.91–2.79 (m, 2H), 2.17–1.99 (m, 2H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 162.0 (d, <i>J</i> = 244.9 Hz), 149.2, 139.5, 130.5 (d, <i>J</i> = 3.2 Hz), 126.5 (d, <i>J</i> = 7.9 Hz), 115.4 (d, <i>J</i> = 21.5 Hz), 114.9, 76.7, 71.7, 58.6, 56.1, 28.3, 23.5. TLC-MS (ESI+): calculated, 278.14 for C<sub>15</sub>H<sub>19</sub>FN<sub>2</sub>O<sub>2</sub>. Found: 278.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> 4-(4-Fluorophenyl)-5-iodo-1-(methoxymethyl)-2-(3-methoxypropyl)-1<i>H</i>-imidazole (<b>11</b>)</h3><div class="NLM_p last">To a cooled solution of <b>10</b> (284 mg, 1.09 mmol) in 10 mL of MeCN was added dropwise at 0 °C <i>N</i>-iodosuccinimide (281 mg, 1.25 mmol) dissolved in 5 mL of MeCN. The solution was stirred for 10 min at 0 °C, the ice bath was removed, and stirring continued overnight at room temperature. The solvent was removed in vacuum and the oily residue purified by gradient flash chromatography (from 100% DCM to DCM/MeOH 97:3) to give the pure product as an orange oil in 94% yield (412 mg, 1.02 mmol). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 7.90–7.79 (m, 2H), 7.15–7.02 (m, 2H), 5.30 (s, 2H), 3.47 (t, <i>J</i> = 6.0 Hz, 2H), 3.38 (s, 3H), 3.34 (s, 3H), 3.00–2.89 (m, 2H), 2.16–2.00 (m, 2H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 162.4 (d, <i>J</i> = 246.5 Hz), 152.6, 142.9, 130.1 (d, <i>J</i> = 3.2 Hz), 129.6 (d, <i>J</i> = 8.1 Hz), 115.2 (d, <i>J</i> = 21.5 Hz), 77.4, 71.6, 67.7, 58.7, 56.2, 28.1, 24.5. TLC-MS (ESI+) (<i>m</i>/<i>z</i>): calculated, 404.04 for C<sub>15</sub>H<sub>18</sub>FIN<sub>2</sub>O<sub>2</sub>. Found: 404.7 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> 4-(4-Fluorophenyl)-1-(methoxymethyl)-2-(3-methoxypropyl)-5-(tributylstannyl)-1<i>H</i>-imidazole (<b>12</b>)</h3><div class="NLM_p last">A cooled solution of <b>11</b> (513 mg, 1.27 mmol) in 15 mL of dry THF was treated with a solution of <i>i</i>-PrMgCl·LiCl (1.3 M in THF, 1.65 mmol, 1.27 mL) dropwise at 0 °C. The mixture was stirred for 30 min at 0 °C. Next, tributyltin chloride (1.78 mmol, 482 μL) was added and the reaction stirred for 10 min at 0 °C. The ice bath was removed and the solution stirred at room temperature overnight. The reaction was quenched by the addition of an aqueous NaHCO<sub>3</sub> solution. The aqueous mixture was extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was used in the next step without further purification or characterization of the mixture.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> 4-(4-(4-Fluorophenyl)-1-(methoxymethyl)-2-(3-methoxypropyl)-1<i>H</i>-imidazol-5-yl)-1-(methoxymethyl)-2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>13</b>)</h3><div class="NLM_p last">A mixture of Pd(OAc)<sub>2</sub> (2 mol %) and XPhos (6 mol %) was dissolved in dry and degassed 1,4-dioxane (5 mL) under an atmosphere of argon and stirred for 30 min at room temperature. To this solution, crude <b>12</b> and 4-chloro-1-(methoxymethyl)-2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (690 mg, 2.54 mmol) dissolved in 10 mL of 1,4-dioxane were added. The mixture was refluxed until complete consumption of the azaindol. After cooling to room temperature, a 40% aqueous KF solution was added and the mixture stirred for 1 h at room temperature. The aqueous mixture was extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified with flash chromatography (DCM/MeOH 97:3 + 2% AcOH) to give the pure product as a yellow gum in 52% yield (170 mg, 0.33 mmol). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 8.66 (s, 2H), 8.43 (d, <i>J</i> = 5.0 Hz, 1H), 7.62–7.51 (m, 2H), 7.48–7.32 (m, 5H), 7.16 (d, <i>J</i> = 5.0 Hz, 1H), 6.92–6.78 (m, 2H), 6.18 (s, 1H), 5.63 (dd, <i>J</i> = 26.9, 10.3 Hz, 2H), 5.08 (dd, <i>J</i> = 37.3, 10.6 Hz, 2H), 3.58–3.46 (m, 5H), 3.37 (s, 3H), 3.10 (s, 3H), 3.00 (t, <i>J</i> = 7.5 Hz, 2H), 2.25–2.11 (m, 2H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 162.0 (d, <i>J</i> = 245.7 Hz), 150.6, 150.2, 143.3, 137.3, 131.4, 130.4, 130.0 (d, <i>J</i> = 2.8 Hz), 129.3, 129.1, 129.0, 128.9, 124.8, 120.7, 119.1, 115.2 (d, <i>J</i> = 21.4 Hz), 100.5, 74.4, 73.0, 71.9, 58.6, 56.7, 55.9, 28.3, 23.8. TLC-MS (ESI+) (<i>m</i>/<i>z</i>): calculated, 514.24 for C<sub>30</sub>H<sub>31</sub>FN<sub>4</sub>O<sub>3</sub>. Found: 514.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 4-(4-(4-Fluorophenyl)-2-(3-methoxypropyl)-1<i>H</i>-imidazol-5-yl)-2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>2</b>)</h3><div class="NLM_p last">A solution of <b>13</b> (170 mg, 0,33 mmol) in 5 mL of methanol and 5 mL of concentrated hydrochloric acid was stirred under reflux for 24 h. After complete conversion, the mixture was cooled to room temperature and neutralized with a saturated aqueous solution of K<sub>2</sub>CO<sub>3</sub>. The aqueous mixture was extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified with gradient flash chromatography (from 100% DCM to DCM/MeOH 90:10) to give the pure product as a yellow solid in 58% yield (82 mg, 0.19 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.36 (s, 1H), 12.17 (s, 1H), 8.16 (s, 1H), 7.77 (d, <i>J</i> = 7.4 Hz, 2H), 7.49–7.37 (m, 4H), 7.35–7.28 (m, 1H), 7.22–7.08 (m, 2H), 7.04 (d, <i>J</i> = 4.7 Hz, 1H), 6.55 (s, 1H), 3.45 (t, <i>J</i> = 5.9 Hz, 2H), 3.28 (s, 3H), 2.79 (t, <i>J</i> = 7.4 Hz, 2H), 2.09–1.95 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.1 (d, <i>J</i> = 243.8 Hz), 150.5, 148.8, 142.7, 137.7, 131.5, 129.3, 129.3, 128.8, 127.9, 125.1, 118.3, 115.1 (d, <i>J</i> = 21.4 Hz), 114.9, 97.9, 71.3, 57.8, 27.9, 24.6. TLC-MS (ESI−) (<i>m</i>/<i>z</i>): calculated, 426.19 for C<sub>26</sub>H<sub>23</sub>FN<sub>4</sub>O. Found: 425.0 [M–H]<sup>−</sup>.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 2-(4-Fluorophenyl)-2-oxoethan-1-aminium Chloride (<b>14</b>)</h3><div class="NLM_p last">2-Bromo-1-(4-fluorophenyl)ethan-1-one (7.9 g, 36.6 mmol) and urotropine (5.6 g, 39.9 mmol) were dissolved in 150 mL of dry chloroform and stirred at 50 °C for 2 h. The precipitate was removed by filtration and washed with chloroform and ethanol. The solid was dissolved in 150 mL of absolute ethanol and 20 mL of concentrated hydrochloric acid and refluxed for 2 h. The mixture was filtered and the filtrate was evaporated to dryness to give the pure product as a white solid in 97% yield (6.7 g, 35.2 mmol). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 3H), 8.22–8.05 (m, 2H), 7.47–7.38 (m, 2H), 4.58 (s, 2H). 13C NMR (50 MHz, DMSO-d6) δ 191.78, 165.97 (d, <i>J</i> = 253 Hz), 131.75 (d, <i>J</i> = 9.8 Hz), 130.82 (d, <i>J</i> = 3.6 Hz), 116.46 (d, <i>J</i> = 22.2 Hz), 45.08.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 4-(4-Fluorophenyl)-1,3-dihydro-2<i>H</i>-imidazole-2-thione (<b>15</b>)</h3><div class="NLM_p last">A suspension of <b>14</b> (2.0 g, 10.7 mmol) and potassium thiocyanate (2.61 g, 26.8 mmol) in 15 mL of glacial acid was refluxed for 1 h. After cooling to 0 °C and the addition of water, the precipitated solid was collected by filtration. The solid was washed with water and dried in vacuum overnight to give the product as a pale yellow solid in 71% yield (1.5 g, 7.6 mmol). The obtained product was used without further purification. LRMS (ESI-MS): 193.1 [M – H]<sup>−</sup>. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.55 (s, 1H), 12.16 (s, 1H), 7.79–7.65 (m, 2H), 7.37 (s, 1H), 7.23 (t, <i>J</i> = 8.7 Hz, 2H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.14, 161.63 (d, <i>J</i> = 245 Hz) 128.52, 126.34 (d, <i>J</i> = 8.3 Hz), 125.34 (d, <i>J</i> = 3.0 Hz), 116.12 (d, <i>J</i> = 21.9 Hz), 112.44.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 2-((4-(4-Fluorophenyl)-1<i>H</i>-imidazol-2-yl)thio)ethan-1-ol (<b>16</b>)</h3><div class="NLM_p last">Intermediate <b>15</b> (1.0 g, 5.15 mmol) was dissolved in 20 mL of dry methanol. Potassium carbonate (890 mg, 6.44 mmol) was added to the solution at room temperature under vigorous stirring. The resulting suspension was stirred for 30 min at room temperature. 2-Bromoethanol (402 μL, 5.67 mmol) was added, and the suspension was stirred at room temperature overnight. After complete reaction, water and a saturated NH<sub>4</sub>Cl solution were added. The aqueous mixture was extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The obtained pure product was used without further purification. After washing with <i>n</i>-pentane and drying overnight, the product was obtained in quantitative yield. LRMS (ESI-MS): 237.0 [M – H]<sup>−</sup>. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.39 (s, 1H), 7.86–7.70 (m, 2H), 7.65 (s, 1H), 7.26–7.13 (m, 2H), 5.14 (s, 1H), 3.76–3.60 (m, 2H), 3.16 (t, <i>J</i> = 6.5 Hz, 2H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.24 (d, <i>J</i> = 243 Hz), 140.67, 140.41, 131.24, 126.28 (d, <i>J</i> = 8.0 Hz), 115.61 (d, <i>J</i> = 21.1 Hz), 114.85, 61.06, 36.11.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 2-((4-(4-Fluorophenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)thio)ethan-1-ol (<b>17</b>)</h3><div class="NLM_p last">To a solution of <b>16</b> (965 mg, 4.05 mmol) in dry THF (20 mL) was added sodium hydride (60%, 4.45 mmol) at −15 °C under vigorous stirring. The cooling bath was removed and the mixture warmed to room temperature over 30 min. The solution was again cooled to −15 °C, and SEM-Cl (716 μL, 4.05 mmol) was added dropwise. After complete consumption of the starting material, brine was added. The aqueous mixture was extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude mixture of regioisomers was dissolved in MeCN (2 mL) and treated with a catalytic amount of SEM-Cl (5 mol %). The solution was stirred at 70 °C overnight. After cooling to room temperature, the solvent was removed in vacuum. The crude product was purified with gradient flash chromatography (from 100% <i>n</i>-hexane to <i>n</i>-hexane/ethyl acetate 3:2) to give the pure product as a pale yellow oil in 67% yield (1.03 g, 2.71 mmol). LRMS (ESI-MS): 369.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 7.88–7.59 (m, 2H), 7.30 (s, 1H), 7.18–6.98 (m, 2H), 5.49–5.27 (m, 3H), 4.14–4.04 (m, 2H), 3.68–3.53 (m, 2H), 3.33–3.23 (m, 2H), 1.04–0.93 (m, 2H), 0.04 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 162.10 (d, <i>J</i> = 246 Hz), 143.50, 140.74, 128.88 (d, <i>J</i> = 3.1 Hz), 126.31 (d, <i>J</i> = 8.3 Hz), 116.21, 115.51 (d, <i>J</i> = 21.5 Hz), 66.64, 63.72, 37.02, 17.64, −1.48.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 2-((5-Bromo-4-(4-fluorophenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)thio)ethan-1-ol (<b>18</b>)</h3><div class="NLM_p last">To a cooled solution of <b>17</b> (1.0 g, 2.71 mmol) in 30 mL of MeCN was added dropwise at −30 °C <i>N</i>-bromosuccinimide (507 mg, 2.85 mmol) dissolved in 15 mL of MeCN. The solution was stirred for 1 h at −30 °C, the ice bath was removed, and stirring continued at room temperature until complete consumption of the starting material. Saturated NaHCO<sub>3</sub> solution and solid sodium thiosulfate were added, and the mixture was stirred for 10 min. The aqueous mixture was extracted three times with ethyl acetate. The combined organic layers were washed with saturated NaHCO<sub>3</sub> solution, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The obtained pure product was used without further purification. The product was isolated as a yellow oil in 64% yield (771 mg, 0.64 mmol). LRMS (ESI-MS): 447.1/449.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.81–7.54 (m, 2H), 7.54–7.26 (m, 2H), 5.55 (s, 2H), 3.96–3.40 (m, 7H), 0.85 (t, <i>J</i> = 6.1 Hz, 2H), 0.03 (s, 9H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.95 (d, <i>J</i> = 252 Hz), 143.32, 138.48, 128.28 (d, <i>J</i> = 8 Hz), 127.88 (d, <i>J</i> = 3 Hz), 116.31 (d, <i>J</i> = 22 Hz), 98.09, 75.29, 66.42, 60.44, 35.33, 18.06, −1.43.</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 5-Bromo-4-(4-fluorophenyl)-2-((2-methoxyethyl)thio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole (<b>19</b>)</h3><div class="NLM_p last">Intermediate <b>18</b> (193 mg, 0.43 mmol) was dissolved in 10 mL of dry THF and cooled to −15 °C. To the vigorously stirred solution was added sodium hydride (60%, 21 mg, 0.52 mmol) portionwise. After complete addition the reaction was slowly warmed to room temperature and methyl iodide (33 μL, 0.52 mmol) was added. The mixture was stirred for 1 h at room temperature. After complete reaction, saturated NH<sub>4</sub>Cl solution was added. The aqueous mixture was extracted three times with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified with gradient flash chromatography (from 100% <i>n</i>-hexane to <i>n</i>-hexane/ethyl acetate 3:1) to give the pure product as a colorless oil in 75% yield (148 mg, 0.32 mmol). <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.14–7.87 (m, 2H), 7.23–7.01 (m, 2H), 5.41 (s, 2H), 3.85–3.55 (m, 4H), 3.46–3.36 (m, 5H), 1.14–0.86 (m, 2H), 0.04 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 162.06 (d, <i>J</i> = 247 Hz), 143.67, 138.43, 128.91 (d, <i>J</i> = 3.3 Hz), 128.35 (d, <i>J</i> = 8.2 Hz), 115.06 (d, <i>J</i> = 21.5 Hz), 100.06, 73.80, 71.00, 66.53, 58.55, 33.30, 17.76, −1.46.</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> <i>N</i>-(4-(4-(4-Fluorophenyl)-2-((2-methoxyethyl)thio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)acetamide (<b>20</b>)</h3><div class="NLM_p last">To a solution of <b>19</b> (148 mg, 0.32 mmol) and <i>N</i>-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetamide (126 mg, 0.48 mmol) in 4 mL of degassed 1,4-dioxane was added an aqueous 1 M K<sub>3</sub>PO<sub>4</sub> solution (1 mL). The biphasic mixture was degassed 3 times by evacuating and backfilling with argon. Under argon, P(<i>t</i>-Bu)<sub>3</sub>Pd G3 (5 mol %, 9 mg) was added, the reaction flask was sealed, and the suspension stirred for 5 h at 50 °C. After complete reaction, the mixture was cooled to room temperature and brine was added. The aqueous mixture was extracted three times with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified with gradient flash chromatography (from 100% <i>n</i>-hexane to <i>n</i>-hexane/ethyl acetate 1:1) to give the pure product as a colorless oil in 56% yield (92 mg, 0.17 mmol). LRMS (ESI-MS): 539.6 [M + Na]<sup>+</sup>. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 9.25 (s, 1H), 8.42–8.09 (m, 2H), 7.55–7.37 (m, 2H), 7.13–6.85 (m, 3H), 5.25 (s, 2H), 3.76 (t, <i>J</i> = 6.2 Hz, 2H), 3.64–3.36 (m, 7H), 2.22 (s, 3H), 0.94 (t, <i>J</i> = 8.3 Hz, 2H), −0.00 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 168.76, 162.02 (d, <i>J</i> = 246 Hz), 152.25, 147.90, 144.49, 140.87, 139.49, 129.61 (d, <i>J</i> = 3.0 Hz), 129.12 (d, <i>J</i> = 7.9 Hz), 127.42, 121.19, 115.30, 115.05 (d, <i>J</i> = 21.4 Hz), 71.12, 66.32, 58.59, 33.35, 24.77, 24.49, 17.70, −1.53.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 4-(4-(4-Fluorophenyl)-2-((2-methoxyethyl)thio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-amine (<b>21</b>)</h3><div class="NLM_p last">The intermediate <b>20</b> (92 mg, 0.17 mmol) was dissolved in 5 mL of methanol, and 1 mL of an aqueous solution of NaOH (5M) was added under stirring. The suspension was stirred for 3 h at 50 °C. After complete reaction, the mixture was cooled to room temperature and a saturated aqueous NH<sub>4</sub>Cl solution was added. The aqueous mixture was extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified with gradient flash chromatography (from 100% <i>n</i>-hexane to <i>n</i>-hexane/ethyl acetate 1:1) to give the pure product as a white solid in 59% yield (50 mg, 0.11 mmol). LRMS (ESI-MS): 475.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.11 (d, <i>J</i> = 5.4 Hz, 1H), 7.60–7.39 (m, 2H), 6.97 (t, <i>J</i> = 8.6 Hz, 2H), 6.69 (d, <i>J</i> = 5.2 Hz, 1H), 6.59 (s, 1H), 5.19 (s, 2H), 4.71 (s, 2H), 3.77 (t, <i>J</i> = 6.2 Hz, 2H), 3.60 (t, <i>J</i> = 8.2 Hz, 2H), 3.52–3.38 (m, 5H), 0.95 (t, <i>J</i> = 8.3 Hz, 2H), 0.03 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 161.93 (d, <i>J</i> = 246 Hz), 159.48, 148.32, 144.04, 140.06, 138.76, 129.75, (d, <i>J</i> = 3.1 Hz), 128.86 (d, <i>J</i> = 8.0 Hz), 127.95, 115.35, 115.07 (d, <i>J</i> = 21.5 Hz), 109.65, 72.87, 71.11, 66.46, 58.59, 33.30, 17.89, −1.48.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-((2-methoxyethyl)thio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide (<b>22</b>)</h3><div class="NLM_p last">A solution of <b>21</b> (50 mg, 0,11 mmol) and <i>N</i>-(3-bromo-4-methoxyphenyl)acrylamide (32 mg, 0.126 mmol) and cesium carbonate (171 mg, 0.525 mmol) in a mixture of 1,4-dioxane/<i>t</i>-BuOH (4 mL + 1 mL) was degassed three times by evacuating and backfilling with argon under stirring. Under an atmosphere of argon, Brettphos Pd G3 (5 mol %, 5 mg, 0.005 mmol) was added. The solution was stirred under reflux for 3 h. The mixture was cooled to room temperature, and a saturated aqueous NH<sub>4</sub>Cl solution was added. The aqueous mixture was extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified with gradient flash chromatography (from 100% <i>n</i>-hexane to 100% ethyl acetate) to give the pure product as a white solid in 44% yield (30 mg, 0.046 mmol). LRMS (ESI-MS): 651.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.28 (d, <i>J</i> = 5.3 Hz, 1H), 8.11 (s, 1H), 7.60–7.45 (m, 4H), 7.23 (s, 1H), 7.05–6.81 (m, 5H), 6.53–6.20 (m, 2H), 5.80–5.70 (m, 1H), 5.23 (s, 2H), 3.88 (s, 3H), 3.78 (t, <i>J</i> = 6.1 Hz, 3H), 3.64–3.44 (m, 6H), 0.98–0.89 (m, 2H), 0.02 (s, 9H).</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-((2-methoxyethyl)thio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide (<b>23</b>)</h3><div class="NLM_p last">The intermediate <b>22</b> (30 mg, 0.046 mmol) was dissolved in an ethanolic HCl solution (1.25 M) and stirred overnight at room temperature. After complete consumption of the starting material, the solution was evaporated to dryness and the oily residue taken up in ethyl acetate. The organic solution was washed with a saturated aqueous NaHCO<sub>3</sub> solution, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was dissolved in a minimum amount of ethyl acetate and triturated with <i>n</i>-pentane to give the pure product as a pale yellow solid in 70% yield (16 mg, 0.031 mmol). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.73 (s, 1H), 10.00 (s, 1H), 8.31 (d, <i>J</i> = 9.7 Hz, 1H), 8.19–7.95 (m, 2H), 7.62–7.40 (m, 3H), 7.37–7.12 (m, 3H), 6.95 (dd, <i>J</i> = 8.9, 3.5 Hz, 1H), 6.73–6.18 (m, 3H), 5.80–5.61 (m, 1H), 3.81 (s, 3H), 3.64 (t, <i>J</i> = 6.3 Hz, 2H), 3.32–3.24 (m, 5H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.07, 162,20 (d, <i>J</i> = 249 Hz), 156.74, 147.32, 146.03, 143.33, 141.78, 140.92, 135.31, 132.54, 132.27, 130.95 (d, <i>J</i> = 8.3 Hz), 130.51, 129.97, 129.76, 126.45, 116.11 (d, <i>J</i> = 21.6 Hz), 113.22, 112.41, 111.22, 108.32, 71.15, 58.26, 56.23, 32.35. LRMS (ESI-MS): 517.9 [M – H]<sup>−</sup>.</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Synthesis of 4-(4-Fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazole (<b>23</b>)</h3><div class="NLM_p last">3.00 g (13.82 mmol) of 2-bromo-1-(4-fluorophenyl)ethan-1-one in 15 mL of THF was added dropwise to a refluxing mixture of 1.92 g (13.82 mmol) of 2-methyl-2-thiopseudourea hemisulfate salt and 3.82 g (27.64 mmol) of K<sub>2</sub>CO<sub>3</sub> in THF/H<sub>2</sub>O (8 mL/2 mL). The mixture was refluxed for an additional hour until TLC indicated complete consumption of the starting material. The mixture was evaporated to dryness and the residue dissolved in EtOAc and water. The layers were separated. The organic layer was washed twice with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. The crude mixture was purified via flash chromatography (<i>n</i>-hexane/EtOAc 1:1) to obtain the title product as a beige solid in 50% yield (1.44 g, 6.91 mmol). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.61–12.10 17 (m, 1H), 7.83–7.66 (m, 2H), 7.62 (s, 1H), 7.28–7.05 (m, 2H), 2.55 (s, 3H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.2(d, <i>J</i> = 242 Hz) 141.5, 140.5, 131.3 (d, <i>J</i> = 3 Hz), 126.3, 126.2 (d, <i>J</i> = 8 Hz), 115.5 (d, <i>J</i> = 21 Hz), 114.6, 15.8. ESI-MS: 209.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-(4-Fluorophenyl)-2-(methylthio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole (<b>24</b>)</h3><div class="NLM_p last">710 mg (3.41 mmol) of <b>23</b> was dissolved in 10 mL of dry THF and cooled to −15 °C with an ice/acetone mixture under an argon atmosphere. 150 mg of NaH (3.75 mmol, 60% dispersion in mineral oil) was added in small portions. The resulting suspension was stirred for 20 min at −15 °C, after which 663 μL (3.75 mmol) of SEM-Cl was added dropwise to the mixture. The mixture was allowed to warm to room temperature slowly. The reaction was quenched by the addition of saturated aqueous NH4Cl solution, and the crude product was extracted three times with DCM. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. The resulting mixture of regioisomeres (60:40) was dissolved in 10 mL of dry acetonitrile under an argon atmosphere. 28 μL (0.171 mmol) of SEM-Cl was added, and the biphasic mixture was stirred for 4 h at 80 °C to perform the “SEM-switch”. The reaction was quenched by the addition of a few drops of 10% aqueous ammonia solution. The mixture was evaporated to dryness and the crude product was purified by flash chromatography (from <i>n</i>-hexane 100% to <i>n</i>-hexane/EtOAc 3:1) to obtain the title compound as a colorless oil in 91% yield (1050 mg, 3.11 mmol). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.88–7.67 (m, 3H), 7.31–7.02 (m, 2H), 5.26 (s, 2H), 3.52 (t, <i>J</i> = 7.9 Hz, 2H), 2.58 (s, 3H), 0.81–0.90 (t, <i>J</i> = 7.9 Hz, 2H), 0.01 (s, 9H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.6, 161.0 (d, <i>J</i> = 243 Hz), 143.5, 139.9, 130.4 (d, <i>J</i> = 3 Hz), 126.2 (d, <i>J</i> = 8 Hz), 118.5, 18 115.6 (d, <i>J</i> = 22 Hz), 74.9, 65.9, 17.5, 16.2, −1.0. ESI-MS: 339.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 5-Bromo-4-(4-fluorophenyl)-2-(methylthio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole (<b>25</b>)</h3><div class="NLM_p last">895 mg (2.64 mmol) of <b>24</b> was dissolved in 20 mL of dry acetonitrile under argon atmosphere. The solution was cooled to −30 °C. 470 mg (2.64 mmol) of <i>N</i>-bromosuccinimide dissolved in 5 mL of dry acetonitrile was added dropwise under vigorous stirring, maintaining −30 °C. The reaction mixture was stirred for 1 h at −30 °C and allowed to slowly warm to room temperature. TLC indicated complete consumption of the starting material. The reaction was quenched by the addition of an aqueous sodium thiosulfate solution (10%). The product was partitioned between water and DCM. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. The crude product was purified via flash chromatography (hexane/EtOAc 5:1) to yield the title product as a colorless oil in 85% yield (940 mg, 2.25 mmol). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.97–7.85 (m, 2H), 7.34–7.19 (m, 2H), 5.30 (s, 2H), 3.58 (t, <i>J</i> = 7.9 Hz, 2H), 2.60 (s, 3H), 0.95–0.77 (t, <i>J</i> = 7.9 Hz, 2H), −0.05 (s, 9H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.7 (d, <i>J</i> = 244 Hz), 145.3, 137.5, 129.5 (d, <i>J</i> = 3 Hz), 128.4 (d, <i>J</i> = 8 Hz), 115.7 (d, <i>J</i> = 22 Hz), 100.8, 100.8, 74.0, 66.3, 17.5, 15.8, −1.03. ESI-MS: found, 417/418 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 4-Bromo-5-(4-fluorophenyl)-1-methyl-2-(methylthio)-1<i>H</i>-imidazole (<b>26</b>)</h3><div class="NLM_p last"><b>25</b> (675 mg, 1.62 mmol) was dissolved in dry DCM and stirred at room temperature. To this solution, methyl trifluoromethanesulfonate (230 μL, 2.10 mmol) was added and stirring continued for 2 h. 1 mL of trifluoroacetic acid was added and the solution stirred for 30 min at room temperature. After complete consumption of the imidazolium intermediate, the reaction was quenched by the addition of concentrated ammonia. The aqueous mixture was extracted three times with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified with flash chromatography (100% DCM) to give the pure product as colorless crystals in 70% yield (252 mg, 1.13 mmol). <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 7.37–7.26 (m, 2H), 7.17–7.07 (m, 2H), 3.53 (s, 3H), 2.65 (s, 3H). LRMS (ESI-MS): not detected.</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(4-(5-(4-Fluorophenyl)-1-methyl-2-(methylthio)-1<i>H</i>-imidazol-4-yl)pyridin-2-yl)acetamide (<b>27</b>)</h3><div class="NLM_p last">To a solution of <b>26</b> (158 mg, 0.52 mmol) and <i>N</i>-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetamide (343 mg, 1.31 mmol) in 6 mL of degassed 1,4-dioxane was added an aqueous 1 M K<sub>3</sub>PO<sub>4</sub> solution (1.5 mL). The biphasic mixture was degassed 3 times by evacuating and backfilling with argon. Under argon, P(<i>t</i>-Bu)<sub>3</sub>Pd G3 (5 mol %, 9 mg) was added, the reaction flask was sealed and the suspension stirred for 5 h at 50 °C. After complete reaction, the mixture was cooled to room temperature and brine was added. The aqueous mixture was extracted three times with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified with gradient flash chromatography (from 100% <i>n</i>-hexane to <i>n</i>-hexane/ethyl acetate 1:2) to give the pure product as a colorless solid in 39% yield (72 mg, 0.20 mmol). <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 9.46 (s, 1H), 8.27 (s, 1H), 8.03 (d, <i>J</i> = 5.4 Hz, 1H), 7.36–7.07 (m, 5H), 3.33 (s, 3H), 2.71 (s, 3H), 2.09 (s, 3H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 163.12 (d, <i>J</i> = 250 Hz), 151.90, 146.89, 144.31, 144.27, 135.56, 132.34 (d, <i>J</i> = 8.4 Hz), 132.07, 125.78 (d, <i>J</i> = 3.8 Hz), 116.42 (d, <i>J</i> = 22 Hz), 110.99, 31.15, 24.38, 15.53. LRMS (ESI-MS): not detected.</div></div><div id="sec5_2_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 4-(5-(4-Fluorophenyl)-1-methyl-2-(methylthio)-1<i>H</i>-imidazol-4-yl)pyridin-2-amine (<b>7</b>)</h3><div class="NLM_p last">The intermediate <b>27</b> (70 mg, 0.223 mmol) was dissolved in 5 mL of methanol, and 1 mL of of an aqueous solution of NaOH (5 M) was added under stirring. The suspension was stirred for 3 h at 60 °C. After complete reaction, the mixture was cooled to room temperature and a saturated aqueous NH<sub>4</sub>Cl solution was added. The aqueous mixture was extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified with gradient flash chromatography (from 100% <i>n</i>-hexane to <i>n</i>-hexane/ethyl acetate 1:1) to give the pure product as a pale yellow solid in 88% yield (62 mg, 0.196 mmol). LRMS (ESI-MS): 315.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 7.78 (d, <i>J</i> = 5.5 Hz, 1H), 7.34–7.23 (m, 2H), 7.22–7.09 (m, 2H), 6.76 (d, <i>J</i> = 1.3 Hz, 1H), 6.51 (dd, <i>J</i> = 5.5, 1.5 Hz, 1H), 4.50 (s, 2H), 3.33 (s, 3H), 2.68 (s, 3H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 163.01 (d, <i>J</i> = 249.7 Hz), 158.58, 147.25, 143.85, 143.34, 135.83, 132.39 (d, <i>J</i> = 8.3 Hz), 131.44, 126.15 (d, <i>J</i> = 3.5 Hz), 116.28 (d, <i>J</i> = 21.7 Hz), 111.42, 105.22, 31.22, 15.85.</div></div><div id="sec5_2_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-(3-((4-(5-(4-Fluorophenyl)-1-methyl-2-(methylthio)-1<i>H</i>-imidazol-4-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide (<b>7</b>)</h3><div class="NLM_p last">A solution of <b>7</b> (63 mg, 0,20 mmol), <i>N</i>-(3-bromo-4-methoxyphenyl)acrylamide (23 mg, 0.24 mmol), and cesium carbonate (326 mg, 1.0 mmol) in a mixture of 1,4-dioxane/<i>t</i>-BuOH (8 mL + 2 mL) was degassed three times by evacuating and backfilling with argon under stirring. Under an atmosphere of argon, Brettphos Pd G3 (5 mol %, 9 mg, 0.01 mmol) was added. The solution was stirred under reflux for 3 h. The mixture was cooled to room temperature, and a saturated aqueous NH<sub>4</sub>Cl solution was added. The aqueous mixture was extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified with gradient flash chromatography (from 100% <i>n</i>-hexane to 100% ethyl acetate) to give the pure product as a white solid in 67% yield (74 mg, 0.15 mmol). LRMS (ESI-MS): 490 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.98 (s, 1H), 8.22 (s, 1H), 8.01 (s, 1H), 7.91 (d, <i>J</i> = 5.4 Hz, 1H), 7.59–7.26 (m, 5H), 7.22 (s, 1H), 6.94 (d, <i>J</i> = 8.8 Hz, 1H), 6.62–6.12 (m, 3H), 5.71 (d, <i>J</i> = 9.7 Hz, 1H), 3.81 (s, 3H), 3.34 (s, 3H), 2.68 (s, 3H). <sup>13</sup>C NMR (50 MHz, DMSO) δ 163.07, 162.85(d, <i>J</i> = 246.7 Hz), 156.72, 147.25, 146.17, 143.38, 142.94, 135.38, 133.22 (d, <i>J</i> = 8.4 Hz), 132.55, 132.30, 131.94, 130.43, 126.54 (d, <i>J</i> = 3.1 Hz), 126.39, 116.55 (d, <i>J</i> = 21.6 Hz), 113.36, 112.53, 111.82, 111.24, 107.27, 56.20, 31.59, 15.72.</div></div><div id="sec5_2_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-1-methyl-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide (<b>6</b>)</h3><div class="NLM_p last">A solution of 4-(4-(4-fluorophenyl)-1-methyl-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-amine (60 mg, 0,190 mmol, synthesized according to WO 2006089798 A1, Aug 31, 2006) and <i>N</i>-(3-bromo-4-methoxyphenyl)acrylamide (63 mg, 0.247 mmol) and cesium carbonate (311 mg, 0.954 mmol) in a mixture of 1,4-dioxane/<i>t</i>-BuOH (8 mL + 2 mL) was degassed three times by evacuating and backfilling with argon under stirring. Under an atmosphere of argon, Brettphos Pd G3 (5 mol %, 9 mg, 0.01 mmol) was added. The solution was stirred under reflux for 3 h. The mixture was cooled to room temperature, and a saturated aqueous NH<sub>4</sub>Cl solution was added. The aqueous mixture was extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvents removed in vacuum. The crude product was purified with gradient flash chromatography (from 100% <i>n</i>-hexane to <i>n</i>-hexane/ethyl acetate 1:1) to give the pure product as a white solid in 81% yield (75 mg, 0.154 mmol). LRMS (ESI-MS): 490.5 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.01 (s, 1H), 8.46 (d, <i>J</i> = 2.6 Hz, 1H), 8.32 (s, 1H), 8.23 (d, <i>J</i> = 5.2 Hz, 1H), 7.46 (dd, <i>J</i> = 8.7, 5.7 Hz, 2H), 7.42–7.37 (m, 1H), 7.16–7.08 (m, 2H), 7.04 (s, 1H), 6.96 (d, <i>J</i> = 8.8 Hz, 1H), 6.74–6.67 (m, 1H), 6.51–6.41 (m, 1H), 6.23 (dd, <i>J</i> = 17.0, 2.2 Hz, 1H), 5.71 (dd, <i>J</i> = 10.1, 2.2 Hz, 1H), 3.80 (s, 3H), 3.44 (s, 3H), 2.64 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 163.29, 161.51 (d, <i>J</i> = 243.7 Hz), 156.96, 148.52, 146.01, 143.92, 139.53, 137.23, 132.59, 132.35, 131.05, 130.11, 128.77, 128.68 (d, <i>J</i> = 8.0 Hz), 126.55, 115.98, 115.57 (d, <i>J</i> = 21.4 Hz), 113.76, 112.56, 112.41, 111.34, 56.35, 31.98, 15.84.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> EGFR Protein Purification</h3><div class="NLM_p last">Constructs spanning residues 696–1022 of the human EGFR (including WT and T790M/V948R mutant sequences) were prepared in a GST-fusion format using the pTriEX system (Novagen) for expression in Sf9 insect cells as described previously.<a onclick="showRef(event, 'ref3 ref33'); return false;" href="javascript:void(0);" class="ref ref3 ref33">(3,33)</a> Briefly, EGFR kinase proteins were purified by Ni-NTA and glutathione-affinity chromatography in 50 mM Tris-HCl (pH = 8.0), 500 mM NaCl, 5% glycerol, 5 mM TCEP followed by size-exclusion chromatography after cleavage with Tomato etch virus (TEV) to remove the GST fusion partner following established procedures.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Structure Determination</h3><div class="NLM_p last">EGFR(T790M/V948R) preincubated with 1 mM AMP-PNP and 10 mM MgCl<sub>2</sub> on ice was prepared by hanging-drop vapor diffusion over a reservoir solution containing 0.1 M Bis-Tris (pH = 5.5), 25% PEG-3350, and 5 mM TCEP (buffer A). WT EGFR crystals were prepared by hanging-drop vapor diffusion over a reservoir solution containing 1.3 M sodium citrate and 0.1 M MES, pH = 6.5 (buffer B). Drops containing crystals in buffer A were exchanged with solutions of buffer A containing ∼1.0 mM <b>1</b>–<b>5</b> three times for an hour and then left overnight. WT crystals were soaked with solutions of buffer B containing 10% DMSO and were soaked for 24–48 h prior to harvesting. In both cases, crystals were flash frozen after rapid immersion in a cryoprotectant solution with buffer A or B for T790M/V948R or WT, respectively, containing 25% ethylene glycol. X-ray diffraction data were collected at 100 K at the Advanced Light Source, a part of the Northeastern Collaborative Access Team (NE-CAT), on beamline 24-ID-C or 24-ID-E or at the National Synchrotron Light Source II 17-ID-1. Diffraction data were processed and merged in Xia2 using aimless and XDS. The structure was determined by molecular replacement with the program PHASER using the inactive EGFR kinase from our previous allosteric inhibitor work excluding the EAI001 ligand (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41">5D41</a>)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> or WT EGFR (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D8E">6D8E</a>)<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Repeated rounds of manual refitting and crystallographic refinement were performed using COOT and Phenix. The inhibitor was modeled into the closely fitting positive <i>F</i><sub>0</sub> – <i>F</i><sub>c</sub> electron density and then included in following refinement cycles. Statistics for diffraction data processing and structure refinement are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_002.pdf" class="ext-link">Tables S1 and S2</a>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Biochemical Assays</h3><div class="NLM_p last">Inhibition data (IC<sub>50</sub>) against EGFR-wild type, EGFR-L858R/T790M, and EGFR-L858R/T790M/C797S were obtained at Reaction Biology Corp. (Malvern, PA) via commercial radiolabeled <sup>33</sup>P(ATP) kinase assays. IC<sub>50</sub> values were measured in duplicates at 5 different concentration with 10-fold dilution steps starting from 5 μM. Staurosporine was tested as control compound in singlicate at 10 different concentrations with a 4-fold dilution starting at 20 μM. A detailed description of the assay format is given in the literature.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00200" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86188" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86188" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00200?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00200</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">SMILES molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">X-ray crystallography statistics, supporting structural images, biochemical potencies of <b>1</b>–<b>3</b> and <b>5</b>, and additional chemistry for precursor (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_001.csv">jm0c00200_si_001.csv (0.63 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_002.pdf">jm0c00200_si_002.pdf (898.36 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">X-ray coordinates and structures factors have been deposited in the Protein Data Bank. PDB accession codes are the following. EGFR(T790M/V948R): <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5N">6V5N</a> (<b>1</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5P">6V5P</a> (<b>2</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6O">6V6O</a> (<b>3</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6K">6V6K</a> (<b>4</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V66">6V66</a> (<b>5</b>). Wild-type EGFR: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VH4">6VH4</a> (<b>3</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VHN">6VHN</a> (<b>4</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VHP">6VHP</a> (<b>5</b>). Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00200" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32270" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32270" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan A. Laufer</span> - <span class="hlFld-Affiliation affiliation">Institute
for Pharmaceutical Sciences, Eberhard Karls
Universität Tübingen, Tübingen 72076, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6952-1486" title="Orcid link">http://orcid.org/0000-0001-6952-1486</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#acdfd8c9cacdc282c0cdd9cac9deecd9c2c5d8d9c9cec5c2cbc9c282c8c9"><span class="__cf_email__" data-cfemail="89fafdecefe8e7a7e5e8fcefecfbc9fce7e0fdfcecebe0e7eeece7a7edec">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Eck</span> - <span class="hlFld-Affiliation affiliation">Department
of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#94f1f7ffd4f7e6ede7e0f5f8bafcf5e6e2f5e6f0baf1f0e1"><span class="__cf_email__" data-cfemail="5c393f371c3f2e252f283d3072343d2e2a3d2e3872393829">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David E. Heppner</span> - <span class="hlFld-Affiliation affiliation">Department
of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0722-5160" title="Orcid link">http://orcid.org/0000-0002-0722-5160</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcel Günther</span> - <span class="hlFld-Affiliation affiliation">Institute
for Pharmaceutical Sciences, Eberhard Karls
Universität Tübingen, Tübingen 72076, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florian Wittlinger</span> - <span class="hlFld-Affiliation affiliation">Institute
for Pharmaceutical Sciences, Eberhard Karls
Universität Tübingen, Tübingen 72076, Germany</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This work was supported by the National Institutes of Health Grants R01CA201049 and R01CA116020 (to M.J.E) and funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy Grant EXC 2180-390900677 (to S.A.L.). This work is based upon research as a part of the Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Germany. This work is based upon research conducted at the Northeastern Collaborative Access Team (NECAT) beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (Grant P30 GM124165). The Pilatus 6M detector on 24-ID-C beamline is funded by a NIH-ORIP HEI grant (S10 RR029205). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract DE-AC02-06CH11357. This research used resources 17-ID FMX and AMX of the National Synchrotron Light Source II, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Brookhaven National Laboratory under Contract DE-SC0012704. The Life Science Biomedical Technology Research resource is primarily supported by the National Institutes of Health, National Institute of General Medical Sciences (NIGMS) through a Biomedical Technology Research Resource P41 grant (P41GM111244), and by the DOE Office of Biological and Environmental Research (Grant KP1605010).</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): M.J.E. reports receiving a commercial research grant from Novartis Institutes for Biomedical Research, reports receiving other commercial research support from Takeda, and has been a consultant for Novartis Institutes for Biomedical Research.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80522" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80522" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Tyler S. Beyett for technical assistance and helpful discussions.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">H-bond</td><td class="NLM_def"><p class="first last">hydrogen bond</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37578" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37578" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span> <span> </span><span class="NLM_article-title">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span> (<span class="NLM_issue">5676</span>),  <span class="NLM_fpage">1497</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&issue=5676&author=J.+G.+Paezauthor=P.+A.+J%C3%A4nneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+Mutations+in+Lung+Cancer%3A+Correlation+with+Clinical+Response+to+Gefitinib+Therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lgVY1Q80-bSag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520Mutations%2520in%2520Lung%2520Cancer%253A%2520Correlation%2520with%2520Clinical%2520Response%2520to%2520Gefitinib%2520Therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26issue%3D5676%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurubhagavatula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannigan, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haserlat, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiani, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>350</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2139</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&issue=21&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+Mutations+in+the+Epidermal+Growth+Factor+Receptor+Underlying+Responsiveness+of+Non-Small-Cell+Lung+Cancer+to+Gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lgVzeAVHBb9HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520Mutations%2520in%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Underlying%2520Responsiveness%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26issue%3D21%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M Mutation in EGFR Kinase Causes Drug Resistance by Increasing the Affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2070</span>– <span class="NLM_lpage">2075</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&issue=6&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+Mutation+in+EGFR+Kinase+Causes+Drug+Resistance+by+Increasing+the+Affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lgVzeAVHBb9HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520Mutation%2520in%2520EGFR%2520Kinase%2520Causes%2520Drug%2520Resistance%2520by%2520Increasing%2520the%2520Affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D6%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayaram, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocher, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span> <span> </span><span class="NLM_article-title">EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&issue=8&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+Mutation+and+Resistance+of+Non-Small-Cell+Lung+Cancer+to+Gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljKyeQCqXnYLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520Mutation%2520and%2520Resistance%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D8%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel Mutant-Selective EGFR Kinase Inhibitors Against EGFR T790M</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span> (<span class="NLM_issue">7276</span>),  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1074</span>, <span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&issue=7276&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+Mutant-Selective+EGFR+Kinase+Inhibitors+Against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0ljKyeQCqXnYLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520Mutant-Selective%2520EGFR%2520Kinase%2520Inhibitors%2520Against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26issue%3D7276%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, An Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&issue=9&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+An+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0ljKyeQCqXnYLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520An%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggstrom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frewer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&issue=18&author=P.+A.+J%C3%A4nneauthor=J.+C.-H.+Yangauthor=D.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.-J.+Ahnauthor=S.-W.+Kimauthor=W.-C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.-H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+Inhibitor-Resistant+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2eZPUuhB3sPNrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520Inhibitor-Resistant%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26issue%3D18%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechaphunkul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1713137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1056%2FNEJMoa1713137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=29151359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=113-125&issue=2&author=J.-C.+Soriaauthor=Y.+Oheauthor=J.+Vansteenkisteauthor=T.+Reungwetwattanaauthor=B.+Chewaskulyongauthor=K.+H.+Leeauthor=A.+Dechaphunkulauthor=F.+Imamuraauthor=N.+Nogamiauthor=T.+Kurataauthor=I.+Okamotoauthor=C.+Zhouauthor=B.+C.+Choauthor=Y.+Chengauthor=E.+K.+Choauthor=P.+J.+Voonauthor=D.+Planchardauthor=W.-C.+Suauthor=J.+E.+Grayauthor=S.-M.+Leeauthor=R.+Hodgeauthor=M.+Marottiauthor=Y.+Rukazenkovauthor=S.+S.+Ramalingam&title=Osimertinib+in+Untreated+EGFR-Mutated+Advanced+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1713137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B. C.; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W.-C.; Gray, J. E.; Lee, S.-M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.  We compared osimertinib with std. EGFR-TKIs in patients with previously untreated, EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-pos. (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a std. EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).  The primary end point was investigator-assessed progression-free survival.  RESULTS: The median progression-free survival was significantly longer with osimertinib than with std. EGFR-TKIs (18.9 mo vs. 10.2 mo; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).  The objective response rate was similar in the two groups: 80% with osimertinib and 76% with std. EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24).  The median duration of response was 17.2 mo (95% CI, 13.8 to 22.0) with osimertinib vs. 8.5 mo (95% CI, 7.3 to 9.8) with std. EGFR-TKIs.  Data on overall survival were immature at the interim anal. (25% maturity).  The survival rate at 18 mo was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with std. EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim anal.]).  Adverse events of grade 3 or higher were less frequent with osimertinib than with std. EGFR-TKIs (34% vs. 45%).  CONCLUSIONS: Osimertinib showed efficacy superior to that of std. EGFR-TKIs in the first-line treatment of EGFR mutation-pos. advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov no., NCT02296125.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-szlfPjG9LVg90H21EOLACvtfcHk0lgoaEraUVtkBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D&md5=a83147d4e067da1c11d2f096615b1cc8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1713137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1713137%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDechaphunkul%26aufirst%3DA.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DE.%2BK.%26aulast%3DVoon%26aufirst%3DP.%2BJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.-M.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DOsimertinib%2520in%2520Untreated%2520EGFR-Mutated%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D2%26spage%3D113%26epage%3D125%26doi%3D10.1056%2FNEJMoa1713137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non-Small Cell Lung Cancer Harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&issue=6&author=K.+S+Thressauthor=C.+P+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E+Matthewsauthor=M.+Cantariniauthor=J+C.+Barrettauthor=P.+A+Janneauthor=G.+R+Oxnard&title=Acquired+EGFR+C797S+Mutation+Mediates+Resistance+to+AZD9291+in+Non-Small+Cell+Lung+Cancer+Harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0lgXLnFcgqUgIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS%26aulast%3DPaweletz%26aufirst%3DC.%2BP%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA%26aulast%3DOxnard%26aufirst%3DG.%2BR%26atitle%3DAcquired%2520EGFR%2520C797S%2520Mutation%2520Mediates%2520Resistance%2520to%2520AZD9291%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D6%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3924</span>– <span class="NLM_lpage">3933</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1158%2F1078-0432.CCR-15-0560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=25964297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3924-3933&issue=17&author=M.+J.+Niederstauthor=H.+Huauthor=H.+E.+Mulveyauthor=E.+L.+Lockermanauthor=A.+R.+Garciaauthor=Z.+Piotrowskaauthor=L.+V.+Sequistauthor=J.+A.+Engelman&title=The+Allelic+Context+of+the+C797S+Mutation+Acquired+upon+Treatment+with+Third-Generation+EGFR+Inhibitors+Impacts+Sensitivity+to+Subsequent+Treatment+Strategies&doi=10.1158%2F1078-0432.CCR-15-0560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span></div><div class="casAuthors">Niederst, Matthew J.; Hu, Haichuan; Mulvey, Hillary E.; Lockerman, Elizabeth L.; Garcia, Angel R.; Piotrowska, Zofia; Sequist, Lecia V.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3924-3933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have progressed on erlotinib.  Third-generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in nearly two thirds of patients.  However, acquired resistance mechanisms in patients treated with these drugs are yet to be described.  Exptl. Design: To study acquired resistance to third-generation EGFR inhibitors, T790M-pos. cells derived from an erlotinib-resistant cancer were made resistant to a third-generation TKI and then characterized using cell and mol. analyses.  Results: Cells resistant to a third-generation TKI acquired an addnl. EGFR mutation, C797S, which prevented suppression of EGFR.  Our results demonstrate that the allelic context in which C797S was acquired may predict responsiveness to alternative treatments.  If the C797S and T790M mutations are in trans, cells will be resistant to third-generation EGFR TKIs, but will be sensitive to a combination of first- and third-generation TKIs.  If the mutations are in cis, no EGFR TKIs alone or in combination can suppress activity.  If C797S develops in cells wild-type for T790 (when third-generation TKIs are administered in the first-line setting), the cells are resistant to third-generation TKIs, but retain sensitivity to first-generation TKIs.  Conclusions: Mutation of C797S in EGFR is a novel mechanism of acquired resistance to third-generation TKIs.  The context in which the C797S develops with respect to the other EGFR alleles affects the efficacy of subsequent treatments.  Clin Cancer Res; 21(17); 3924-33. ©2015 AACR.  See related commentary by Ayeni et al., p. 3818.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRS-15mDgObVg90H21EOLACvtfcHk0lgXLnFcgqUgIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF&md5=47a45613979464e3859c7c3e0538d0f8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0560%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Allelic%2520Context%2520of%2520the%2520C797S%2520Mutation%2520Acquired%2520upon%2520Treatment%2520with%2520Third-Generation%2520EGFR%2520Inhibitors%2520Impacts%2520Sensitivity%2520to%2520Subsequent%2520Treatment%2520Strategies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D17%26spage%3D3924%26epage%3D3933%26doi%3D10.1158%2F1078-0432.CCR-15-0560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span> <span> </span><span class="NLM_article-title">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4290</span>– <span class="NLM_lpage">4300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4290-4300&issue=10&author=L.+Chenauthor=W.+Fuauthor=L.+Zhengauthor=Z.+Liuauthor=G.+Liang&title=Recent+Progress+of+Small-Molecule+Epidermal+Growth+Factor+Receptor+%28EGFR%29+Inhibitors+against+C797S+Resistance+in+Non-Small-Cell+Lung+Cancer&doi=10.1021%2Facs.jmedchem.7b01310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Chen, Lingfeng; Fu, Weitao; Zheng, Lulu; Liu, Zhiguo; Liang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4290-4300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC).  The current third-generation EGFR small-mol. inhibitors, esp. osimertinib, are at the forefront clin. for treatment of patients with NSCLC.  However, a high percentage of these treated patients developed a tertiary cysteine-797 to serine-790 (C797S) mutation in the EGFR kinase domain.  This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs.  In this Miniperspective, the authors present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance.  Specifically, the authors analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations.  Lastly, the authors provide some perspectives on new challenges and future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIcPvOmj29UbVg90H21EOLACvtfcHk0lgXLnFcgqUgIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK&md5=6d3bc978d3896a4e1027cbacd2dad9e9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DG.%26atitle%3DRecent%2520Progress%2520of%2520Small-Molecule%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%2520Inhibitors%2520against%2520C797S%2520Resistance%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4290%26epage%3D4300%26doi%3D10.1021%2Facs.jmedchem.7b01310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goettert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schattel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schollmeyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">A Frozen Analogue Approach to Aminopyridinylimidazoles Leading to Novel and Promising p38 MAP Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">8429</span>– <span class="NLM_lpage">8439</span>, <span class="refDoi"> DOI: 10.1021/jm300852w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300852w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSmtrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8429-8439&issue=19&author=R.+Seligauthor=M.+Goettertauthor=V.+Schattelauthor=D.+Schollmeyerauthor=W.+Albrechtauthor=S.+Laufer&title=A+Frozen+Analogue+Approach+to+Aminopyridinylimidazoles+Leading+to+Novel+and+Promising+p38+MAP+Kinase+Inhibitors&doi=10.1021%2Fjm300852w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A Frozen Analogue Approach to Aminopyridinylimidazoles Leading to Novel and Promising p38 MAP Kinase Inhibitors</span></div><div class="casAuthors">Selig, Roland; Goettert, Marcia; Schattel, Verena; Schollmeyer, Dieter; Albrecht, Wolfgang; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8429-8439</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study the design, synthesis, and biol. evaluation of constrained aminopyridinyl- and aminopyrimidinyl-imidazoles, e.g. I [X, Y = CH, N: R1 = H, Ph, PhCH2, cyclohexyl; R2 = H, 4-HO, 3,4,5-(MeO)3, etc.], as p38α MAP kinase inhibitors are reported.  The frozen analog approach focused on the pyridinyl unit, using purine bioisosteres as constrained structure analogs.  The identification of the most potent bioisostere was followed by a further derivatization to address hydrophobic region II.  These studies in combination with C-2 modifications of the imidazole core allowed to design highly active inhibitors on the p38α MAP kinase.  The inhibitor design presented herein represents a promising and highly efficient advancement of recent stages of development in this class of p38 MAP kinase inhibitors.  In combination with the highly flexible synthetic strategy, directions toward further investigations of complex C-5 modifications of diarylimidazoles are indicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0shTYFbqnE7Vg90H21EOLACvtfcHk0lhdOgoHK3qplg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSmtrrO&md5=08ecb5b5ca3034b9ee3c6bc4b52f6ecf</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm300852w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300852w%26sid%3Dliteratum%253Aachs%26aulast%3DSelig%26aufirst%3DR.%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DA%2520Frozen%2520Analogue%2520Approach%2520to%2520Aminopyridinylimidazoles%2520Leading%2520to%2520Novel%2520and%2520Promising%2520p38%2520MAP%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D19%26spage%3D8429%26epage%3D8439%26doi%3D10.1021%2Fjm300852w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity Against a Therapy-Resistant L858R/T790M/C797S mutant</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">10890</span>– <span class="NLM_lpage">10894</span>, <span class="refDoi"> DOI: 10.1002/anie.201603736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1002%2Fanie.201603736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GmtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10890-10894&issue=36&author=M.+G%C3%BCntherauthor=M.+Juchumauthor=G.+Kelterauthor=H.+Fiebigauthor=S.+Laufer&title=Lung+Cancer%3A+EGFR+Inhibitors+with+Low+Nanomolar+Activity+Against+a+Therapy-Resistant+L858R%2FT790M%2FC797S+mutant&doi=10.1002%2Fanie.201603736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant</span></div><div class="casAuthors">Guenther, Marcel; Juchum, Michael; Kelter, Gerhard; Fiebig, Heiner; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10890-10894</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors is made challenging by acquired resistance caused by somatic mutations.  Third-generation EGFR inhibitors have been designed to overcome resistance through covalent binding to the Cys 797 residue of the enzyme, and these inhibitors are effective against most clin. relevant EGFR mutants.  However, the high dependence of these recent EGFR inhibitors on this particular interaction means that addnl. mutation of Cys 797 results in poor inhibitory activity, which leads to tumor relapse in initially responding patients.  A new generation of irreversible and reversible mutant EGFR inhibitors was developed with strong noncovalent binding properties, and these compds. show high inhibitory activities against the cysteine-mutated L858R/T790M/C797S EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY1QH6nrxYrVg90H21EOLACvtfcHk0lhdOgoHK3qplg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GmtbzK&md5=c3909faa7f781c2a3679f75bd3b6c5ac</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603736%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DFiebig%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DLung%2520Cancer%253A%2520EGFR%2520Inhibitors%2520with%2520Low%2520Nanomolar%2520Activity%2520Against%2520a%2520Therapy-Resistant%2520L858R%252FT790M%252FC797S%2520mutant%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26issue%3D36%26spage%3D10890%26epage%3D10894%26doi%3D10.1002%2Fanie.201603736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5613</span>– <span class="NLM_lpage">5637</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00316</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00316" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5613-5637&issue=13&author=M.+G%C3%BCntherauthor=J.+Lategahnauthor=M.+Juchumauthor=E.+D%C3%B6ringauthor=M.+Keulauthor=J.+Engelauthor=H.+L.+Tumbrinkauthor=D.+Rauhauthor=S.+Laufer&title=Trisubstituted+Pyridinylimidazoles+as+Potent+Inhibitors+of+the+Clinically+Resistant+L858R%2FT790M%2FC797S+EGFR+Mutant%3A+Targeting+of+Both+Hydrophobic+Regions+and+the+Phosphate+Binding+Site&doi=10.1021%2Facs.jmedchem.7b00316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span></div><div class="casAuthors">Guenther, Marcel; Lategahn, Jonas; Juchum, Michael; Doering, Eva; Keul, Marina; Engel, Julian; Tumbrink, Hannah L.; Rauh, Daniel; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5613-5637</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer.  Acquired resistance compromises the clin. efficacy of EGFR inhibitors during long-term treatment.  The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors.  Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition.  We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity.  Guided by mol. modeling, we synthesized and studied the structure-activity relationship of 40 compds. against clin. relevant EGFR mutants.  We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line.  We identified addnl. noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrikF9dZWUv2bVg90H21EOLACvtfcHk0lhdOgoHK3qplg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D&md5=b258bbd393c9738cb68062c53dcc093f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00316%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520Pyridinylimidazoles%2520as%2520Potent%2520Inhibitors%2520of%2520the%2520Clinically%2520Resistant%2520L858R%252FT790M%252FC797S%2520EGFR%2520Mutant%253A%2520Targeting%2520of%2520Both%2520Hydrophobic%2520Regions%2520and%2520the%2520Phosphate%2520Binding%2520Site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D13%26spage%3D5613%26epage%3D5637%26doi%3D10.1021%2Facs.jmedchem.7b00316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lämmerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4656</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4636-4656&issue=11&author=M.+Juchumauthor=M.+G%C3%BCntherauthor=E.+D%C3%B6ringauthor=A.+Sievers-Englerauthor=M.+L%C3%A4mmerhoferauthor=S.+Laufer&title=Trisubstituted+Imidazoles+with+a+Rigidized+Hinge+Binding+Motif+Act+As+Single+Digit+nM+Inhibitors+of+Clinically+Relevant+EGFR+L858R%2FT790M+and+L858R%2FT790M%2FC797S+Mutants%3A+An+Example+of+Target+Hopping&doi=10.1021%2Facs.jmedchem.7b00178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span></div><div class="casAuthors">Juchum, Michael; Guenther, Marcel; Doering, Eva; Sievers-Engler, Adrian; Laemmerhofer, Michael; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4636-4656</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif such as I were prepd. as inhibitors of EGFR tyrosine kinase with L858R/T790M/C797S mutations (against which current EGFR inhibitors are ineffective) for potential use in the treatment of non-small-cell lung cancer.  II [X = (CH2)2, (CH2)4] reversibly inhibited the clin. challenging EGFR tyrosine kinase triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range.  I inhibited EGFR tyrosine kinase irreversibly with IC50 value of 1 nM against the EGFR L858R/T790M double mutant; I was selective for EGFR tyrosine kinase over other related kinases except for MAP4K4, MAP4K5, and MINK.  The kinetics of target inhibition, aq. soly, and metabolites were detd. for I and for selected compds.; mol. docking calcns. were also performed for selected compds. with EGFR isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzeDYy9aSCrLVg90H21EOLACvtfcHk0lhz1WRJTFPVvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D&md5=a7003c8160b506ce964edce6adf7c3ff</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00178%26sid%3Dliteratum%253Aachs%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DL%25C3%25A4mmerhofer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520Imidazoles%2520with%2520a%2520Rigidized%2520Hinge%2520Binding%2520Motif%2520Act%2520As%2520Single%2520Digit%2520nM%2520Inhibitors%2520of%2520Clinically%2520Relevant%2520EGFR%2520L858R%252FT790M%2520and%2520L858R%252FT790M%252FC797S%2520Mutants%253A%2520An%2520Example%2520of%2520Target%2520Hopping%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D11%26spage%3D4636%26epage%3D4656%26doi%3D10.1021%2Facs.jmedchem.7b00178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uchibori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inase, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span> <span> </span><span class="NLM_article-title">Brigatinib Combined with Anti-EGFR Antibody Overcomes Osimertinib Resistance in EGFR-Mutated Non-Small-Cell Lung Cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14768</span>, <span class="refDoi"> DOI: 10.1038/ncomms14768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1038%2Fncomms14768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=28287083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14768&author=K.+Uchiboriauthor=N.+Inaseauthor=M.+Arakiauthor=M.+Kamadaauthor=S.+Satoauthor=Y.+Okunoauthor=N.+Fujitaauthor=R.+Katayama&title=Brigatinib+Combined+with+Anti-EGFR+Antibody+Overcomes+Osimertinib+Resistance+in+EGFR-Mutated+Non-Small-Cell+Lung+Cancer&doi=10.1038%2Fncomms14768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Uchibori, Ken; Inase, Naohiko; Araki, Mitsugu; Kamada, Mayumi; Sato, Shigeo; Okuno, Yasushi; Fujita, Naoya; Katayama, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14768</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs).  However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib.  Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance.  In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo.  Our original computational simulation demonstrates that brigatinib fits into the ATP-binding pocket of triple-mutant EGFR.  The structure-activity relationship anal. reveals the key component in brigatinib to inhibit the triple-mutant EGFR.  The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibody because of the decrease of surface and total EGFR expression.  Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPEfk1WSIOnLVg90H21EOLACvtfcHk0lhz1WRJTFPVvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D&md5=4c932113642da4a0190e9fcd00222b6e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fncomms14768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14768%26sid%3Dliteratum%253Aachs%26aulast%3DUchibori%26aufirst%3DK.%26aulast%3DInase%26aufirst%3DN.%26aulast%3DAraki%26aufirst%3DM.%26aulast%3DKamada%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26atitle%3DBrigatinib%2520Combined%2520with%2520Anti-EGFR%2520Antibody%2520Overcomes%2520Osimertinib%2520Resistance%2520in%2520EGFR-Mutated%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14768%26doi%3D10.1038%2Fncomms14768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of EGF Receptor Inhibitors That Are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7638</span>, <span class="refDoi"> DOI: 10.1002/anie.201703389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1002%2Fanie.201703389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=7634-7638&issue=26&author=H.+Parkauthor=H.-Y.+Jungauthor=S.+Mahauthor=S.+Hong&title=Discovery+of+EGF+Receptor+Inhibitors+That+Are+Selective+for+the+d746-750%2FT790M%2FC797S+Mutant+through+Structure-Based+de+Novo+Design&doi=10.1002%2Fanie.201703389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of EGF Receptor Inhibitors that are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design</span></div><div class="casAuthors">Park, Hwangseo; Jung, Hoi-Yun; Mah, Shinmee; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7634-7638</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Next-generation epidermal growth factor receptor (EGFR) inhibitors against the d746-750/T790M/C797S mutation were discovered through two-track virtual screening and de novo design.  A no. of nanomolar inhibitors were identified using 2-aryl-4-aminoquinazoline as the mol. core and the modified binding energy function involving a proper dehydration term, which provides important structural insight into the key principles for high inhibitory activities against the d746-750/T790M/C797S mutant.  Furthermore, some of these EGFR inhibitors showed a greater than 1000-fold selectivity for the d746-750/T790M/C797S mutant over the wild type, as well as nanomolar activity against the mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGVR5gzqeK27Vg90H21EOLACvtfcHk0lgs_SsKDI3S6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D&md5=93fd25a8b5af1add58fe8b27723edb0e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fanie.201703389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201703389%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DH.-Y.%26aulast%3DMah%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520EGF%2520Receptor%2520Inhibitors%2520That%2520Are%2520Selective%2520for%2520the%2520d746-750%252FT790M%252FC797S%2520Mutant%2520through%2520Structure-Based%2520de%2520Novo%2520Design%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26issue%3D26%26spage%3D7634%26epage%3D7638%26doi%3D10.1002%2Fanie.201703389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1123-1127&issue=11&author=X.+Luauthor=T.+Zhangauthor=S.-J.+Zhuauthor=Q.+Xunauthor=L.+Tongauthor=X.+Huauthor=Y.+Liauthor=S.+Chanauthor=Y.+Suauthor=Y.+Sunauthor=Y.+Chenauthor=J.+Dingauthor=C.-H.+Yunauthor=H.+Xieauthor=K.+Ding&title=Discovery+of+JND3229+as+a+New+EGFRC797S+Mutant+Inhibitor+with+In+Vivo+Monodrug+Efficacy&doi=10.1021%2Facsmedchemlett.8b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy</span></div><div class="casAuthors">Lu, Xiaoyun; Zhang, Tao; Zhu, Su-Jie; Xun, Qiuju; Tong, Lingjiang; Hu, Xianglong; Li, Yan; Chan, Shingpan; Su, Yi; Sun, Yiming; Chen, Yi; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1123-1127</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EGFRC797S mutation inducing resistance against third generation EGFR inhibitor drugs is an emerging "unmet clin. need" for nonsmall cell lung cancer patients.  The pyrimidopyrimidinone deriv. JND3229 was identified as a new highly potent EGFRC797S inhibitor with single digit nM potency.  It also exhibited good in vitro and in vivo monodrug anticancer efficacy in a xenograft mouse model of BaF3/EGFR19D/T790M/C797S cells.  A high-resoln. x-ray crystallog. structure was also detd. to elucidate the interactions between JND3229 and EGFRT790M/C797S.  The study provides an important structural and chem. basis for future development of new generation EGFRC797S inhibitors as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOPToZCT3HBLVg90H21EOLACvtfcHk0lgs_SsKDI3S6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP&md5=02505ac363697e9a5b1bbe2db0b0357b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DXun%26aufirst%3DQ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520JND3229%2520as%2520a%2520New%2520EGFRC797S%2520Mutant%2520Inhibitor%2520with%2520In%2520Vivo%2520Monodrug%2520Efficacy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127%26doi%3D10.1021%2Facsmedchemlett.8b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7302</span>– <span class="NLM_lpage">7308</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7302-7308&issue=15&author=J.+Shenauthor=T.+Zhangauthor=S.-J.+Zhuauthor=M.+Sunauthor=L.+Tongauthor=M.+Laiauthor=R.+Zhangauthor=W.+Xuauthor=R.+Wuauthor=J.+Dingauthor=C.-H.+Yunauthor=H.+Xieauthor=X.+Luauthor=K.+Ding&title=Structure-Based+Design+of+5-Methylpyrimidopyridone+Derivatives+as+New+Wild-Type+Sparing+Inhibitors+of+the+Epidermal+Growth+Factor+Receptor+Triple+Mutant+%28EGFRL858R%2FT790M%2FC797S%29&doi=10.1021%2Facs.jmedchem.9b00576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)</span></div><div class="casAuthors">Shen, Jiayi; Zhang, Tao; Zhu, Su-Jie; Sun, Min; Tong, Linjiang; Lai, Mengzhen; Zhang, Rong; Xu, Wei; Wu, Ruibo; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7302-7308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Azaheterocyclyl-substituted pyridopyrimidinones such as I were prepd. as selective inhibitors of the mutant epidermal growth factor receptor (EGFR) EGFRL858R/T790M/C797S with selectivity over the wild-type EGFR for potential use in treating osimertinib-resistant non-small-cell lung cancer.  I exhibited an IC50 of 27.5 nM against the EGFRL858R/T790M/C797S mutant, while being significantly less potent against the wild-type EGFR with an IC50 value of > 1.0 μM.  Cocrystallog. structure detn. and computational investigation were conducted to elucidate its target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQFRlnoJItB7Vg90H21EOLACvtfcHk0lgs_SsKDI3S6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI&md5=70ca1144f3b73d0ccd412406b1072a1f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00576%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DStructure-Based%2520Design%2520of%25205-Methylpyrimidopyridone%2520Derivatives%2520as%2520New%2520Wild-Type%2520Sparing%2520Inhibitors%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Triple%2520Mutant%2520%2528EGFRL858R%252FT790M%252FC797S%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D15%26spage%3D7302%26epage%3D7308%26doi%3D10.1021%2Facs.jmedchem.9b00576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klövekorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niggenaber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaßhoff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mühlenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiller, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimsoeth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank-Landeshammer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollipara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengstler, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Otterlo, W. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Osimertinib-Resistant Epidermal Growth Factor Receptor EGFR-T790M/C797S</span>. <i>Chemical Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">10789</span>– <span class="NLM_lpage">10801</span>, <span class="refDoi"> DOI: 10.1039/C9SC03445E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1039%2FC9SC03445E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=31857889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSntr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=10789-10801&author=J.+Lategahnauthor=M.+Keulauthor=P.+Kl%C3%B6vekornauthor=H.+L.+Tumbrinkauthor=J.+Niggenaberauthor=M.+P.+M%C3%BCllerauthor=L.+Hodsonauthor=M.+Fla%C3%9Fhoffauthor=J.+Hardickauthor=T.+Grabeauthor=J.+Engelauthor=C.+Schultz-Fademrechtauthor=M.+Baumannauthor=J.+Ketzerauthor=T.+M%C3%BChlenbergauthor=W.+Hillerauthor=G.+G%C3%BCntherauthor=A.+Ungerauthor=H.+M%C3%BCllerauthor=A.+Heimsoethauthor=C.+Golzauthor=B.+Blank-Landeshammerauthor=L.+Kolliparaauthor=R.+P.+Zahediauthor=C.+Strohmannauthor=J.+G.+Hengstlerauthor=W.+A.+L.+van+Otterloauthor=S.+Bauerauthor=D.+Rauh&title=Inhibition+of+Osimertinib-Resistant+Epidermal+Growth+Factor+Receptor+EGFR-T790M%2FC797S&doi=10.1039%2FC9SC03445E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S</span></div><div class="casAuthors">Lategahn, Jonas; Keul, Marina; Kloevekorn, Philip; Tumbrink, Hannah L.; Niggenaber, Janina; Mueller, Matthias P.; Hodson, Luke; Flasshoff, Maren; Hardick, Julia; Grabe, Tobias; Engel, Julian; Schultz-Fademrecht, Carsten; Baumann, Matthias; Ketzer, Julia; Muehlenberg, Thomas; Hiller, Wolf; Guenther, Georgia; Unger, Anke; Mueller, Heiko; Heimsoeth, Alena; Golz, Christopher; Blank-Landeshammer, Bernhard; Kollipara, Laxmikanth; Zahedi, Rene P.; Strohmann, Carsten; Hengstler, Jan G.; van Otterlo, Willem A. L.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">10789-10801</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Precision medicine has revolutionized the treatment of patients in EGFR driven non-small cell lung cancer (NSCLC).  Targeted drugs show high response rates in genetically defined subsets of cancer patients and markedly increase their progression-free survival as compared to conventional chemotherapy.  However, recurrent acquired drug resistance limits the success of targeted drugs in long-term treatment and requires the const. development of novel efficient inhibitors of drug resistant cancer subtypes.  Herein, we present covalent inhibitors of the drug resistant gatekeeper mutant EGFR-L858R/T790M based on the pyrrolopyrimidine scaffold.  Biochem. and cellular characterization, as well as kinase selectivity profiling and western blot anal., substantiate our approach.  Moreover, the developed compds. possess high activity against multi drug resistant EGFR-L858R/T790M/C797S in biochem. assays due to their highly reversible binding character, that was revealed by characterization of the binding kinetics.  In addn., we present the first X-ray crystal structures of covalent inhibitors in complex with C797S-mutated EGFR which provide detailed insight into their binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpOILrK_TpebVg90H21EOLACvtfcHk0liCLKfKcsxg5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSntr7N&md5=0dd60e9ade21e33ae5656d50175e39ba</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2FC9SC03445E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9SC03445E%26sid%3Dliteratum%253Aachs%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKl%25C3%25B6vekorn%26aufirst%3DP.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DNiggenaber%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%2BP.%26aulast%3DHodson%26aufirst%3DL.%26aulast%3DFla%25C3%259Fhoff%26aufirst%3DM.%26aulast%3DHardick%26aufirst%3DJ.%26aulast%3DGrabe%26aufirst%3DT.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DHiller%26aufirst%3DW.%26aulast%3DG%25C3%25BCnther%26aufirst%3DG.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DH.%26aulast%3DHeimsoeth%26aufirst%3DA.%26aulast%3DGolz%26aufirst%3DC.%26aulast%3DBlank-Landeshammer%26aufirst%3DB.%26aulast%3DKollipara%26aufirst%3DL.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DStrohmann%26aufirst%3DC.%26aulast%3DHengstler%26aufirst%3DJ.%2BG.%26aulast%3Dvan%2BOtterlo%26aufirst%3DW.%2BA.%2BL.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInhibition%2520of%2520Osimertinib-Resistant%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520EGFR-T790M%252FC797S%26jtitle%3DChemical%2520Science%26date%3D2019%26volume%3D10%26spage%3D10789%26epage%3D10801%26doi%3D10.1039%2FC9SC03445E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel 9-Heterocyclyl Substituted 9H-Purines as L858R/T790M/C797S Mutant EGFR Tyrosine Kinase Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">111888</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1016%2Fj.ejmech.2019.111888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=31787359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12isrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2020&pages=111888&author=H.+Leiauthor=S.+Fanauthor=H.+Zhangauthor=Y.-J.+Liuauthor=Y.-Y.+Heiauthor=J.-J.+Zhangauthor=A.+Q.+Zhengauthor=M.+Xinauthor=S.-Q.+Zhang&title=Discovery+of+Novel+9-Heterocyclyl+Substituted+9H-Purines+as+L858R%2FT790M%2FC797S+Mutant+EGFR+Tyrosine+Kinase+Inhibitors&doi=10.1016%2Fj.ejmech.2019.111888"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="#"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=&md5=9874b665cc7a056b8e2f928dd3112440</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111888%26sid%3Dliteratum%253Aachs%26aulast%3DLei%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.-J.%26aulast%3DHei%26aufirst%3DY.-Y.%26aulast%3DZhang%26aufirst%3DJ.-J.%26aulast%3DZheng%26aufirst%3DA.%2BQ.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.-Q.%26atitle%3DDiscovery%2520of%2520Novel%25209-Heterocyclyl%2520Substituted%25209H-Purines%2520as%2520L858R%252FT790M%252FC797S%2520Mutant%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D186%26spage%3D111888%26doi%3D10.1016%2Fj.ejmech.2019.111888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döbel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfgartner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simov, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span> <span> </span><span class="NLM_article-title">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10272</span>– <span class="NLM_lpage">10293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10272-10293&issue=22&author=H.+Engelhardtauthor=D.+B%C3%B6seauthor=M.+Petronczkiauthor=D.+Scharnauthor=G.+Baderauthor=A.+Baumauthor=A.+Bergnerauthor=E.+Chongauthor=S.+D%C3%B6belauthor=G.+Eggerauthor=C.+Engelhardtauthor=P.+Ettmayerauthor=J.+E.+Fuchsauthor=T.+Gerstbergerauthor=N.+Gonnellaauthor=A.+Grimmauthor=E.+Grondalauthor=N.+Haddadauthor=B.+Hopfgartnerauthor=R.+Kousekauthor=M.+Krawiecauthor=M.+Krizauthor=L.+Lamarreauthor=J.+Leungauthor=M.+Mayerauthor=N.+D.+Patelauthor=B.+P.+Simovauthor=J.+T.+Reevesauthor=R.+Schnitzerauthor=A.+Schrenkauthor=B.+Sharpsauthor=F.+Solcaauthor=H.+Stadtm%C3%BCllerauthor=Z.+Tanauthor=T.+Wunbergauthor=A.+Zoephelauthor=D.+B.+McConnell&title=Start+Selective+and+Rigidify%3A+The+Discovery+Path+toward+a+Next+Generation+of+EGFR+Tyrosine+Kinase+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Engelhardt, Harald; Boese, Dietrich; Petronczki, Mark; Scharn, Dirk; Bader, Gerd; Baum, Anke; Bergner, Andreas; Chong, Eugene; Doebel, Sandra; Egger, Georg; Engelhardt, Christian; Ettmayer, Peter; Fuchs, Julian E.; Gerstberger, Thomas; Gonnella, Nina; Grimm, Andreas; Grondal, Elisabeth; Haddad, Nizar; Hopfgartner, Barbara; Kousek, Roland; Krawiec, Mariusz; Kriz, Monika; Lamarre, Lyne; Leung, Joyce; Mayer, Moriz; Patel, Nitinchandra D.; Simov, Biljana Peric; Reeves, Jonathan T.; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Solca, Flavio; Stadtmueller, Heinz; Tan, Zhulin; Wunberg, Tobias; Zoephel, Andreas; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10272-10293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.  While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable.  Most patients relapse within two years of therapy often due to acquisition of an addnl. mutation in EGFR kinase domain that confers resistance to TKIs.  Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs.  Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI.  BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.  Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the mol. through macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmZRwjkT9vdLVg90H21EOLACvtfcHk0ljAyHKg50KlAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK&md5=0f8d0eed6ae93bfbb8f7a6337bb1ecd3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DB%25C3%25B6se%26aufirst%3DD.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DBergner%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DE.%26aulast%3DD%25C3%25B6bel%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DEngelhardt%26aufirst%3DC.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGonnella%26aufirst%3DN.%26aulast%3DGrimm%26aufirst%3DA.%26aulast%3DGrondal%26aufirst%3DE.%26aulast%3DHaddad%26aufirst%3DN.%26aulast%3DHopfgartner%26aufirst%3DB.%26aulast%3DKousek%26aufirst%3DR.%26aulast%3DKrawiec%26aufirst%3DM.%26aulast%3DKriz%26aufirst%3DM.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BD.%26aulast%3DSimov%26aufirst%3DB.%2BP.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DStadtm%25C3%25BCller%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26atitle%3DStart%2520Selective%2520and%2520Rigidify%253A%2520The%2520Discovery%2520Path%2520toward%2520a%2520Next%2520Generation%2520of%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293%26doi%3D10.1021%2Facs.jmedchem.9b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gureasko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1016%2Fj.cell.2006.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=16777603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=1137-1149&issue=6&author=X.+Zhangauthor=J.+Gureaskoauthor=K.+Shenauthor=P.+A.+Coleauthor=J.+Kuriyan&title=An+Allosteric+Mechanism+for+Activation+of+the+Kinase+Domain+of+Epidermal+Growth+Factor+Receptor&doi=10.1016%2Fj.cell.2006.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span></div><div class="casAuthors">Zhang, Xuewu; Gureasko, Jodi; Shen, Kui; Cole, Philip A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1137-1149</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition.  We find that the EGFR kinase domain can be activated by increasing its local concn. or by mutating a leucine (L834R) in the activation loop, the phosphorylation of which is not required for activation.  This suggests that the kinase domain is intrinsically auto-inhibited, and an intermol. interaction promotes its activation.  Using further mutational anal. and crystallog. we demonstrate that the auto-inhibited conformation of the EGFR kinase domain resembles that of Src and cyclin-dependent kinases (CDKs).  EGFR activation results from the formation of an asym. dimer in which the C-terminal lobe of one kinase domain plays a role analogous to that of cyclin in activated CDK/cyclin complexes.  The CDK/cyclin-like complex formed by two kinase domains thus explains the activation of EGFR-family receptors by homo- or heterodimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRAzLF-wK7Vg90H21EOLACvtfcHk0ljAyHKg50KlAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D&md5=f7b6795851425346f588cbd682125c93</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGureasko%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DAn%2520Allosteric%2520Mechanism%2520for%2520Activation%2520of%2520the%2520Kinase%2520Domain%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%26jtitle%3DCell%26date%3D2006%26volume%3D125%26issue%3D6%26spage%3D1137%26epage%3D1149%26doi%3D10.1016%2Fj.cell.2006.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaffrey, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazhanisamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bemis, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgibbon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murcko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M. S. S.</span></span> <span> </span><span class="NLM_article-title">The Structural Basis for the Specificity of Pyridinylimidazole Inhibitors of p38 MAP Kinase</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">423</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/S1074-5521(97)90194-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1016%2FS1074-5521%2897%2990194-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=9224565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADyaK2sXks1yju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=423-431&issue=6&author=K.+P.+Wilsonauthor=P.+G.+McCaffreyauthor=K.+Hsiaoauthor=S.+Pazhanisamyauthor=V.+Galulloauthor=G.+W.+Bemisauthor=M.+J.+Fitzgibbonauthor=P.+R.+Caronauthor=M.+A.+Murckoauthor=M.+S.+S.+Su&title=The+Structural+Basis+for+the+Specificity+of+Pyridinylimidazole+Inhibitors+of+p38+MAP+Kinase&doi=10.1016%2FS1074-5521%2897%2990194-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase</span></div><div class="casAuthors">Wilson, Keith P.; McCaffrey, Patricia G.; Hsiao, Kathy; Pazhinisamy, Sam; Galullo, Vincent; Bemis, Guy W.; Fitzgibbon, Matthew J.; Caron, Paul R.; Murcko, Mark A.; Su, Michael S. S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">423-431</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">The p38 mitogen-activated protein (MAP) kinase regulates signal transduction in response to environmental stress.  Pyridinylimidazole compds. are specific inhibitors of p38 MAP kinase that block the prodn. of the cytokines interleukin-1β and tumor necrosis factor α, and they are effective in animal models of arthritis, bone resorption and endotoxin shock.  These compds. have been useful probes for studying the physiol. functions of the p38-mediated MAP kinase pathway.  We report the crystal structure of a novel pyridinylimidazole compd. complexed with p38 MAP kinase, and we demonstrate that this compd. binds to the same site on the kinase as does ATP.  Mutagenesis showed that a single residue difference between p38 MAP kinase and other MAP kinases is sufficient to confer selectivity among pyridinylimidazole compds.  Our results reveal how pyridinylimidazole compds. are potent and selective inhibitors of p38 MAP kinase but not other MAP kinases.  It should now be possible to design other specific inhibitors of activated p38 MAP kinase using the structure of the nonphosphorylated enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpURyeat1gd6LVg90H21EOLACvtfcHk0lhmwRuM4EUX3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXks1yju7w%253D&md5=5d8f3b10eceae3f344d4daa7852ac190</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2897%2990194-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252897%252990194-0%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DK.%2BP.%26aulast%3DMcCaffrey%26aufirst%3DP.%2BG.%26aulast%3DHsiao%26aufirst%3DK.%26aulast%3DPazhanisamy%26aufirst%3DS.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DFitzgibbon%26aufirst%3DM.%2BJ.%26aulast%3DCaron%26aufirst%3DP.%2BR.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26aulast%3DSu%26aufirst%3DM.%2BS.%2BS.%26atitle%3DThe%2520Structural%2520Basis%2520for%2520the%2520Specificity%2520of%2520Pyridinylimidazole%2520Inhibitors%2520of%2520p38%2520MAP%2520Kinase%26jtitle%3DChem.%2520Biol.%26date%3D1997%26volume%3D4%26issue%3D6%26spage%3D423%26epage%3D431%26doi%3D10.1016%2FS1074-5521%2897%2990194-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikounis, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Keefe, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scapin, G.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for p38α MAP Kinase Quinazolinone and Pyridol-Pyrimidine Inhibitor Specificity</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">764</span>– <span class="NLM_lpage">769</span>, <span class="refDoi"> DOI: 10.1038/nsb949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1038%2Fnsb949" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=764-769&issue=9&author=C.+E.+Fitzgeraldauthor=S.+B.+Patelauthor=J.+W.+Beckerauthor=P.+M.+Cameronauthor=D.+Zallerauthor=V.+B.+Pikounisauthor=S.+J.+O%E2%80%99Keefeauthor=G.+Scapin&title=Structural+Basis+for+p38%CE%B1+MAP+Kinase+Quinazolinone+and+Pyridol-Pyrimidine+Inhibitor+Specificity&doi=10.1038%2Fnsb949"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnsb949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb949%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DC.%2BE.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DBecker%26aufirst%3DJ.%2BW.%26aulast%3DCameron%26aufirst%3DP.%2BM.%26aulast%3DZaller%26aufirst%3DD.%26aulast%3DPikounis%26aufirst%3DV.%2BB.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DS.%2BJ.%26aulast%3DScapin%26aufirst%3DG.%26atitle%3DStructural%2520Basis%2520for%2520p38%25CE%25B1%2520MAP%2520Kinase%2520Quinazolinone%2520and%2520Pyridol-Pyrimidine%2520Inhibitor%2520Specificity%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D10%26issue%3D9%26spage%3D764%26epage%3D769%26doi%3D10.1038%2Fnsb949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ansideri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macedo, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eitel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Gokha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinad, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpellini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schollmeyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaum, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span> <span> </span><span class="NLM_article-title">Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">7809</span>– <span class="NLM_lpage">7831</span>, <span class="refDoi"> DOI: 10.1021/acsomega.8b00668</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.8b00668" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlSjtLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=7809-7831&issue=7&author=F.+Ansideriauthor=J.+T.+Macedoauthor=M.+Eitelauthor=A.+El-Gokhaauthor=D.+S.+Zinadauthor=C.+Scarpelliniauthor=M.+Kudoloauthor=D.+Schollmeyerauthor=F.+M.+Boecklerauthor=B.+S.+Blaumauthor=S.+A.+Lauferauthor=P.+Koch&title=Structural+Optimization+of+a+Pyridinylimidazole+Scaffold%3A+Shifting+the+Selectivity+from+p38%CE%B1+Mitogen-Activated+Protein+Kinase+to+c-Jun+N-Terminal+Kinase+3&doi=10.1021%2Facsomega.8b00668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3</span></div><div class="casAuthors">Ansideri, Francesco; Macedo, Joana T.; Eitel, Michael; El-Gokha, Ahmed; Zinad, Dhafer S.; Scarpellini, Camilla; Kudolo, Mark; Schollmeyer, Dieter; Boeckler, Frank M.; Blaum, Baerbel S.; Laufer, Stefan A.; Koch, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">7809-7831</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from known p38α mitogen-activated protein kinase (MAPK) inhibitors, a series of inhibitors of the c-Jun N-terminal kinase (JNK) 3 was obtained.  Altering the substitution pattern of the pyridinylimidazole scaffold proved to be effective in shifting the inhibitory activity from the original target p38α MAPK to the closely related JNK3.  In particular, a significant improvement for JNK3 selectivity could be achieved by addressing the hydrophobic region I with a small Me group.  Furthermore, addnl. structural modifications permitted to explore structure-activity relationships.  The most potent inhibitor 4-(4-methyl-2-(methylthio)-1H-imidazol-5-yl)-N-(4-morpholinophenyl)pyridin-2-amine showed an IC50 value for the JNK3 in the low triple digit nanomolar range and its binding mode was confirmed by x-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNY36Te3RXDLVg90H21EOLACvtfcHk0lhmwRuM4EUX3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlSjtLvF&md5=4cddf5cade2457ceefe9e5468f2d27ca</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsomega.8b00668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.8b00668%26sid%3Dliteratum%253Aachs%26aulast%3DAnsideri%26aufirst%3DF.%26aulast%3DMacedo%26aufirst%3DJ.%2BT.%26aulast%3DEitel%26aufirst%3DM.%26aulast%3DEl-Gokha%26aufirst%3DA.%26aulast%3DZinad%26aufirst%3DD.%2BS.%26aulast%3DScarpellini%26aufirst%3DC.%26aulast%3DKudolo%26aufirst%3DM.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26aulast%3DBlaum%26aufirst%3DB.%2BS.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DKoch%26aufirst%3DP.%26atitle%3DStructural%2520Optimization%2520of%2520a%2520Pyridinylimidazole%2520Scaffold%253A%2520Shifting%2520the%2520Selectivity%2520from%2520p38%25CE%25B1%2520Mitogen-Activated%2520Protein%2520Kinase%2520to%2520c-Jun%2520N-Terminal%2520Kinase%25203%26jtitle%3DACS%2520Omega%26date%3D2018%26volume%3D3%26issue%3D7%26spage%3D7809%26epage%3D7831%26doi%3D10.1021%2Facsomega.8b00668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&issue=10&author=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+Brigatinib+%28AP26113%29%2C+a+Phosphine+Oxide-Containing%2C+Potent%2C+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0lj97NZPOq8d_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520Brigatinib%2520%2528AP26113%2529%252C%2520a%2520Phosphine%2520Oxide-Containing%252C%2520Potent%252C%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D10%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahcall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent Dual ALK and EGFR T790M Inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1016%2Fj.ejmech.2017.04.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=28528303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlWnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=497-510&author=J.+Jangauthor=J.+B.+Sonauthor=C.+Toauthor=M.+Bahcallauthor=S.+Y.+Kimauthor=S.+Y.+Kangauthor=M.+Mushajiangauthor=Y.+Leeauthor=P.+A.+J%C3%A4nneauthor=H.+G.+Choiauthor=N.+S.+Gray&title=Discovery+of+a+Potent+Dual+ALK+and+EGFR+T790M+Inhibitor&doi=10.1016%2Fj.ejmech.2017.04.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a potent dual ALK and EGFR T790M inhibitor</span></div><div class="casAuthors">Jang, Jaebong; Son, Jung Beom; To, Ciric; Bahcall, Magda; Kim, So Young; Kang, Seock Yong; Mushajiang, Mierzhati; Lee, Younho; Janne, Pasi A.; Choi, Hwan Geun; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">497-510</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The mutational activations of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) are validated oncogenic events and the targets of approved drugs to treat non-small cell lung cancer (NSCLC).  Here we report highly potent dual small mol. inhibitors of both ALK and EGFR, particularly the T790M mutant which confers resistance to first generation EGFR inhibitors.  Dual ALK/EGFR inhibitors may provide an efficient approach to prevent resistance that arises as a consequence of clin. reported reciprocal activation mechanisms.  Our lead compd. 7c displayed remarkable inhibitory activities against both ALK and EGFR in enzymic and cellular assays.  We demonstrate that 7c is capable of recapitulating the signaling effects and antiproliferative activity of combined treatment with the approved ALK inhibitor ceritinib and T790M EGFR inhibitor osimertinib against patient-derived non-small cell lung cancer cell line, DFCI032 which harbors both EML4-ALK and activated EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox5vB-cOxtibVg90H21EOLACvtfcHk0lj97NZPOq8d_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlWnsLY%253D&md5=69112257da96f04666227d52bd102ae7</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.079%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DSon%26aufirst%3DJ.%2BB.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520Dual%2520ALK%2520and%2520EGFR%2520T790M%2520Inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D136%26spage%3D497%26epage%3D510%26doi%3D10.1016%2Fj.ejmech.2017.04.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) Resistance with Mutant-Selective Allosteric Inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">129</span>, <span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129&author=Y.+Jiaauthor=C.-H.+Yunauthor=E.+Parkauthor=D.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+Zhangauthor=S.+Palakurthiauthor=J.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.-Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+Resistance+with+Mutant-Selective+Allosteric+Inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0liNIFmuIxAF9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520Resistance%2520with%2520Mutant-Selective%2520Allosteric%2520Inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D129%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1158%2F2159-8290.CD-18-0903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=31092401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=926-943&issue=7&author=C.+Toauthor=J.+Jangauthor=T.+Chenauthor=E.+Parkauthor=M.+Mushajiangauthor=D.+J.+H.+De+Clercqauthor=M.+Xuauthor=S.+Wangauthor=M.+D.+Cameronauthor=D.+E.+Heppnerauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=A.+Yangauthor=S.+E.+Dahlbergauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Single+and+Dual+Targeting+of+Mutant+EGFR+with+an+Allosteric+Inhibitor&doi=10.1158%2F2159-8290.CD-18-0903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Single and dual targeting of mutant EGFR with an allosteric inhibitor</span></div><div class="casAuthors">To, Ciric; Jang, Jaebong; Chen, Ting; Park, Eunyoung; Mushajiang, Mierzhati; De Clercq, Dries J. H.; Xu, Man; Wang, Stephen; Cameron, Michael D.; Heppner, David E.; Shin, Bo Hee; Gero, Thomas W.; Yang, Annan; Dahlberg, Suzanne E.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">926-943</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding.  In this study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent can inhibit cell proliferation and EGFRL858R/T790M/C797S signaling in vitro and in vivo.  However, increased EGFR dimer formation limits treatment efficacy and leads to drug resistance.  Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR.  The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared with either single agent alone.  Collectively, our findings suggest that the combination of a covalent mutant-selective ATP-competitive inhibitor and an allosteric EGFR inhibitor may be an effective therapeutic approach for patients with EGFR-mutant lung cancer.  Significance: The clin. efficacy of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant lung cancer is limited by acquired drug resistance, thus highlighting the need for alternative strategies to inhibit EGFR.  Here, we identify a mutant EGFR allosteric inhibitor that is effective as a single agent and in combination with the EGFR TKI osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAPeE4TuEx6bVg90H21EOLACvtfcHk0liNIFmuIxAF9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGg&md5=cc2f3b0eb997626cf8243988f91c8818</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0903%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DSingle%2520and%2520Dual%2520Targeting%2520of%2520Mutant%2520EGFR%2520with%2520an%2520Allosteric%2520Inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26issue%3D7%26spage%3D926%26epage%3D943%26doi%3D10.1158%2F2159-8290.CD-18-0903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1549</span>– <span class="NLM_lpage">1553</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00381</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00381" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1549-1553&issue=11&author=D.+J.+H.+De%0AClercqauthor=D.+E.+Heppnerauthor=C.+Toauthor=J.+Jangauthor=E.+Parkauthor=C.-H.+Yunauthor=M.+Mushajiangauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=D.+A.+Scottauthor=P.+A.+J%C3%A4nneauthor=M.+J.+Eckauthor=N.+S.+Gray&title=Discovery+and+Optimization+of+Dibenzodiazepinones+as+Allosteric+Mutant-Selective+EGFR+Inhibitors&doi=10.1021%2Facsmedchemlett.9b00381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors</span></div><div class="casAuthors">De Clercq, Dries J. H.; Heppner, David E.; To, Ciric; Jang, Jaebong; Park, Eunyoung; Yun, Cai-Hong; Mushajiang, Mierzhati; Shin, Bo Hee; Gero, Thomas W.; Scott, David A.; Janne, Pasi A.; Eck, Michael J.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1549-1553</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors represent a promising new therapeutic strategy for targeting kinases harboring oncogenic driver mutations in cancers.  Here, we report the discovery, optimization, and structural characterization of allosteric mutant-selective EGFR inhibitors comprising a 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one scaffold.  Our structure-based medicinal chem. effort yielded an inhibitor (3) of the EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) mutants with an IC50 of ∼10 nM and high selectivity, as assessed by kinome profiling.  Further efforts to develop allosteric dibenzodiazepinone inhibitors may serve as the basis for new therapeutic options for targeting drug-resistant EGFR mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreyvHIT2KWY7Vg90H21EOLACvtfcHk0liNIFmuIxAF9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajt7%252FM&md5=9d8771e7444fa58f06dff284f6f393da</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00381%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Dibenzodiazepinones%2520as%2520Allosteric%2520Mutant-Selective%2520EGFR%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D11%26spage%3D1549%26epage%3D1553%26doi%3D10.1021%2Facsmedchemlett.9b00381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">873</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00564</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00564" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=869-873&issue=6&author=Q.+Liauthor=T.+Zhangauthor=S.+Liauthor=L.+Tongauthor=J.+Liauthor=Z.+Suauthor=F.+Fengauthor=D.+Sunauthor=Y.+Tongauthor=X.+Wangauthor=Z.+Zhaoauthor=L.+Zhuauthor=J.+Dingauthor=H.+Liauthor=H.+Xieauthor=Y.+Xu&title=Discovery+of+Potent+and+Noncovalent+Reversible+EGFR+Kinase+Inhibitors+of+EGFRL858R%2FT790M%2FC797S&doi=10.1021%2Facsmedchemlett.8b00564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S</span></div><div class="casAuthors">Li, Qiannan; Zhang, Tao; Li, Shiliang; Tong, Linjiang; Li, Junyu; Su, Zhicheng; Feng, Fang; Sun, Deheng; Tong, Yi; Wang, Xia; Zhao, Zhenjiang; Zhu, Lili; Ding, Jian; Li, Honglin; Xie, Hua; Xu, Yufang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">869-873</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we describe the discovery and optimization of a series of noncovalent reversible epidermal growth factor receptor inhibitors of EGFRL858R/T790M/C797S.  One of the most promising compds., I, inhibited the enzymic activity of EGFRL858R/T790M/C797S with an IC50 value of 2.2 nM.  Cell proliferation assays showed that I effectively and selectively inhibited the growth of EGFRL858R/T790M/C797S-dependent cells.  This series of compds., which occupy both the ATP binding site and the allosteric site of the EGFR kinase, may serve as a basis for the development of fourth-generation EGFR inhibitors for L858R/T790M/C797S mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcQ04p4560bVg90H21EOLACvtfcHk0liDn3yzj_EyGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFams7o%253D&md5=396eb9b29217fbb74189193a544819b3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00564%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Potent%2520and%2520Noncovalent%2520Reversible%2520EGFR%2520Kinase%2520Inhibitors%2520of%2520EGFRL858R%252FT790M%252FC797S%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D6%26spage%3D869%26epage%3D873%26doi%3D10.1021%2Facsmedchemlett.8b00564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&issue=3&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+Lung+Cancer-Derived+EGFR+Mutants+and+Inhibitor+Complexes%3A+Mechanism+of+Activation+and+Insights+into+Differential+Inhibitor+Sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0liDn3yzj_EyGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520Lung%2520Cancer-Derived%2520EGFR%2520Mutants%2520and%2520Inhibitor%2520Complexes%253A%2520Mechanism%2520of%2520Activation%2520and%2520Insights%2520into%2520Differential%2520Inhibitor%2520Sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26issue%3D3%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">11629</span>– <span class="NLM_lpage">11633</span>, <span class="refDoi"> DOI: 10.1002/anie.201805187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1002%2Fanie.201805187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVCgsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=11629-11633&issue=36&author=J.+Jangauthor=J.+Sonauthor=E.+Parkauthor=T.+Kosakaauthor=J.+A.+Saxonauthor=D.+J.+H.+De+Clercqauthor=H.+G.+Choiauthor=J.+Tanizakiauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+a+Highly+Potent+and+Broadly+Effective+Epidermal+Growth+Factor+Receptor+and+HER2+Exon+20+Insertion+Mutant+Inhibitor&doi=10.1002%2Fanie.201805187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor</span></div><div class="casAuthors">Jang, Jaebong; Son, Jieun; Park, Eunyoung; Kosaka, Takayuki; Saxon, Jamie A.; De Clercq, Dries J. H.; Choi, Hwan Geun; Tanizaki, Junko; Eck, Michael J.; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">11629-11633</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Exon 20 insertion (Ex20Ins) mutations are the third most prevalent epidermal growth factor receptor (EGFR) activating mutation and the most prevalent HER2 mutation in non-small cell lung cancer (NSCLC).  Novel therapeutics for the patients with Ex20Ins mutations are urgently needed, due to their poor responses to the currently approved EGFR and HER2 inhibitors.  Here the authors report the discovery of highly potent and broadly effective EGFR and HER2 Ex20Ins mutant inhibitors.  The co-crystal structure of compd. 1b (4-fluorobenzyl (3-acrylamidophenyl)(2-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)carbamate) in complex with wild type EGFR clearly revealed an addnl. hydrophobic interaction of 4-fluorobenzene ring within a deep hydrophobic pocket, which has not been widely exploited in the development of EGFR and HER2 inhibitors.  As compared with afatinib, compd. 1a (4-fluorobenzyl (3-acrylamidophenyl)(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)carbamate) exhibited superior inhibition of proliferation and signaling pathways in Ba/F3 cells harboring either EGFR or HER2 Ex20Ins mutations, and in the EGFR P772_H773insPNP patient-derived lung cancer cell line DFCI127.  The authors' study identifies promising strategies for development of EGFR and HER2 Ex20Ins mutant inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8fG9GbrLyY7Vg90H21EOLACvtfcHk0liDn3yzj_EyGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVCgsLrI&md5=06891dff2f3b84f25fe0a895ba368b00</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fanie.201805187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201805187%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DSon%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DSaxon%26aufirst%3DJ.%2BA.%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520Highly%2520Potent%2520and%2520Broadly%2520Effective%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520and%2520HER2%2520Exon%252020%2520Insertion%2520Mutant%2520Inhibitor%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26issue%3D36%26spage%3D11629%26epage%3D11633%26doi%3D10.1002%2Fanie.201805187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Ly, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J. R.</span></span> <span> </span><span class="NLM_article-title">A High-Throughput Radiometric Kinase Assay</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1360</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-3073-9_7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1007%2F978-1-4939-3073-9_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=26501904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVems78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1360&publication_year=2016&pages=87-95&author=K.+C.+Duong-Lyauthor=J.+R.+Peterson&title=A+High-Throughput+Radiometric+Kinase+Assay&doi=10.1007%2F978-1-4939-3073-9_7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A High-Throughput Radiometric Kinase Assay</span></div><div class="casAuthors">Duong-Ly, Krisna C.; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1360</span>
        (<span class="NLM_cas:issue">Kinase Screening and Profiling</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aberrant kinase signaling has been implicated in a no. of diseases.  While kinases have become attractive drug targets, only a small fraction of human protein kinases have validated inhibitors.  Screening of libraries of compds. against a kinase or kinases of interest is routinely performed during kinase inhibitor development to identify promising scaffolds for a particular target and to identify kinase targets for compds. of interest.  Screening of more focused compd. libraries may also be conducted in the later stages of inhibitor development to improve potency and optimize selectivity.  The dot blot kinase assay is a robust, high-throughput kinase assay that can be used to screen a no. of small-mol. compds. against one kinase of interest or several kinases.  Here, a protocol for a dot blot kinase assay used for measuring insulin receptor kinase activity is presented.  This protocol can be readily adapted for use with other protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1VWJf_NuisLVg90H21EOLACvtfcHk0libSE6jfhLF6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVems78%253D&md5=27351bf4930bd2a5168b109436b17945</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-3073-9_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-3073-9_7%26sid%3Dliteratum%253Aachs%26aulast%3DDuong-Ly%26aufirst%3DK.%2BC.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DA%2520High-Throughput%2520Radiometric%2520Kinase%2520Assay%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2016%26volume%3D1360%26spage%3D87%26epage%3D95%26doi%3D10.1007%2F978-1-4939-3073-9_7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastassiadis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deacon, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J. R.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Assay of Kinase Catalytic Activity Reveals Features of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1038/nbt.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1038%2Fnbt.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=22037377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1039-45&issue=11&author=T.+Anastassiadisauthor=S.+W.+Deaconauthor=K.+Devarajanauthor=H.+Maauthor=J.+R.+Peterson&title=Comprehensive+Assay+of+Kinase+Catalytic+Activity+Reveals+Features+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span></div><div class="casAuthors">Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1045</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents.  Owing to evolutionary conservation of the ATP-binding site, most kinase inhibitors that target this site promiscuously inhibit multiple kinases.  Interpretation of expts. that use these compds. is confounded by a lack of data on the comprehensive kinase selectivity of most inhibitors.  Here we used functional assays to profile the activity of 178 com. available kinase inhibitors against a panel of 300 recombinant protein kinases.  Quant. anal. revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.  Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.  The results have implications for drug development and provide a resource for selecting compds. to elucidate kinase function and for interpreting the results of expts. involving kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUljWIhZGPkrVg90H21EOLACvtfcHk0libSE6jfhLF6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E&md5=b2f705509b0e09afa46b01d4669f0515</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2017%26sid%3Dliteratum%253Aachs%26aulast%3DAnastassiadis%26aufirst%3DT.%26aulast%3DDeacon%26aufirst%3DS.%2BW.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DComprehensive%2520Assay%2520of%2520Kinase%2520Catalytic%2520Activity%2520Reveals%2520Features%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26issue%3D11%26spage%3D1039%26epage%3D45%26doi%3D10.1038%2Fnbt.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yonggang Meng, Bin Yu, He Huang, Youmei Peng, Ertong Li, Yongfang Yao, Chuanjun Song, Wenquan Yu, Kaikai Zhu, Kai Wang, Dongxu Yi, Jinfa Du, <span class="NLM_string-name hlFld-ContribAuthor">Junbiao Chang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 925-937. <a href="https://doi.org/10.1021/acs.jmedchem.0c02005" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BDosimertinib%25252C%252Ba%252BHighly%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BEfficacious%252BDeuterated%252BEGFR%252BTargeting%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DMeng%26aufirst%3DYonggang%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D19112020%26date%3D18012021%26volume%3D64%26issue%3D2%26spage%3D925%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10726-10741. <a href="https://doi.org/10.1021/acs.jmedchem.0c00507" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00507%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252BChemistry%252BStrategies%252Bfor%252Bthe%252BDevelopment%252Bof%252BKinase%252BInhibitors%252BTargeting%252BPoint%252BMutations%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27032020%26date%3D02062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10726%26epage%3D10741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Scalvini</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>, <span class="hlFld-ContribAuthor ">Silvia  La Monica</span>, <span class="hlFld-ContribAuthor ">Marcello  Tiseo</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>. </span><span class="cited-content_cbyCitation_article-title">Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>190 </em>, 114643. <a href="https://doi.org/10.1016/j.bcp.2021.114643" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114643%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DFighting%252Btertiary%252Bmutations%252Bin%252BEGFR-driven%252Blung-cancers%25253A%252BCurrent%252Badvances%252Band%252Bfuture%252Bperspectives%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DScalvini%26aufirst%3DLaura%26date%3D2021%26volume%3D190%26spage%3D114643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David E.  Heppner</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>. </span><span class="cited-content_cbyCitation_article-title">A structural perspective on targeting the
              RTK
              /Ras/
              MAP
              kinase pathway in cancer. </span><span class="cited-content_cbyCitation_journal-name">Protein Science</span><span> <strong>2021,</strong> <em>30 </em>
                                    (8)
                                     , 1535-1553. <a href="https://doi.org/10.1002/pro.4125" title="DOI URL">https://doi.org/10.1002/pro.4125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pro.4125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpro.4125%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520Science%26atitle%3DA%252Bstructural%252Bperspective%252Bon%252Btargeting%252Bthe%252BRTK%252B%25252FRas%25252F%252BMAP%252Bkinase%252Bpathway%252Bin%252Bcancer%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D8%26spage%3D1535%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Trisubstituted imidazole inhibitor chemical structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures and binding modes of <b>1</b> (A, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5N">6V5N</a>), <b>2</b> (B, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5P">6V5P</a>), <b>3</b> (C, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6O">6V6O</a>), <b>4</b> (D, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6K">6V6K</a>), and <b>5</b> (E, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V66">6V66</a>) in complex with EGFR(T790M/V948R). The V948R mutation enables the kinase domain to crystallize in the inactive state.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures and binding modes of <b>3</b> (A, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VH4">6VH4</a>), <b>4</b> (B, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VHN">6VHN</a>), and <b>5</b> (C, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VHP">6VHP</a>) bound to WT EGFR kinase domain in the active state.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structural overlay of <b>3</b> crystallized in complex with EGFR(T790M/V948R) (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6O">6V6O</a>) in the inactive state and WT EGFR (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VH4">6VH4</a>) in the active state.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SeO<sub>2</sub>, 1,4-dioxane, H<sub>2</sub>O, 60 °C to rf (73%); (b) 4-methoxybutanal, NH<sub>4</sub>OAc, MeOH, rt (16%); (c) NaH, MOM-Cl, THF, 0 °C to rt (77%); (d) <i>N</i>-iodosuccinimide, MeOH, 0°C (94%); (e) <i>i</i>-PrMgCl·LiCl, Sn(Bu)<sub>3</sub>Cl, THF (quant); (f) 4-chloro-1-(methoxymethyl)-2-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine, Pd(OAc)<sub>2</sub>, XPhos, 1,4-dioxane, rf (52%); (g) HCl(aq), MeOH, rf (58%).</p></p></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>S</i>-methylisothiourea, NaHCO<sub>3</sub>, THF/water, reflux (50%); (b) NaH, SEM-Cl, THF, 0 °C to rt (91%); (c) NBS, THF, −30°C (85%); (d) MeOtf, DCM, TFA, rt (70%); (e)<i>N</i>-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetamide, P(<i>t</i>-Bu)<sub>3</sub> Pd G3, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane/water, 50°C (39%); (f) NaOH, MeOH/water, 50 °C (88%); (g) <i>N</i>-(3-bromo-4-methoxyphenyl)acrylamide, Brettphos Pd G3, Cs<sub>2</sub>CO<sub>3</sub>, t-BuOH/1,4-dioxane, rf (67%).</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) urotropine, chloroform, 50 °C, then EtOH, HCl(aq), rf (97%); (b) KSCN, HOAc, rf (71%); (c) 2-bromoethan-1-ol, K<sub>2</sub>CO<sub>3</sub>, MeOH, rt (quant); (d) NaH, SEM-Cl, THF, 0 °C (67%); (e) NBS, MeCN, −30°C (quant); (f) NaH, MeI, THF, −15°C (75%); (g) <i>N</i>-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetamide, P(<i>t</i>-Bu)<sub>3</sub> Pd G3, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane/water, 50 °C (56%%); (h) NaOH, THF/water, 50°C (59%); (i) <i>N</i>-(3-bromo-4-methoxyphenyl)acrylamide, Brettphos Pd G3, Cs2CO3, <i>t</i>-BuOH/1,4-dioxane, rf (44%); (j) HCl in EtOH 2.5 M, rt (70%).</p></p></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/medium/jm0c00200_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Structural overlay of EGFR crystals structures in complex with <b>1</b> (green, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5N">6V5N</a>) and WZ4002 (magenta, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>). (B) EGFR crystal structures of JN3229 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZT0">5ZT0</a>) and (C) aminobenzimidazole compound <b>1</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B">6S9B</a>) from ref <a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.0c00200/20200416/images/large/jm0c00200_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00200&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00510" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00510" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span> <span> </span><span class="NLM_article-title">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span> (<span class="NLM_issue">5676</span>),  <span class="NLM_fpage">1497</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&issue=5676&author=J.+G.+Paezauthor=P.+A.+J%C3%A4nneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+Mutations+in+Lung+Cancer%3A+Correlation+with+Clinical+Response+to+Gefitinib+Therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lg0OrDIZx7RsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520Mutations%2520in%2520Lung%2520Cancer%253A%2520Correlation%2520with%2520Clinical%2520Response%2520to%2520Gefitinib%2520Therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26issue%3D5676%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurubhagavatula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannigan, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haserlat, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiani, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>350</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2139</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&issue=21&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+Mutations+in+the+Epidermal+Growth+Factor+Receptor+Underlying+Responsiveness+of+Non-Small-Cell+Lung+Cancer+to+Gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lg0OrDIZx7RsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520Mutations%2520in%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Underlying%2520Responsiveness%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26issue%3D21%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M Mutation in EGFR Kinase Causes Drug Resistance by Increasing the Affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2070</span>– <span class="NLM_lpage">2075</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&issue=6&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+Mutation+in+EGFR+Kinase+Causes+Drug+Resistance+by+Increasing+the+Affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lheIioJQnwvuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520Mutation%2520in%2520EGFR%2520Kinase%2520Causes%2520Drug%2520Resistance%2520by%2520Increasing%2520the%2520Affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D6%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayaram, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocher, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span> <span> </span><span class="NLM_article-title">EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&issue=8&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+Mutation+and+Resistance+of+Non-Small-Cell+Lung+Cancer+to+Gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lheIioJQnwvuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520Mutation%2520and%2520Resistance%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D8%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel Mutant-Selective EGFR Kinase Inhibitors Against EGFR T790M</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span> (<span class="NLM_issue">7276</span>),  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1074</span>, <span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&issue=7276&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+Mutant-Selective+EGFR+Kinase+Inhibitors+Against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lheIioJQnwvuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520Mutant-Selective%2520EGFR%2520Kinase%2520Inhibitors%2520Against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26issue%3D7276%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, An Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&issue=9&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+An+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0ljg8bWtLfJnwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520An%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggstrom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frewer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&issue=18&author=P.+A.+J%C3%A4nneauthor=J.+C.-H.+Yangauthor=D.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.-J.+Ahnauthor=S.-W.+Kimauthor=W.-C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.-H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+Inhibitor-Resistant+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2ebSzYai5Gdjfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520Inhibitor-Resistant%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26issue%3D18%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechaphunkul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1713137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1056%2FNEJMoa1713137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=29151359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=113-125&issue=2&author=J.-C.+Soriaauthor=Y.+Oheauthor=J.+Vansteenkisteauthor=T.+Reungwetwattanaauthor=B.+Chewaskulyongauthor=K.+H.+Leeauthor=A.+Dechaphunkulauthor=F.+Imamuraauthor=N.+Nogamiauthor=T.+Kurataauthor=I.+Okamotoauthor=C.+Zhouauthor=B.+C.+Choauthor=Y.+Chengauthor=E.+K.+Choauthor=P.+J.+Voonauthor=D.+Planchardauthor=W.-C.+Suauthor=J.+E.+Grayauthor=S.-M.+Leeauthor=R.+Hodgeauthor=M.+Marottiauthor=Y.+Rukazenkovauthor=S.+S.+Ramalingam&title=Osimertinib+in+Untreated+EGFR-Mutated+Advanced+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1713137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B. C.; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W.-C.; Gray, J. E.; Lee, S.-M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.  We compared osimertinib with std. EGFR-TKIs in patients with previously untreated, EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-pos. (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a std. EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).  The primary end point was investigator-assessed progression-free survival.  RESULTS: The median progression-free survival was significantly longer with osimertinib than with std. EGFR-TKIs (18.9 mo vs. 10.2 mo; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).  The objective response rate was similar in the two groups: 80% with osimertinib and 76% with std. EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24).  The median duration of response was 17.2 mo (95% CI, 13.8 to 22.0) with osimertinib vs. 8.5 mo (95% CI, 7.3 to 9.8) with std. EGFR-TKIs.  Data on overall survival were immature at the interim anal. (25% maturity).  The survival rate at 18 mo was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with std. EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim anal.]).  Adverse events of grade 3 or higher were less frequent with osimertinib than with std. EGFR-TKIs (34% vs. 45%).  CONCLUSIONS: Osimertinib showed efficacy superior to that of std. EGFR-TKIs in the first-line treatment of EGFR mutation-pos. advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov no., NCT02296125.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-szlfPjG9LVg90H21EOLACvtfcHk0liM3brFsXygMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D&md5=a83147d4e067da1c11d2f096615b1cc8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1713137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1713137%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDechaphunkul%26aufirst%3DA.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DE.%2BK.%26aulast%3DVoon%26aufirst%3DP.%2BJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.-M.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DOsimertinib%2520in%2520Untreated%2520EGFR-Mutated%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D2%26spage%3D113%26epage%3D125%26doi%3D10.1056%2FNEJMoa1713137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non-Small Cell Lung Cancer Harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&issue=6&author=K.+S+Thressauthor=C.+P+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E+Matthewsauthor=M.+Cantariniauthor=J+C.+Barrettauthor=P.+A+Janneauthor=G.+R+Oxnard&title=Acquired+EGFR+C797S+Mutation+Mediates+Resistance+to+AZD9291+in+Non-Small+Cell+Lung+Cancer+Harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0liM3brFsXygMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS%26aulast%3DPaweletz%26aufirst%3DC.%2BP%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA%26aulast%3DOxnard%26aufirst%3DG.%2BR%26atitle%3DAcquired%2520EGFR%2520C797S%2520Mutation%2520Mediates%2520Resistance%2520to%2520AZD9291%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D6%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3924</span>– <span class="NLM_lpage">3933</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1158%2F1078-0432.CCR-15-0560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=25964297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3924-3933&issue=17&author=M.+J.+Niederstauthor=H.+Huauthor=H.+E.+Mulveyauthor=E.+L.+Lockermanauthor=A.+R.+Garciaauthor=Z.+Piotrowskaauthor=L.+V.+Sequistauthor=J.+A.+Engelman&title=The+Allelic+Context+of+the+C797S+Mutation+Acquired+upon+Treatment+with+Third-Generation+EGFR+Inhibitors+Impacts+Sensitivity+to+Subsequent+Treatment+Strategies&doi=10.1158%2F1078-0432.CCR-15-0560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span></div><div class="casAuthors">Niederst, Matthew J.; Hu, Haichuan; Mulvey, Hillary E.; Lockerman, Elizabeth L.; Garcia, Angel R.; Piotrowska, Zofia; Sequist, Lecia V.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3924-3933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have progressed on erlotinib.  Third-generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in nearly two thirds of patients.  However, acquired resistance mechanisms in patients treated with these drugs are yet to be described.  Exptl. Design: To study acquired resistance to third-generation EGFR inhibitors, T790M-pos. cells derived from an erlotinib-resistant cancer were made resistant to a third-generation TKI and then characterized using cell and mol. analyses.  Results: Cells resistant to a third-generation TKI acquired an addnl. EGFR mutation, C797S, which prevented suppression of EGFR.  Our results demonstrate that the allelic context in which C797S was acquired may predict responsiveness to alternative treatments.  If the C797S and T790M mutations are in trans, cells will be resistant to third-generation EGFR TKIs, but will be sensitive to a combination of first- and third-generation TKIs.  If the mutations are in cis, no EGFR TKIs alone or in combination can suppress activity.  If C797S develops in cells wild-type for T790 (when third-generation TKIs are administered in the first-line setting), the cells are resistant to third-generation TKIs, but retain sensitivity to first-generation TKIs.  Conclusions: Mutation of C797S in EGFR is a novel mechanism of acquired resistance to third-generation TKIs.  The context in which the C797S develops with respect to the other EGFR alleles affects the efficacy of subsequent treatments.  Clin Cancer Res; 21(17); 3924-33. ©2015 AACR.  See related commentary by Ayeni et al., p. 3818.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRS-15mDgObVg90H21EOLACvtfcHk0liM3brFsXygMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF&md5=47a45613979464e3859c7c3e0538d0f8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0560%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Allelic%2520Context%2520of%2520the%2520C797S%2520Mutation%2520Acquired%2520upon%2520Treatment%2520with%2520Third-Generation%2520EGFR%2520Inhibitors%2520Impacts%2520Sensitivity%2520to%2520Subsequent%2520Treatment%2520Strategies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D17%26spage%3D3924%26epage%3D3933%26doi%3D10.1158%2F1078-0432.CCR-15-0560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span> <span> </span><span class="NLM_article-title">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4290</span>– <span class="NLM_lpage">4300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4290-4300&issue=10&author=L.+Chenauthor=W.+Fuauthor=L.+Zhengauthor=Z.+Liuauthor=G.+Liang&title=Recent+Progress+of+Small-Molecule+Epidermal+Growth+Factor+Receptor+%28EGFR%29+Inhibitors+against+C797S+Resistance+in+Non-Small-Cell+Lung+Cancer&doi=10.1021%2Facs.jmedchem.7b01310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Chen, Lingfeng; Fu, Weitao; Zheng, Lulu; Liu, Zhiguo; Liang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4290-4300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC).  The current third-generation EGFR small-mol. inhibitors, esp. osimertinib, are at the forefront clin. for treatment of patients with NSCLC.  However, a high percentage of these treated patients developed a tertiary cysteine-797 to serine-790 (C797S) mutation in the EGFR kinase domain.  This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs.  In this Miniperspective, the authors present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance.  Specifically, the authors analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations.  Lastly, the authors provide some perspectives on new challenges and future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIcPvOmj29UbVg90H21EOLACvtfcHk0lhK78cOe4HGDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK&md5=6d3bc978d3896a4e1027cbacd2dad9e9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DG.%26atitle%3DRecent%2520Progress%2520of%2520Small-Molecule%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%2520Inhibitors%2520against%2520C797S%2520Resistance%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4290%26epage%3D4300%26doi%3D10.1021%2Facs.jmedchem.7b01310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goettert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schattel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schollmeyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">A Frozen Analogue Approach to Aminopyridinylimidazoles Leading to Novel and Promising p38 MAP Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">8429</span>– <span class="NLM_lpage">8439</span>, <span class="refDoi"> DOI: 10.1021/jm300852w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300852w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSmtrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8429-8439&issue=19&author=R.+Seligauthor=M.+Goettertauthor=V.+Schattelauthor=D.+Schollmeyerauthor=W.+Albrechtauthor=S.+Laufer&title=A+Frozen+Analogue+Approach+to+Aminopyridinylimidazoles+Leading+to+Novel+and+Promising+p38+MAP+Kinase+Inhibitors&doi=10.1021%2Fjm300852w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A Frozen Analogue Approach to Aminopyridinylimidazoles Leading to Novel and Promising p38 MAP Kinase Inhibitors</span></div><div class="casAuthors">Selig, Roland; Goettert, Marcia; Schattel, Verena; Schollmeyer, Dieter; Albrecht, Wolfgang; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8429-8439</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study the design, synthesis, and biol. evaluation of constrained aminopyridinyl- and aminopyrimidinyl-imidazoles, e.g. I [X, Y = CH, N: R1 = H, Ph, PhCH2, cyclohexyl; R2 = H, 4-HO, 3,4,5-(MeO)3, etc.], as p38α MAP kinase inhibitors are reported.  The frozen analog approach focused on the pyridinyl unit, using purine bioisosteres as constrained structure analogs.  The identification of the most potent bioisostere was followed by a further derivatization to address hydrophobic region II.  These studies in combination with C-2 modifications of the imidazole core allowed to design highly active inhibitors on the p38α MAP kinase.  The inhibitor design presented herein represents a promising and highly efficient advancement of recent stages of development in this class of p38 MAP kinase inhibitors.  In combination with the highly flexible synthetic strategy, directions toward further investigations of complex C-5 modifications of diarylimidazoles are indicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0shTYFbqnE7Vg90H21EOLACvtfcHk0lhK78cOe4HGDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSmtrrO&md5=08ecb5b5ca3034b9ee3c6bc4b52f6ecf</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm300852w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300852w%26sid%3Dliteratum%253Aachs%26aulast%3DSelig%26aufirst%3DR.%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DA%2520Frozen%2520Analogue%2520Approach%2520to%2520Aminopyridinylimidazoles%2520Leading%2520to%2520Novel%2520and%2520Promising%2520p38%2520MAP%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D19%26spage%3D8429%26epage%3D8439%26doi%3D10.1021%2Fjm300852w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity Against a Therapy-Resistant L858R/T790M/C797S mutant</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">10890</span>– <span class="NLM_lpage">10894</span>, <span class="refDoi"> DOI: 10.1002/anie.201603736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1002%2Fanie.201603736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GmtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10890-10894&issue=36&author=M.+G%C3%BCntherauthor=M.+Juchumauthor=G.+Kelterauthor=H.+Fiebigauthor=S.+Laufer&title=Lung+Cancer%3A+EGFR+Inhibitors+with+Low+Nanomolar+Activity+Against+a+Therapy-Resistant+L858R%2FT790M%2FC797S+mutant&doi=10.1002%2Fanie.201603736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant</span></div><div class="casAuthors">Guenther, Marcel; Juchum, Michael; Kelter, Gerhard; Fiebig, Heiner; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10890-10894</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors is made challenging by acquired resistance caused by somatic mutations.  Third-generation EGFR inhibitors have been designed to overcome resistance through covalent binding to the Cys 797 residue of the enzyme, and these inhibitors are effective against most clin. relevant EGFR mutants.  However, the high dependence of these recent EGFR inhibitors on this particular interaction means that addnl. mutation of Cys 797 results in poor inhibitory activity, which leads to tumor relapse in initially responding patients.  A new generation of irreversible and reversible mutant EGFR inhibitors was developed with strong noncovalent binding properties, and these compds. show high inhibitory activities against the cysteine-mutated L858R/T790M/C797S EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY1QH6nrxYrVg90H21EOLACvtfcHk0lhK78cOe4HGDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GmtbzK&md5=c3909faa7f781c2a3679f75bd3b6c5ac</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603736%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DFiebig%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DLung%2520Cancer%253A%2520EGFR%2520Inhibitors%2520with%2520Low%2520Nanomolar%2520Activity%2520Against%2520a%2520Therapy-Resistant%2520L858R%252FT790M%252FC797S%2520mutant%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26issue%3D36%26spage%3D10890%26epage%3D10894%26doi%3D10.1002%2Fanie.201603736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5613</span>– <span class="NLM_lpage">5637</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00316</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00316" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5613-5637&issue=13&author=M.+G%C3%BCntherauthor=J.+Lategahnauthor=M.+Juchumauthor=E.+D%C3%B6ringauthor=M.+Keulauthor=J.+Engelauthor=H.+L.+Tumbrinkauthor=D.+Rauhauthor=S.+Laufer&title=Trisubstituted+Pyridinylimidazoles+as+Potent+Inhibitors+of+the+Clinically+Resistant+L858R%2FT790M%2FC797S+EGFR+Mutant%3A+Targeting+of+Both+Hydrophobic+Regions+and+the+Phosphate+Binding+Site&doi=10.1021%2Facs.jmedchem.7b00316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span></div><div class="casAuthors">Guenther, Marcel; Lategahn, Jonas; Juchum, Michael; Doering, Eva; Keul, Marina; Engel, Julian; Tumbrink, Hannah L.; Rauh, Daniel; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5613-5637</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer.  Acquired resistance compromises the clin. efficacy of EGFR inhibitors during long-term treatment.  The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors.  Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition.  We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity.  Guided by mol. modeling, we synthesized and studied the structure-activity relationship of 40 compds. against clin. relevant EGFR mutants.  We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line.  We identified addnl. noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrikF9dZWUv2bVg90H21EOLACvtfcHk0li3452IZrRZcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D&md5=b258bbd393c9738cb68062c53dcc093f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00316%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520Pyridinylimidazoles%2520as%2520Potent%2520Inhibitors%2520of%2520the%2520Clinically%2520Resistant%2520L858R%252FT790M%252FC797S%2520EGFR%2520Mutant%253A%2520Targeting%2520of%2520Both%2520Hydrophobic%2520Regions%2520and%2520the%2520Phosphate%2520Binding%2520Site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D13%26spage%3D5613%26epage%3D5637%26doi%3D10.1021%2Facs.jmedchem.7b00316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lämmerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4656</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4636-4656&issue=11&author=M.+Juchumauthor=M.+G%C3%BCntherauthor=E.+D%C3%B6ringauthor=A.+Sievers-Englerauthor=M.+L%C3%A4mmerhoferauthor=S.+Laufer&title=Trisubstituted+Imidazoles+with+a+Rigidized+Hinge+Binding+Motif+Act+As+Single+Digit+nM+Inhibitors+of+Clinically+Relevant+EGFR+L858R%2FT790M+and+L858R%2FT790M%2FC797S+Mutants%3A+An+Example+of+Target+Hopping&doi=10.1021%2Facs.jmedchem.7b00178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span></div><div class="casAuthors">Juchum, Michael; Guenther, Marcel; Doering, Eva; Sievers-Engler, Adrian; Laemmerhofer, Michael; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4636-4656</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif such as I were prepd. as inhibitors of EGFR tyrosine kinase with L858R/T790M/C797S mutations (against which current EGFR inhibitors are ineffective) for potential use in the treatment of non-small-cell lung cancer.  II [X = (CH2)2, (CH2)4] reversibly inhibited the clin. challenging EGFR tyrosine kinase triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range.  I inhibited EGFR tyrosine kinase irreversibly with IC50 value of 1 nM against the EGFR L858R/T790M double mutant; I was selective for EGFR tyrosine kinase over other related kinases except for MAP4K4, MAP4K5, and MINK.  The kinetics of target inhibition, aq. soly, and metabolites were detd. for I and for selected compds.; mol. docking calcns. were also performed for selected compds. with EGFR isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzeDYy9aSCrLVg90H21EOLACvtfcHk0li3452IZrRZcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D&md5=a7003c8160b506ce964edce6adf7c3ff</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00178%26sid%3Dliteratum%253Aachs%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DL%25C3%25A4mmerhofer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520Imidazoles%2520with%2520a%2520Rigidized%2520Hinge%2520Binding%2520Motif%2520Act%2520As%2520Single%2520Digit%2520nM%2520Inhibitors%2520of%2520Clinically%2520Relevant%2520EGFR%2520L858R%252FT790M%2520and%2520L858R%252FT790M%252FC797S%2520Mutants%253A%2520An%2520Example%2520of%2520Target%2520Hopping%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D11%26spage%3D4636%26epage%3D4656%26doi%3D10.1021%2Facs.jmedchem.7b00178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uchibori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inase, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span> <span> </span><span class="NLM_article-title">Brigatinib Combined with Anti-EGFR Antibody Overcomes Osimertinib Resistance in EGFR-Mutated Non-Small-Cell Lung Cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14768</span>, <span class="refDoi"> DOI: 10.1038/ncomms14768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1038%2Fncomms14768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=28287083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14768&author=K.+Uchiboriauthor=N.+Inaseauthor=M.+Arakiauthor=M.+Kamadaauthor=S.+Satoauthor=Y.+Okunoauthor=N.+Fujitaauthor=R.+Katayama&title=Brigatinib+Combined+with+Anti-EGFR+Antibody+Overcomes+Osimertinib+Resistance+in+EGFR-Mutated+Non-Small-Cell+Lung+Cancer&doi=10.1038%2Fncomms14768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Uchibori, Ken; Inase, Naohiko; Araki, Mitsugu; Kamada, Mayumi; Sato, Shigeo; Okuno, Yasushi; Fujita, Naoya; Katayama, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14768</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs).  However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib.  Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance.  In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo.  Our original computational simulation demonstrates that brigatinib fits into the ATP-binding pocket of triple-mutant EGFR.  The structure-activity relationship anal. reveals the key component in brigatinib to inhibit the triple-mutant EGFR.  The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibody because of the decrease of surface and total EGFR expression.  Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPEfk1WSIOnLVg90H21EOLACvtfcHk0li3452IZrRZcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D&md5=4c932113642da4a0190e9fcd00222b6e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fncomms14768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14768%26sid%3Dliteratum%253Aachs%26aulast%3DUchibori%26aufirst%3DK.%26aulast%3DInase%26aufirst%3DN.%26aulast%3DAraki%26aufirst%3DM.%26aulast%3DKamada%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26atitle%3DBrigatinib%2520Combined%2520with%2520Anti-EGFR%2520Antibody%2520Overcomes%2520Osimertinib%2520Resistance%2520in%2520EGFR-Mutated%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14768%26doi%3D10.1038%2Fncomms14768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of EGF Receptor Inhibitors That Are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7638</span>, <span class="refDoi"> DOI: 10.1002/anie.201703389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1002%2Fanie.201703389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=7634-7638&issue=26&author=H.+Parkauthor=H.-Y.+Jungauthor=S.+Mahauthor=S.+Hong&title=Discovery+of+EGF+Receptor+Inhibitors+That+Are+Selective+for+the+d746-750%2FT790M%2FC797S+Mutant+through+Structure-Based+de+Novo+Design&doi=10.1002%2Fanie.201703389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of EGF Receptor Inhibitors that are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design</span></div><div class="casAuthors">Park, Hwangseo; Jung, Hoi-Yun; Mah, Shinmee; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7634-7638</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Next-generation epidermal growth factor receptor (EGFR) inhibitors against the d746-750/T790M/C797S mutation were discovered through two-track virtual screening and de novo design.  A no. of nanomolar inhibitors were identified using 2-aryl-4-aminoquinazoline as the mol. core and the modified binding energy function involving a proper dehydration term, which provides important structural insight into the key principles for high inhibitory activities against the d746-750/T790M/C797S mutant.  Furthermore, some of these EGFR inhibitors showed a greater than 1000-fold selectivity for the d746-750/T790M/C797S mutant over the wild type, as well as nanomolar activity against the mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGVR5gzqeK27Vg90H21EOLACvtfcHk0lj3ulEUAodfXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D&md5=93fd25a8b5af1add58fe8b27723edb0e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fanie.201703389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201703389%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DH.-Y.%26aulast%3DMah%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520EGF%2520Receptor%2520Inhibitors%2520That%2520Are%2520Selective%2520for%2520the%2520d746-750%252FT790M%252FC797S%2520Mutant%2520through%2520Structure-Based%2520de%2520Novo%2520Design%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26issue%3D26%26spage%3D7634%26epage%3D7638%26doi%3D10.1002%2Fanie.201703389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1123-1127&issue=11&author=X.+Luauthor=T.+Zhangauthor=S.-J.+Zhuauthor=Q.+Xunauthor=L.+Tongauthor=X.+Huauthor=Y.+Liauthor=S.+Chanauthor=Y.+Suauthor=Y.+Sunauthor=Y.+Chenauthor=J.+Dingauthor=C.-H.+Yunauthor=H.+Xieauthor=K.+Ding&title=Discovery+of+JND3229+as+a+New+EGFRC797S+Mutant+Inhibitor+with+In+Vivo+Monodrug+Efficacy&doi=10.1021%2Facsmedchemlett.8b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy</span></div><div class="casAuthors">Lu, Xiaoyun; Zhang, Tao; Zhu, Su-Jie; Xun, Qiuju; Tong, Lingjiang; Hu, Xianglong; Li, Yan; Chan, Shingpan; Su, Yi; Sun, Yiming; Chen, Yi; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1123-1127</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EGFRC797S mutation inducing resistance against third generation EGFR inhibitor drugs is an emerging "unmet clin. need" for nonsmall cell lung cancer patients.  The pyrimidopyrimidinone deriv. JND3229 was identified as a new highly potent EGFRC797S inhibitor with single digit nM potency.  It also exhibited good in vitro and in vivo monodrug anticancer efficacy in a xenograft mouse model of BaF3/EGFR19D/T790M/C797S cells.  A high-resoln. x-ray crystallog. structure was also detd. to elucidate the interactions between JND3229 and EGFRT790M/C797S.  The study provides an important structural and chem. basis for future development of new generation EGFRC797S inhibitors as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOPToZCT3HBLVg90H21EOLACvtfcHk0lj3ulEUAodfXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP&md5=02505ac363697e9a5b1bbe2db0b0357b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DXun%26aufirst%3DQ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520JND3229%2520as%2520a%2520New%2520EGFRC797S%2520Mutant%2520Inhibitor%2520with%2520In%2520Vivo%2520Monodrug%2520Efficacy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127%26doi%3D10.1021%2Facsmedchemlett.8b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">7302</span>– <span class="NLM_lpage">7308</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7302-7308&issue=15&author=J.+Shenauthor=T.+Zhangauthor=S.-J.+Zhuauthor=M.+Sunauthor=L.+Tongauthor=M.+Laiauthor=R.+Zhangauthor=W.+Xuauthor=R.+Wuauthor=J.+Dingauthor=C.-H.+Yunauthor=H.+Xieauthor=X.+Luauthor=K.+Ding&title=Structure-Based+Design+of+5-Methylpyrimidopyridone+Derivatives+as+New+Wild-Type+Sparing+Inhibitors+of+the+Epidermal+Growth+Factor+Receptor+Triple+Mutant+%28EGFRL858R%2FT790M%2FC797S%29&doi=10.1021%2Facs.jmedchem.9b00576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)</span></div><div class="casAuthors">Shen, Jiayi; Zhang, Tao; Zhu, Su-Jie; Sun, Min; Tong, Linjiang; Lai, Mengzhen; Zhang, Rong; Xu, Wei; Wu, Ruibo; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7302-7308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Azaheterocyclyl-substituted pyridopyrimidinones such as I were prepd. as selective inhibitors of the mutant epidermal growth factor receptor (EGFR) EGFRL858R/T790M/C797S with selectivity over the wild-type EGFR for potential use in treating osimertinib-resistant non-small-cell lung cancer.  I exhibited an IC50 of 27.5 nM against the EGFRL858R/T790M/C797S mutant, while being significantly less potent against the wild-type EGFR with an IC50 value of > 1.0 μM.  Cocrystallog. structure detn. and computational investigation were conducted to elucidate its target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQFRlnoJItB7Vg90H21EOLACvtfcHk0lj3ulEUAodfXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI&md5=70ca1144f3b73d0ccd412406b1072a1f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00576%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DStructure-Based%2520Design%2520of%25205-Methylpyrimidopyridone%2520Derivatives%2520as%2520New%2520Wild-Type%2520Sparing%2520Inhibitors%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Triple%2520Mutant%2520%2528EGFRL858R%252FT790M%252FC797S%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D15%26spage%3D7302%26epage%3D7308%26doi%3D10.1021%2Facs.jmedchem.9b00576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klövekorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niggenaber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaßhoff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mühlenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiller, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimsoeth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank-Landeshammer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollipara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengstler, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Otterlo, W. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Osimertinib-Resistant Epidermal Growth Factor Receptor EGFR-T790M/C797S</span>. <i>Chemical Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">10789</span>– <span class="NLM_lpage">10801</span>, <span class="refDoi"> DOI: 10.1039/C9SC03445E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1039%2FC9SC03445E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=31857889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSntr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=10789-10801&author=J.+Lategahnauthor=M.+Keulauthor=P.+Kl%C3%B6vekornauthor=H.+L.+Tumbrinkauthor=J.+Niggenaberauthor=M.+P.+M%C3%BCllerauthor=L.+Hodsonauthor=M.+Fla%C3%9Fhoffauthor=J.+Hardickauthor=T.+Grabeauthor=J.+Engelauthor=C.+Schultz-Fademrechtauthor=M.+Baumannauthor=J.+Ketzerauthor=T.+M%C3%BChlenbergauthor=W.+Hillerauthor=G.+G%C3%BCntherauthor=A.+Ungerauthor=H.+M%C3%BCllerauthor=A.+Heimsoethauthor=C.+Golzauthor=B.+Blank-Landeshammerauthor=L.+Kolliparaauthor=R.+P.+Zahediauthor=C.+Strohmannauthor=J.+G.+Hengstlerauthor=W.+A.+L.+van+Otterloauthor=S.+Bauerauthor=D.+Rauh&title=Inhibition+of+Osimertinib-Resistant+Epidermal+Growth+Factor+Receptor+EGFR-T790M%2FC797S&doi=10.1039%2FC9SC03445E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S</span></div><div class="casAuthors">Lategahn, Jonas; Keul, Marina; Kloevekorn, Philip; Tumbrink, Hannah L.; Niggenaber, Janina; Mueller, Matthias P.; Hodson, Luke; Flasshoff, Maren; Hardick, Julia; Grabe, Tobias; Engel, Julian; Schultz-Fademrecht, Carsten; Baumann, Matthias; Ketzer, Julia; Muehlenberg, Thomas; Hiller, Wolf; Guenther, Georgia; Unger, Anke; Mueller, Heiko; Heimsoeth, Alena; Golz, Christopher; Blank-Landeshammer, Bernhard; Kollipara, Laxmikanth; Zahedi, Rene P.; Strohmann, Carsten; Hengstler, Jan G.; van Otterlo, Willem A. L.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">10789-10801</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Precision medicine has revolutionized the treatment of patients in EGFR driven non-small cell lung cancer (NSCLC).  Targeted drugs show high response rates in genetically defined subsets of cancer patients and markedly increase their progression-free survival as compared to conventional chemotherapy.  However, recurrent acquired drug resistance limits the success of targeted drugs in long-term treatment and requires the const. development of novel efficient inhibitors of drug resistant cancer subtypes.  Herein, we present covalent inhibitors of the drug resistant gatekeeper mutant EGFR-L858R/T790M based on the pyrrolopyrimidine scaffold.  Biochem. and cellular characterization, as well as kinase selectivity profiling and western blot anal., substantiate our approach.  Moreover, the developed compds. possess high activity against multi drug resistant EGFR-L858R/T790M/C797S in biochem. assays due to their highly reversible binding character, that was revealed by characterization of the binding kinetics.  In addn., we present the first X-ray crystal structures of covalent inhibitors in complex with C797S-mutated EGFR which provide detailed insight into their binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpOILrK_TpebVg90H21EOLACvtfcHk0lhxThlULO7tIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSntr7N&md5=0dd60e9ade21e33ae5656d50175e39ba</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2FC9SC03445E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9SC03445E%26sid%3Dliteratum%253Aachs%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKl%25C3%25B6vekorn%26aufirst%3DP.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DNiggenaber%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%2BP.%26aulast%3DHodson%26aufirst%3DL.%26aulast%3DFla%25C3%259Fhoff%26aufirst%3DM.%26aulast%3DHardick%26aufirst%3DJ.%26aulast%3DGrabe%26aufirst%3DT.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DHiller%26aufirst%3DW.%26aulast%3DG%25C3%25BCnther%26aufirst%3DG.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DH.%26aulast%3DHeimsoeth%26aufirst%3DA.%26aulast%3DGolz%26aufirst%3DC.%26aulast%3DBlank-Landeshammer%26aufirst%3DB.%26aulast%3DKollipara%26aufirst%3DL.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DStrohmann%26aufirst%3DC.%26aulast%3DHengstler%26aufirst%3DJ.%2BG.%26aulast%3Dvan%2BOtterlo%26aufirst%3DW.%2BA.%2BL.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInhibition%2520of%2520Osimertinib-Resistant%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520EGFR-T790M%252FC797S%26jtitle%3DChemical%2520Science%26date%3D2019%26volume%3D10%26spage%3D10789%26epage%3D10801%26doi%3D10.1039%2FC9SC03445E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel 9-Heterocyclyl Substituted 9H-Purines as L858R/T790M/C797S Mutant EGFR Tyrosine Kinase Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">111888</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1016%2Fj.ejmech.2019.111888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=31787359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12isrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2020&pages=111888&author=H.+Leiauthor=S.+Fanauthor=H.+Zhangauthor=Y.-J.+Liuauthor=Y.-Y.+Heiauthor=J.-J.+Zhangauthor=A.+Q.+Zhengauthor=M.+Xinauthor=S.-Q.+Zhang&title=Discovery+of+Novel+9-Heterocyclyl+Substituted+9H-Purines+as+L858R%2FT790M%2FC797S+Mutant+EGFR+Tyrosine+Kinase+Inhibitors&doi=10.1016%2Fj.ejmech.2019.111888"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="#"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=&md5=9874b665cc7a056b8e2f928dd3112440</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111888%26sid%3Dliteratum%253Aachs%26aulast%3DLei%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.-J.%26aulast%3DHei%26aufirst%3DY.-Y.%26aulast%3DZhang%26aufirst%3DJ.-J.%26aulast%3DZheng%26aufirst%3DA.%2BQ.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.-Q.%26atitle%3DDiscovery%2520of%2520Novel%25209-Heterocyclyl%2520Substituted%25209H-Purines%2520as%2520L858R%252FT790M%252FC797S%2520Mutant%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D186%26spage%3D111888%26doi%3D10.1016%2Fj.ejmech.2019.111888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döbel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfgartner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simov, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span> <span> </span><span class="NLM_article-title">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10272</span>– <span class="NLM_lpage">10293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10272-10293&issue=22&author=H.+Engelhardtauthor=D.+B%C3%B6seauthor=M.+Petronczkiauthor=D.+Scharnauthor=G.+Baderauthor=A.+Baumauthor=A.+Bergnerauthor=E.+Chongauthor=S.+D%C3%B6belauthor=G.+Eggerauthor=C.+Engelhardtauthor=P.+Ettmayerauthor=J.+E.+Fuchsauthor=T.+Gerstbergerauthor=N.+Gonnellaauthor=A.+Grimmauthor=E.+Grondalauthor=N.+Haddadauthor=B.+Hopfgartnerauthor=R.+Kousekauthor=M.+Krawiecauthor=M.+Krizauthor=L.+Lamarreauthor=J.+Leungauthor=M.+Mayerauthor=N.+D.+Patelauthor=B.+P.+Simovauthor=J.+T.+Reevesauthor=R.+Schnitzerauthor=A.+Schrenkauthor=B.+Sharpsauthor=F.+Solcaauthor=H.+Stadtm%C3%BCllerauthor=Z.+Tanauthor=T.+Wunbergauthor=A.+Zoephelauthor=D.+B.+McConnell&title=Start+Selective+and+Rigidify%3A+The+Discovery+Path+toward+a+Next+Generation+of+EGFR+Tyrosine+Kinase+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Engelhardt, Harald; Boese, Dietrich; Petronczki, Mark; Scharn, Dirk; Bader, Gerd; Baum, Anke; Bergner, Andreas; Chong, Eugene; Doebel, Sandra; Egger, Georg; Engelhardt, Christian; Ettmayer, Peter; Fuchs, Julian E.; Gerstberger, Thomas; Gonnella, Nina; Grimm, Andreas; Grondal, Elisabeth; Haddad, Nizar; Hopfgartner, Barbara; Kousek, Roland; Krawiec, Mariusz; Kriz, Monika; Lamarre, Lyne; Leung, Joyce; Mayer, Moriz; Patel, Nitinchandra D.; Simov, Biljana Peric; Reeves, Jonathan T.; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Solca, Flavio; Stadtmueller, Heinz; Tan, Zhulin; Wunberg, Tobias; Zoephel, Andreas; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10272-10293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.  While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable.  Most patients relapse within two years of therapy often due to acquisition of an addnl. mutation in EGFR kinase domain that confers resistance to TKIs.  Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs.  Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI.  BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.  Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the mol. through macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmZRwjkT9vdLVg90H21EOLACvtfcHk0lg9i8yH8-LFRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK&md5=0f8d0eed6ae93bfbb8f7a6337bb1ecd3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DB%25C3%25B6se%26aufirst%3DD.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DBergner%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DE.%26aulast%3DD%25C3%25B6bel%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DEngelhardt%26aufirst%3DC.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGonnella%26aufirst%3DN.%26aulast%3DGrimm%26aufirst%3DA.%26aulast%3DGrondal%26aufirst%3DE.%26aulast%3DHaddad%26aufirst%3DN.%26aulast%3DHopfgartner%26aufirst%3DB.%26aulast%3DKousek%26aufirst%3DR.%26aulast%3DKrawiec%26aufirst%3DM.%26aulast%3DKriz%26aufirst%3DM.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BD.%26aulast%3DSimov%26aufirst%3DB.%2BP.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DStadtm%25C3%25BCller%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26atitle%3DStart%2520Selective%2520and%2520Rigidify%253A%2520The%2520Discovery%2520Path%2520toward%2520a%2520Next%2520Generation%2520of%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293%26doi%3D10.1021%2Facs.jmedchem.9b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gureasko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1016%2Fj.cell.2006.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=16777603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=1137-1149&issue=6&author=X.+Zhangauthor=J.+Gureaskoauthor=K.+Shenauthor=P.+A.+Coleauthor=J.+Kuriyan&title=An+Allosteric+Mechanism+for+Activation+of+the+Kinase+Domain+of+Epidermal+Growth+Factor+Receptor&doi=10.1016%2Fj.cell.2006.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span></div><div class="casAuthors">Zhang, Xuewu; Gureasko, Jodi; Shen, Kui; Cole, Philip A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1137-1149</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition.  We find that the EGFR kinase domain can be activated by increasing its local concn. or by mutating a leucine (L834R) in the activation loop, the phosphorylation of which is not required for activation.  This suggests that the kinase domain is intrinsically auto-inhibited, and an intermol. interaction promotes its activation.  Using further mutational anal. and crystallog. we demonstrate that the auto-inhibited conformation of the EGFR kinase domain resembles that of Src and cyclin-dependent kinases (CDKs).  EGFR activation results from the formation of an asym. dimer in which the C-terminal lobe of one kinase domain plays a role analogous to that of cyclin in activated CDK/cyclin complexes.  The CDK/cyclin-like complex formed by two kinase domains thus explains the activation of EGFR-family receptors by homo- or heterodimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRAzLF-wK7Vg90H21EOLACvtfcHk0lg9i8yH8-LFRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D&md5=f7b6795851425346f588cbd682125c93</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGureasko%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DAn%2520Allosteric%2520Mechanism%2520for%2520Activation%2520of%2520the%2520Kinase%2520Domain%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%26jtitle%3DCell%26date%3D2006%26volume%3D125%26issue%3D6%26spage%3D1137%26epage%3D1149%26doi%3D10.1016%2Fj.cell.2006.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaffrey, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazhanisamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bemis, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgibbon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murcko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M. S. S.</span></span> <span> </span><span class="NLM_article-title">The Structural Basis for the Specificity of Pyridinylimidazole Inhibitors of p38 MAP Kinase</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">423</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/S1074-5521(97)90194-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1016%2FS1074-5521%2897%2990194-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=9224565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADyaK2sXks1yju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=423-431&issue=6&author=K.+P.+Wilsonauthor=P.+G.+McCaffreyauthor=K.+Hsiaoauthor=S.+Pazhanisamyauthor=V.+Galulloauthor=G.+W.+Bemisauthor=M.+J.+Fitzgibbonauthor=P.+R.+Caronauthor=M.+A.+Murckoauthor=M.+S.+S.+Su&title=The+Structural+Basis+for+the+Specificity+of+Pyridinylimidazole+Inhibitors+of+p38+MAP+Kinase&doi=10.1016%2FS1074-5521%2897%2990194-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase</span></div><div class="casAuthors">Wilson, Keith P.; McCaffrey, Patricia G.; Hsiao, Kathy; Pazhinisamy, Sam; Galullo, Vincent; Bemis, Guy W.; Fitzgibbon, Matthew J.; Caron, Paul R.; Murcko, Mark A.; Su, Michael S. S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">423-431</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">The p38 mitogen-activated protein (MAP) kinase regulates signal transduction in response to environmental stress.  Pyridinylimidazole compds. are specific inhibitors of p38 MAP kinase that block the prodn. of the cytokines interleukin-1β and tumor necrosis factor α, and they are effective in animal models of arthritis, bone resorption and endotoxin shock.  These compds. have been useful probes for studying the physiol. functions of the p38-mediated MAP kinase pathway.  We report the crystal structure of a novel pyridinylimidazole compd. complexed with p38 MAP kinase, and we demonstrate that this compd. binds to the same site on the kinase as does ATP.  Mutagenesis showed that a single residue difference between p38 MAP kinase and other MAP kinases is sufficient to confer selectivity among pyridinylimidazole compds.  Our results reveal how pyridinylimidazole compds. are potent and selective inhibitors of p38 MAP kinase but not other MAP kinases.  It should now be possible to design other specific inhibitors of activated p38 MAP kinase using the structure of the nonphosphorylated enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpURyeat1gd6LVg90H21EOLACvtfcHk0lg9i8yH8-LFRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXks1yju7w%253D&md5=5d8f3b10eceae3f344d4daa7852ac190</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2897%2990194-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252897%252990194-0%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DK.%2BP.%26aulast%3DMcCaffrey%26aufirst%3DP.%2BG.%26aulast%3DHsiao%26aufirst%3DK.%26aulast%3DPazhanisamy%26aufirst%3DS.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DFitzgibbon%26aufirst%3DM.%2BJ.%26aulast%3DCaron%26aufirst%3DP.%2BR.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26aulast%3DSu%26aufirst%3DM.%2BS.%2BS.%26atitle%3DThe%2520Structural%2520Basis%2520for%2520the%2520Specificity%2520of%2520Pyridinylimidazole%2520Inhibitors%2520of%2520p38%2520MAP%2520Kinase%26jtitle%3DChem.%2520Biol.%26date%3D1997%26volume%3D4%26issue%3D6%26spage%3D423%26epage%3D431%26doi%3D10.1016%2FS1074-5521%2897%2990194-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikounis, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Keefe, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scapin, G.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for p38α MAP Kinase Quinazolinone and Pyridol-Pyrimidine Inhibitor Specificity</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">764</span>– <span class="NLM_lpage">769</span>, <span class="refDoi"> DOI: 10.1038/nsb949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1038%2Fnsb949" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=764-769&issue=9&author=C.+E.+Fitzgeraldauthor=S.+B.+Patelauthor=J.+W.+Beckerauthor=P.+M.+Cameronauthor=D.+Zallerauthor=V.+B.+Pikounisauthor=S.+J.+O%E2%80%99Keefeauthor=G.+Scapin&title=Structural+Basis+for+p38%CE%B1+MAP+Kinase+Quinazolinone+and+Pyridol-Pyrimidine+Inhibitor+Specificity&doi=10.1038%2Fnsb949"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnsb949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb949%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DC.%2BE.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DBecker%26aufirst%3DJ.%2BW.%26aulast%3DCameron%26aufirst%3DP.%2BM.%26aulast%3DZaller%26aufirst%3DD.%26aulast%3DPikounis%26aufirst%3DV.%2BB.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DS.%2BJ.%26aulast%3DScapin%26aufirst%3DG.%26atitle%3DStructural%2520Basis%2520for%2520p38%25CE%25B1%2520MAP%2520Kinase%2520Quinazolinone%2520and%2520Pyridol-Pyrimidine%2520Inhibitor%2520Specificity%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D10%26issue%3D9%26spage%3D764%26epage%3D769%26doi%3D10.1038%2Fnsb949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ansideri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macedo, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eitel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Gokha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinad, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpellini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schollmeyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaum, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span> <span> </span><span class="NLM_article-title">Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">7809</span>– <span class="NLM_lpage">7831</span>, <span class="refDoi"> DOI: 10.1021/acsomega.8b00668</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.8b00668" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlSjtLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=7809-7831&issue=7&author=F.+Ansideriauthor=J.+T.+Macedoauthor=M.+Eitelauthor=A.+El-Gokhaauthor=D.+S.+Zinadauthor=C.+Scarpelliniauthor=M.+Kudoloauthor=D.+Schollmeyerauthor=F.+M.+Boecklerauthor=B.+S.+Blaumauthor=S.+A.+Lauferauthor=P.+Koch&title=Structural+Optimization+of+a+Pyridinylimidazole+Scaffold%3A+Shifting+the+Selectivity+from+p38%CE%B1+Mitogen-Activated+Protein+Kinase+to+c-Jun+N-Terminal+Kinase+3&doi=10.1021%2Facsomega.8b00668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3</span></div><div class="casAuthors">Ansideri, Francesco; Macedo, Joana T.; Eitel, Michael; El-Gokha, Ahmed; Zinad, Dhafer S.; Scarpellini, Camilla; Kudolo, Mark; Schollmeyer, Dieter; Boeckler, Frank M.; Blaum, Baerbel S.; Laufer, Stefan A.; Koch, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">7809-7831</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from known p38α mitogen-activated protein kinase (MAPK) inhibitors, a series of inhibitors of the c-Jun N-terminal kinase (JNK) 3 was obtained.  Altering the substitution pattern of the pyridinylimidazole scaffold proved to be effective in shifting the inhibitory activity from the original target p38α MAPK to the closely related JNK3.  In particular, a significant improvement for JNK3 selectivity could be achieved by addressing the hydrophobic region I with a small Me group.  Furthermore, addnl. structural modifications permitted to explore structure-activity relationships.  The most potent inhibitor 4-(4-methyl-2-(methylthio)-1H-imidazol-5-yl)-N-(4-morpholinophenyl)pyridin-2-amine showed an IC50 value for the JNK3 in the low triple digit nanomolar range and its binding mode was confirmed by x-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNY36Te3RXDLVg90H21EOLACvtfcHk0lhANJN_DZyS1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlSjtLvF&md5=4cddf5cade2457ceefe9e5468f2d27ca</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsomega.8b00668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.8b00668%26sid%3Dliteratum%253Aachs%26aulast%3DAnsideri%26aufirst%3DF.%26aulast%3DMacedo%26aufirst%3DJ.%2BT.%26aulast%3DEitel%26aufirst%3DM.%26aulast%3DEl-Gokha%26aufirst%3DA.%26aulast%3DZinad%26aufirst%3DD.%2BS.%26aulast%3DScarpellini%26aufirst%3DC.%26aulast%3DKudolo%26aufirst%3DM.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26aulast%3DBlaum%26aufirst%3DB.%2BS.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DKoch%26aufirst%3DP.%26atitle%3DStructural%2520Optimization%2520of%2520a%2520Pyridinylimidazole%2520Scaffold%253A%2520Shifting%2520the%2520Selectivity%2520from%2520p38%25CE%25B1%2520Mitogen-Activated%2520Protein%2520Kinase%2520to%2520c-Jun%2520N-Terminal%2520Kinase%25203%26jtitle%3DACS%2520Omega%26date%3D2018%26volume%3D3%26issue%3D7%26spage%3D7809%26epage%3D7831%26doi%3D10.1021%2Facsomega.8b00668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&issue=10&author=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+Brigatinib+%28AP26113%29%2C+a+Phosphine+Oxide-Containing%2C+Potent%2C+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0lg1ASU1lisedw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520Brigatinib%2520%2528AP26113%2529%252C%2520a%2520Phosphine%2520Oxide-Containing%252C%2520Potent%252C%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D10%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahcall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent Dual ALK and EGFR T790M Inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1016%2Fj.ejmech.2017.04.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=28528303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlWnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=497-510&author=J.+Jangauthor=J.+B.+Sonauthor=C.+Toauthor=M.+Bahcallauthor=S.+Y.+Kimauthor=S.+Y.+Kangauthor=M.+Mushajiangauthor=Y.+Leeauthor=P.+A.+J%C3%A4nneauthor=H.+G.+Choiauthor=N.+S.+Gray&title=Discovery+of+a+Potent+Dual+ALK+and+EGFR+T790M+Inhibitor&doi=10.1016%2Fj.ejmech.2017.04.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a potent dual ALK and EGFR T790M inhibitor</span></div><div class="casAuthors">Jang, Jaebong; Son, Jung Beom; To, Ciric; Bahcall, Magda; Kim, So Young; Kang, Seock Yong; Mushajiang, Mierzhati; Lee, Younho; Janne, Pasi A.; Choi, Hwan Geun; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">497-510</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The mutational activations of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) are validated oncogenic events and the targets of approved drugs to treat non-small cell lung cancer (NSCLC).  Here we report highly potent dual small mol. inhibitors of both ALK and EGFR, particularly the T790M mutant which confers resistance to first generation EGFR inhibitors.  Dual ALK/EGFR inhibitors may provide an efficient approach to prevent resistance that arises as a consequence of clin. reported reciprocal activation mechanisms.  Our lead compd. 7c displayed remarkable inhibitory activities against both ALK and EGFR in enzymic and cellular assays.  We demonstrate that 7c is capable of recapitulating the signaling effects and antiproliferative activity of combined treatment with the approved ALK inhibitor ceritinib and T790M EGFR inhibitor osimertinib against patient-derived non-small cell lung cancer cell line, DFCI032 which harbors both EML4-ALK and activated EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox5vB-cOxtibVg90H21EOLACvtfcHk0lg1ASU1lisedw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlWnsLY%253D&md5=69112257da96f04666227d52bd102ae7</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.079%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DSon%26aufirst%3DJ.%2BB.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520Dual%2520ALK%2520and%2520EGFR%2520T790M%2520Inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D136%26spage%3D497%26epage%3D510%26doi%3D10.1016%2Fj.ejmech.2017.04.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) Resistance with Mutant-Selective Allosteric Inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">129</span>, <span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129&author=Y.+Jiaauthor=C.-H.+Yunauthor=E.+Parkauthor=D.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+Zhangauthor=S.+Palakurthiauthor=J.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.-Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+Resistance+with+Mutant-Selective+Allosteric+Inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0ljV3XCQ2YPFVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520Resistance%2520with%2520Mutant-Selective%2520Allosteric%2520Inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D129%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1158%2F2159-8290.CD-18-0903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=31092401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=926-943&issue=7&author=C.+Toauthor=J.+Jangauthor=T.+Chenauthor=E.+Parkauthor=M.+Mushajiangauthor=D.+J.+H.+De+Clercqauthor=M.+Xuauthor=S.+Wangauthor=M.+D.+Cameronauthor=D.+E.+Heppnerauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=A.+Yangauthor=S.+E.+Dahlbergauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Single+and+Dual+Targeting+of+Mutant+EGFR+with+an+Allosteric+Inhibitor&doi=10.1158%2F2159-8290.CD-18-0903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Single and dual targeting of mutant EGFR with an allosteric inhibitor</span></div><div class="casAuthors">To, Ciric; Jang, Jaebong; Chen, Ting; Park, Eunyoung; Mushajiang, Mierzhati; De Clercq, Dries J. H.; Xu, Man; Wang, Stephen; Cameron, Michael D.; Heppner, David E.; Shin, Bo Hee; Gero, Thomas W.; Yang, Annan; Dahlberg, Suzanne E.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">926-943</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding.  In this study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent can inhibit cell proliferation and EGFRL858R/T790M/C797S signaling in vitro and in vivo.  However, increased EGFR dimer formation limits treatment efficacy and leads to drug resistance.  Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR.  The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared with either single agent alone.  Collectively, our findings suggest that the combination of a covalent mutant-selective ATP-competitive inhibitor and an allosteric EGFR inhibitor may be an effective therapeutic approach for patients with EGFR-mutant lung cancer.  Significance: The clin. efficacy of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant lung cancer is limited by acquired drug resistance, thus highlighting the need for alternative strategies to inhibit EGFR.  Here, we identify a mutant EGFR allosteric inhibitor that is effective as a single agent and in combination with the EGFR TKI osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAPeE4TuEx6bVg90H21EOLACvtfcHk0ljV3XCQ2YPFVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGg&md5=cc2f3b0eb997626cf8243988f91c8818</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0903%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DDahlberg%26aufirst%3DS.%2BE.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DSingle%2520and%2520Dual%2520Targeting%2520of%2520Mutant%2520EGFR%2520with%2520an%2520Allosteric%2520Inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26issue%3D7%26spage%3D926%26epage%3D943%26doi%3D10.1158%2F2159-8290.CD-18-0903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1549</span>– <span class="NLM_lpage">1553</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00381</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00381" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1549-1553&issue=11&author=D.+J.+H.+De%0AClercqauthor=D.+E.+Heppnerauthor=C.+Toauthor=J.+Jangauthor=E.+Parkauthor=C.-H.+Yunauthor=M.+Mushajiangauthor=B.+H.+Shinauthor=T.+W.+Geroauthor=D.+A.+Scottauthor=P.+A.+J%C3%A4nneauthor=M.+J.+Eckauthor=N.+S.+Gray&title=Discovery+and+Optimization+of+Dibenzodiazepinones+as+Allosteric+Mutant-Selective+EGFR+Inhibitors&doi=10.1021%2Facsmedchemlett.9b00381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors</span></div><div class="casAuthors">De Clercq, Dries J. H.; Heppner, David E.; To, Ciric; Jang, Jaebong; Park, Eunyoung; Yun, Cai-Hong; Mushajiang, Mierzhati; Shin, Bo Hee; Gero, Thomas W.; Scott, David A.; Janne, Pasi A.; Eck, Michael J.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1549-1553</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Allosteric kinase inhibitors represent a promising new therapeutic strategy for targeting kinases harboring oncogenic driver mutations in cancers.  Here, we report the discovery, optimization, and structural characterization of allosteric mutant-selective EGFR inhibitors comprising a 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one scaffold.  Our structure-based medicinal chem. effort yielded an inhibitor (3) of the EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) mutants with an IC50 of ∼10 nM and high selectivity, as assessed by kinome profiling.  Further efforts to develop allosteric dibenzodiazepinone inhibitors may serve as the basis for new therapeutic options for targeting drug-resistant EGFR mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreyvHIT2KWY7Vg90H21EOLACvtfcHk0ljN6iZzqFGjIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajt7%252FM&md5=9d8771e7444fa58f06dff284f6f393da</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00381%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DGero%26aufirst%3DT.%2BW.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Dibenzodiazepinones%2520as%2520Allosteric%2520Mutant-Selective%2520EGFR%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D11%26spage%3D1549%26epage%3D1553%26doi%3D10.1021%2Facsmedchemlett.9b00381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">873</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00564</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00564" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=869-873&issue=6&author=Q.+Liauthor=T.+Zhangauthor=S.+Liauthor=L.+Tongauthor=J.+Liauthor=Z.+Suauthor=F.+Fengauthor=D.+Sunauthor=Y.+Tongauthor=X.+Wangauthor=Z.+Zhaoauthor=L.+Zhuauthor=J.+Dingauthor=H.+Liauthor=H.+Xieauthor=Y.+Xu&title=Discovery+of+Potent+and+Noncovalent+Reversible+EGFR+Kinase+Inhibitors+of+EGFRL858R%2FT790M%2FC797S&doi=10.1021%2Facsmedchemlett.8b00564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S</span></div><div class="casAuthors">Li, Qiannan; Zhang, Tao; Li, Shiliang; Tong, Linjiang; Li, Junyu; Su, Zhicheng; Feng, Fang; Sun, Deheng; Tong, Yi; Wang, Xia; Zhao, Zhenjiang; Zhu, Lili; Ding, Jian; Li, Honglin; Xie, Hua; Xu, Yufang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">869-873</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we describe the discovery and optimization of a series of noncovalent reversible epidermal growth factor receptor inhibitors of EGFRL858R/T790M/C797S.  One of the most promising compds., I, inhibited the enzymic activity of EGFRL858R/T790M/C797S with an IC50 value of 2.2 nM.  Cell proliferation assays showed that I effectively and selectively inhibited the growth of EGFRL858R/T790M/C797S-dependent cells.  This series of compds., which occupy both the ATP binding site and the allosteric site of the EGFR kinase, may serve as a basis for the development of fourth-generation EGFR inhibitors for L858R/T790M/C797S mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcQ04p4560bVg90H21EOLACvtfcHk0ljN6iZzqFGjIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFams7o%253D&md5=396eb9b29217fbb74189193a544819b3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00564%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Potent%2520and%2520Noncovalent%2520Reversible%2520EGFR%2520Kinase%2520Inhibitors%2520of%2520EGFRL858R%252FT790M%252FC797S%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D6%26spage%3D869%26epage%3D873%26doi%3D10.1021%2Facsmedchemlett.8b00564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&issue=3&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+Lung+Cancer-Derived+EGFR+Mutants+and+Inhibitor+Complexes%3A+Mechanism+of+Activation+and+Insights+into+Differential+Inhibitor+Sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0ljN6iZzqFGjIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520Lung%2520Cancer-Derived%2520EGFR%2520Mutants%2520and%2520Inhibitor%2520Complexes%253A%2520Mechanism%2520of%2520Activation%2520and%2520Insights%2520into%2520Differential%2520Inhibitor%2520Sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26issue%3D3%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">11629</span>– <span class="NLM_lpage">11633</span>, <span class="refDoi"> DOI: 10.1002/anie.201805187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1002%2Fanie.201805187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVCgsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=11629-11633&issue=36&author=J.+Jangauthor=J.+Sonauthor=E.+Parkauthor=T.+Kosakaauthor=J.+A.+Saxonauthor=D.+J.+H.+De+Clercqauthor=H.+G.+Choiauthor=J.+Tanizakiauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+a+Highly+Potent+and+Broadly+Effective+Epidermal+Growth+Factor+Receptor+and+HER2+Exon+20+Insertion+Mutant+Inhibitor&doi=10.1002%2Fanie.201805187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor</span></div><div class="casAuthors">Jang, Jaebong; Son, Jieun; Park, Eunyoung; Kosaka, Takayuki; Saxon, Jamie A.; De Clercq, Dries J. H.; Choi, Hwan Geun; Tanizaki, Junko; Eck, Michael J.; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">11629-11633</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Exon 20 insertion (Ex20Ins) mutations are the third most prevalent epidermal growth factor receptor (EGFR) activating mutation and the most prevalent HER2 mutation in non-small cell lung cancer (NSCLC).  Novel therapeutics for the patients with Ex20Ins mutations are urgently needed, due to their poor responses to the currently approved EGFR and HER2 inhibitors.  Here the authors report the discovery of highly potent and broadly effective EGFR and HER2 Ex20Ins mutant inhibitors.  The co-crystal structure of compd. 1b (4-fluorobenzyl (3-acrylamidophenyl)(2-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)carbamate) in complex with wild type EGFR clearly revealed an addnl. hydrophobic interaction of 4-fluorobenzene ring within a deep hydrophobic pocket, which has not been widely exploited in the development of EGFR and HER2 inhibitors.  As compared with afatinib, compd. 1a (4-fluorobenzyl (3-acrylamidophenyl)(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)carbamate) exhibited superior inhibition of proliferation and signaling pathways in Ba/F3 cells harboring either EGFR or HER2 Ex20Ins mutations, and in the EGFR P772_H773insPNP patient-derived lung cancer cell line DFCI127.  The authors' study identifies promising strategies for development of EGFR and HER2 Ex20Ins mutant inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8fG9GbrLyY7Vg90H21EOLACvtfcHk0lg37v5Qdg45lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVCgsLrI&md5=06891dff2f3b84f25fe0a895ba368b00</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fanie.201805187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201805187%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DSon%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DSaxon%26aufirst%3DJ.%2BA.%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520Highly%2520Potent%2520and%2520Broadly%2520Effective%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520and%2520HER2%2520Exon%252020%2520Insertion%2520Mutant%2520Inhibitor%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26issue%3D36%26spage%3D11629%26epage%3D11633%26doi%3D10.1002%2Fanie.201805187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Ly, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J. R.</span></span> <span> </span><span class="NLM_article-title">A High-Throughput Radiometric Kinase Assay</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1360</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-3073-9_7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1007%2F978-1-4939-3073-9_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=26501904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVems78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1360&publication_year=2016&pages=87-95&author=K.+C.+Duong-Lyauthor=J.+R.+Peterson&title=A+High-Throughput+Radiometric+Kinase+Assay&doi=10.1007%2F978-1-4939-3073-9_7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A High-Throughput Radiometric Kinase Assay</span></div><div class="casAuthors">Duong-Ly, Krisna C.; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1360</span>
        (<span class="NLM_cas:issue">Kinase Screening and Profiling</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aberrant kinase signaling has been implicated in a no. of diseases.  While kinases have become attractive drug targets, only a small fraction of human protein kinases have validated inhibitors.  Screening of libraries of compds. against a kinase or kinases of interest is routinely performed during kinase inhibitor development to identify promising scaffolds for a particular target and to identify kinase targets for compds. of interest.  Screening of more focused compd. libraries may also be conducted in the later stages of inhibitor development to improve potency and optimize selectivity.  The dot blot kinase assay is a robust, high-throughput kinase assay that can be used to screen a no. of small-mol. compds. against one kinase of interest or several kinases.  Here, a protocol for a dot blot kinase assay used for measuring insulin receptor kinase activity is presented.  This protocol can be readily adapted for use with other protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1VWJf_NuisLVg90H21EOLACvtfcHk0lg37v5Qdg45lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVems78%253D&md5=27351bf4930bd2a5168b109436b17945</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-3073-9_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-3073-9_7%26sid%3Dliteratum%253Aachs%26aulast%3DDuong-Ly%26aufirst%3DK.%2BC.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DA%2520High-Throughput%2520Radiometric%2520Kinase%2520Assay%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2016%26volume%3D1360%26spage%3D87%26epage%3D95%26doi%3D10.1007%2F978-1-4939-3073-9_7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastassiadis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deacon, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J. R.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Assay of Kinase Catalytic Activity Reveals Features of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1038/nbt.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=10.1038%2Fnbt.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=22037377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1039-45&issue=11&author=T.+Anastassiadisauthor=S.+W.+Deaconauthor=K.+Devarajanauthor=H.+Maauthor=J.+R.+Peterson&title=Comprehensive+Assay+of+Kinase+Catalytic+Activity+Reveals+Features+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span></div><div class="casAuthors">Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1045</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents.  Owing to evolutionary conservation of the ATP-binding site, most kinase inhibitors that target this site promiscuously inhibit multiple kinases.  Interpretation of expts. that use these compds. is confounded by a lack of data on the comprehensive kinase selectivity of most inhibitors.  Here we used functional assays to profile the activity of 178 com. available kinase inhibitors against a panel of 300 recombinant protein kinases.  Quant. anal. revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.  Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.  The results have implications for drug development and provide a resource for selecting compds. to elucidate kinase function and for interpreting the results of expts. involving kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUljWIhZGPkrVg90H21EOLACvtfcHk0lg37v5Qdg45lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E&md5=b2f705509b0e09afa46b01d4669f0515</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2017%26sid%3Dliteratum%253Aachs%26aulast%3DAnastassiadis%26aufirst%3DT.%26aulast%3DDeacon%26aufirst%3DS.%2BW.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DComprehensive%2520Assay%2520of%2520Kinase%2520Catalytic%2520Activity%2520Reveals%2520Features%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26issue%3D11%26spage%3D1039%26epage%3D45%26doi%3D10.1038%2Fnbt.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5N" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5N','PDB','6V5N'); return false;">PDB: 6V5N</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5P" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5P','PDB','6V5P'); return false;">PDB: 6V5P</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6O" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6O','PDB','6V6O'); return false;">PDB: 6V6O</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6K','PDB','6V6K'); return false;">PDB: 6V6K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V66" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V66','PDB','6V66'); return false;">PDB: 6V66</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VH4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VH4','PDB','6VH4'); return false;">PDB: 6VH4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VHN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VHN','PDB','6VHN'); return false;">PDB: 6VHN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VHP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VHP','PDB','6VHP'); return false;">PDB: 6VHP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA','PDB','3IKA'); return false;">PDB: 3IKA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZT0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZT0','PDB','5ZT0'); return false;">PDB: 5ZT0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B','PDB','6S9B'); return false;">PDB: 6S9B</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41','PDB','5D41'); return false;">PDB: 5D41</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D8E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D8E','PDB','6D8E'); return false;">PDB: 6D8E</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i37"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00200">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_50586"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00200?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00200</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">SMILES molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_001.csv">CSV</a>)</p></li><li><p class="inline">X-ray crystallography statistics, supporting structural images, biochemical potencies of <b>1</b>–<b>3</b> and <b>5</b>, and additional chemistry for precursor (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_001.csv">jm0c00200_si_001.csv (0.63 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00200/suppl_file/jm0c00200_si_002.pdf">jm0c00200_si_002.pdf (898.36 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">X-ray coordinates and structures factors have been deposited in the Protein Data Bank. PDB accession codes are the following. EGFR(T790M/V948R): <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5N">6V5N</a> (<b>1</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V5P">6V5P</a> (<b>2</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6O">6V6O</a> (<b>3</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V6K">6V6K</a> (<b>4</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V66">6V66</a> (<b>5</b>). Wild-type EGFR: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VH4">6VH4</a> (<b>3</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VHN">6VHN</a> (<b>4</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VHP">6VHP</a> (<b>5</b>). Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-8%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00200%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00200" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a5f2cbae53d06","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
